Participate in our ResearchParticipate in our Research<div class="ExternalClass3324F7F65CD7463C893B4EBDF7FEF36C"><html> <p>​<span style="color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;">At TGen, we are pioneers in precision medicine and believe that every genome tells a story. Whether eye color, laughter, freckles or smile, our genes shape who we are in so many distinct and different ways. So, too, do they play more than a passing role in how we develop and react to disease, and as important, how we react to treatment. </span></p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 10px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"><br style="box-sizing:border-box;border-radius:0px;">To understand complex diseases, we enroll healthy and affected volunteers in TGen's research studies. This may be as simple as donating ten minutes of your time to take a memory quiz or offering a saliva sample from a family pet. In other instances, participation may be restricted to those suffering from a particular genetic condition. We invite you to participate in our current studies and forward them with those who may share your interest. Thank you in advance for helping advance our research.<br></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 10px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <a target="_blank" href="https://www.tgen.org/patients/participate-in-our-research/overview/">C<span style="background-color:window;">URRENT STUDIES​</span></a> </p> </html></div>2020-10-07T07:00:00ZTGen
Event: Sign up for virtual tours of TGen October 20, 2020; November 18, 2020 and December 11, 2020 Event: Sign up for virtual tours of TGen October 20, 2020; November 18, 2020 and December 11, 2020<div class="ExternalClass2075461456724FF7A56B3F39AB3FEBA6"><html> <p>​<span id="ms-rterangepaste-start"></span><strong>Event: </strong><a href="https://www.tgen.org/education/tour-tgen/" target="_blank"><strong>Sign up for virtual tours of TGen October 20, 2020; November 18, 2020 and December 11, 2020</strong></a><strong> </strong>View the next generation sequencing technology and biomedical research laboratories where TGen scientists unlock the mysteries of cancer, diabetes, rare and neurological disease.​<span id="ms-rterangepaste-end"></span><br></p> </html></div>2020-10-07T07:00:00ZTGen
Event: The Foundation, Development, and Evolution of a Self-Management Support System TUESDAY, OCTOBER 13, 2020 2:00 PM TO 2:45 PMEvent: The Foundation, Development, and Evolution of a Self-Management Support System TUESDAY, OCTOBER 13, 2020 2:00 PM TO 2:45 PM<div class="ExternalClassB58A0D76759948A48BF6A4CB3C889FD2"><html> <p>​<span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;">Event: </span><a target="_blank" href="https://phoenixmed.arizona.edu/about/events/tech-talk-tuesdays" style="font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;"><strong>The Foundation, Development, and Evolution of a Self-Management Support System</strong></a><strong style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;"> </strong><span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;">TUESDAY, OCTOBER 13, 2020 2:00 PM TO 2:45 PM</span><span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;">​</span></p><span id="ms-rterangepaste-start"></span><h2 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);">The Foundation, Development, and Evolution of a Self-Management Support System</h2><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">Technology can play a critical role in guiding self-management for older adults. Learn how research findings have led to the development of technologies such as smartphone apps to improve medication adherence and other beneficial  behavioral interventions for an aging population.</p><h3 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);">Presenter</h3><ul style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;"><li style="box-sizing:border-box;">Kathie Insel, PhD, RN, professor and chair, Biobehavioral Health Sciences Division, UArizona College of Nursing</li></ul><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">Upon <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://arizona.zoom.us/meeting/register/tJMlceqvqDkrGdNu1_tcheLeCVY0KAUXytIC" target="_blank">completion of registration</a>, Zoom details will be included in a confirmation email.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;"><span style="box-sizing:border-box;font-weight:bolder;">For inquiries about access</span> or to request any disability-related accommodations that will facilitate your full participation, please contact the Health Sciences Engagement Office at <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="mailto:uahsevents@email.arizona.edu" target="_blank">uahsevents@email.arizona.edu</a> | 520-621-4436.<br style="box-sizing:border-box;"><br style="box-sizing:border-box;"><span style="box-sizing:border-box;font-weight:bolder;">For more information</span>, contact: Kaitlyn Armendariz Shergill, Manager, Outreach and Engagement at <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="mailto:karmendariz@email.arizona.edu" target="_blank">karmendariz@email.arizona.edu</a> | 520-621-4436.​<br></p><span id="ms-rterangepaste-end"></span><p><span style="color:rgb(0, 114, 198);font-family:"Segoe UI Semilight", "Segoe UI", Segoe, Tahoma, Helvetica, Arial, sans-serif;font-size:1.46em;background-color:window;"><br></span></p> <p> <br> </p> </html></div>2020-10-07T07:00:00ZUA
Medical School and Phoenix VA Launch Innovative Research SpaceMedical School and Phoenix VA Launch Innovative Research Space<div class="ExternalClassD67AB264540E446E8D913C200F3A4E2D"><html> <p>​<span id="ms-rterangepaste-start"></span><span style="color:rgb(33, 33, 33);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:20px;font-weight:700;">The Phoenix VA Health Care System (PVAHCS) Research Space will be an Incubator for Medical Discovery, New Technologies and Clinical Care on the Phoenix Biomedical Campus</span>​<span id="ms-rterangepaste-end"></span><br></p> <span id="ms-rterangepaste-start"></span> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">The Phoenix VA Health Care System (PVAHCS) Research Space will open this month in the University of Arizona College of Medicine – Phoenix on the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/campus" target="_blank">Phoenix Biomedical Campus</a>. This innovative partnership will accelerate the application of medical research discovery into clinical practice.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">The newest partnership will allow UArizona researchers access to a secure database of medical and genetic information gathered by the VA (the Million Veterans Program, also known as “MVP”) to provide personalized treatments for veterans. The genetic information will help physicians predict how patients will respond to medications and other treatments. It also will identify patients who may be eligible for a specific research study and invite them to participate in the investigation. The MVP program will help facilitate early disease intervention, prevent adverse reactions to drugs, save lives and decrease health care costs over time.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">“First and foremost, the benefit of this new research facility is the opportunity to provide the best clinical care possible for our veterans,” said Samuel Aguayo, MD, associate chief of staff for research at the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/phoenix-va" target="_blank">Phoenix VA Health Care System</a>.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">Dr. Aguayo, a distinguished pulmonologist, is the inaugural director of this PVAHCS Research Space. “We are blessed with a number of people who have a common vision,” he said. For Dr. Aguayo, this research space is a vision he and others have worked for the last decade to create.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">Phoenix struggles with a shortage of physicians and other health care professionals, despite being the fifth largest city in the United States. The PVAHCS provides health care for more veterans every year, as the growth in enrollments continually climbs. This synergistic collaboration will help serve the community by recruiting renowned clinical talent to practice medicine at the PVAHCS and conduct research at the UArizona College of Medicine – Phoenix. They will also develop the next generation of skilled clinical researchers through a variety of <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/gme" target="_blank">residency and fellowship programs</a>.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">A culmination of tireless efforts among the college, the PVAHCS, the City of Phoenix Economic Development office and the Mayor of Phoenix’s office, the state-of-the-art research space showcases the dedication to driving economic development and providing life-changing medical treatments for veterans and the Phoenix community.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">“The Phoenix VA and University of Arizona College of Medicine – Phoenix continue to lead by developing first-in-the-nation partnerships that serve as a role model for other academic medical centers across the country,” explained City of Phoenix Mayor Kate Gallego. “We are proud to support the Phoenix Biomedical Campus for continuing to be a key generator of economic impact for Phoenix and Arizona.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">Since opening in 2007, the UArizona College of Medicine – Phoenix has partnered with the PVAHCS to prepare the college’s medical students and residents on the diverse health needs of veterans. As part of that collaboration, many third-year medical students rotate through the PVAHCS during their clerkships, in which they learn first-hand from top doctors how to provide excellent care to veterans.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;"></p> <figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:250px;height:auto;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;background-color:rgb(232, 237, 243) !important;"> <div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"> <img style="box-sizing:border-box;border-width:0px;vertical-align:middle;max-width:100%;margin:5px;width:0px;" title="The Phoenix VA Health Care System" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/phoenix-va-story.jpg" data-entity-uuid="fe017c33-b654-489f-82e6-bfdb16cd6290" data-entity-type="file" class="img-fluid" alt="The Phoenix VA Health Care System" /> </div> <figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;font-size:14px;line-height:20px;margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;"> <em style="box-sizing:border-box;">The Phoenix VA Health Care System</em> </figcaption> </figure> <span style="color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">The college has more than 155 faculty members with affiliation at the Phoenix VA who serve as department chairs, committee chairs, mentors and advisors. These faculty members also participate in the doctoring program, clerkships, core lecture series and scholarly projects.</span> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;"></p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">The partnership has grown through the years spanning many departments, including <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/radiology" target="_blank">radiology</a>, <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/neurology" target="_blank">neurology</a>, dermatology, <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/medicine" target="_blank">internal medicine</a> and, most recently, <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/bmi" target="_blank">clinical informatics</a>.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">“We have worked hard to expand our collaboration with the Phoenix VA, and to enhance the scope of research on the campus,” said <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/dean-reed" target="_blank">Guy Reed, MD, MS</a>, dean of the UArizona College of Medicine – Phoenix. “The ability to use big data and translational research to attack problems in mental health, traumatic brain injury, skin cancer, heart disease and others will allow investigators to gain insights that can fuel the development of new therapies, devices, algorithms and other approaches to improve patient care.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;">A direct benefit to patients will be the ability to attract top talent in a variety of specialties, individuals who participate in research and education in addition to treating patients. The Phoenix community will benefit from having a thriving health sciences campus.​<br></p> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/91/research-va-feature.jpg2020-10-05T07:00:00ZUA
TGEN, AVERY THERAPEUTICS COLLABORATION STUDIES MECHANISM OF ACTION IN ENGINEERED HEART TISSUETGEN, AVERY THERAPEUTICS COLLABORATION STUDIES MECHANISM OF ACTION IN ENGINEERED HEART TISSUE<div class="ExternalClassC69398967DEC40DC98615DD68D732637"><html> <p>​<span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a>​</span></p> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="list-inline posted-info"> </ul> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen’s analysis of proteins and metabolites could pave the way for Avery Therapeutics to gain FDA approval of human clinical trials</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX and TUCSON, Ariz. — Oct. 5, 2020 —</span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://averythera.com/" target="_blank">Avery Therapeutics Inc.</a> of Tucson has  developed an engineered heart tissue, a lab-grown cardiac membrane that can help heal the heart, either following a heart attack or as a result of progressive heart disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The heart tissue, called MyCardia™, could revolutionize the treatment of cardiovascular disease, and someday might be applied to other failing organs.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To better understand how MyCardia works — at the infinitesimally small molecular level — Avery has partnered with the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, following an introduction made by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://flinn.org/bioscience/arizonas-bioscience-roadmap/entrepreneurship-program/" target="_blank">Flinn Foundation</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Avery turned to TGen to understand which of their membranes are releasing molecules that produce therapeutic benefits,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/patrick-pirrotte/" target="_blank">Dr. Patrick Pirrotte</a>, Assistant Professor and Director of TGen’s Collaborative Center for Translational Mass Spectrometry. “Our collaboration will help them understand the mechanism of action on the molecular level, and the potential benefits to patients.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">TGen is conducting mass spectrometry analysis of the proteins and metabolites at work in MyCardia’s healing effect on heart-muscle tissue. This supporting data will be used in Avery’s submissions to the Food and Drug Administration (FDA) that could lead to human clinical trials. Up to now, Avery has studied the processes in laboratory and preclinical experiments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Avery’s technology is amazing,” Dr. Pirrotte said, noting that the MyCardia membranes actually beat like a heart. “Their idea is that, for a heart that is potentially weak, an inserted cardiac membrane could support regeneration of heart tissue.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Avery licensed the technology for MyCardia from the University of Arizona, where Avery scientists had worked on developing engineered regenerative tissues to treat cardiovascular disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Key to the technology is the advancement in recent years of induced pluripotent stem cells (iPSCs), which can propagate indefinitely and theoretically give rise to every other cell type in the body. They represent a source of cells that could be used to replace those lost to damage or disease. Advancements in iPSC technology led to a Nobel Prize in 2012.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“It’s the concept of being able to take essentially any cell in the body and convert it into an embryonic-like cell, and then being able to make any cell. That’s how we are making our heart-muscle cells,” said Dr. Jordan Lancaster, Avery’s Chief Executive Officer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Dr. Jen Koevary, Avery’s Chief Operating and Financial Officer, added: “We created the material based on the idea that you can use healthy cells to treat an unhealthy tissue and make it healthy again.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">The Nation’s leading cause of death</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">More than 30 million Americans have heart disease, resulting in over $39 billion annually in medical treatment costs. Nearly 600,000 patients are newly diagnosed each year, and <span style="box-sizing:border-box;border-radius:0px;">650,000 Americans die annually, making it the nation’s leading cause of death.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The condition is most often treated with drugs, but those efforts eventually fail. Heart transplants can help, but suitable donors are scarce, enabling fewer than 3,000 transplants each year. Mechanical hearts that run on battery packs also can help, but they are expensive; patients are often left with limited mobility, poor quality of life and frequent hospital visits.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">How MyCardia works</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;">Through</span> minimally invasive laparoscopic or robotic surgery, MyCardia is precisely grafted onto the surface of a damaged heart. It is loaded with a therapeutic cellular payload; a proprietary combination of cardiomyocytes (heart-muscle cells) and fibroblasts (general cells of the body).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Over time, the MyCardia membrane secretes proteins and metabolites, collectively called the secretome, which helps enable the heart to heal itself. The MyCardia eventually disappears. It’s the unique secretome that is being studied at TGen.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We have lots of data, but we really don’t know what makes it tick,” Dr. Lancaster said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">There are hundreds of factors involved in the MyCardia process, explained Dr. Koevary: “Figuring out exactly how it works is very complex. It’s important for us to know how it’s working so we can, in the future, identify the best patients who would be candidates for treatment.”​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <br> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/92/patrick-pirrotte.png2020-10-05T07:00:00ZTGen
Phoenix Union Bioscience High School was recently notified that Principal Dr. Holly Batsell has earned the 2020 Maricopa County Exemplary Principal Award.Phoenix Union Bioscience High School was recently notified that Principal Dr. Holly Batsell has earned the 2020 Maricopa County Exemplary Principal Award.<div class="ExternalClass6DC17C32A0AD45378B512E7090824B99"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">The Maricopa County Exemplary Principal Award, formerly known as the Rodel Exemplary Principal Award, recognizes principals in Maricopa County who exemplify practices and leadership that contribute to high expectations and exceptional student learning. Principals are chosen based on a robust nomination process that includes five phases. Aspects of the process involve a site visit, interviews with staff members, classroom walkthroughs, and an observation of a leadership team meeting.</p> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">The process includes a review of the last three years of achievement data to identify schools with a history of high student achievement, student growth, and teacher retention. Superintendents are then invited to nominate principals who meet the established criteria.</p> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">“Bioscience High School, with Dr. Holly Batsell’s steady leadership for the past four years, is routinely ranked as one of the top high schools in Arizona, earning an “A” for the past two years”, said PXU Superintendent Dr. Chad Gestson. “With an emphasis on an integrated, rigorous curriculum while incorporating science, technology, engineering, and math, Dr. Batsell has successfully focused on increasing ACT scores and increasing student enrollment and retention. She has high expectations for herself and her staff.” Dr. Gestson continued, “these expectations have translated into positive and supportive school culture. This, in turn, consistently promotes student success. Bioscience students receive hundreds of thousands of dollars in scholarships each year and many go on to successful STEM careers. The honor of being named a National Blue Ribbon School is a reflection of the hard work and dedication of all Bioscience staff.”​<br></p> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/90/Dr. Holly Batsell.png2020-10-02T07:00:00ZPhoenix Bio News
National Blue Ribbon School 2020National Blue Ribbon School 2020<div class="ExternalClassC9AE471B315A43DDAAE053AB6B84BE06"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">The National Blue Ribbon Schools Program recognizes public and private elementary, middle, and high schools based on their overall academic excellence or their progress in closing achievement gaps among student subgroups. “Every year, the U. S. Department of Education seeks out and celebrates great American schools which demonstrate that all students can achieve to high levels. The coveted National Blue Ribbon School award affirms the hard work of students, educators, families, and communities in creating safe and welcoming schools where students master challenging and engaging content.” (<a style="cursor:pointer;" href="https://nationalblueribbonschools.ed.gov/background/" target="_blank">National Blue Ribbon School Website</a>) </p> <p style="font-family:montserrat, arial, sans-serif;font-size:19px;">“Bioscience High School, with Dr. Holly Batsell’s steady leadership for the past four years, is routinely ranked as one of the top high schools in Arizona, earning an “A” for the past two years”, said PXU Superintendent Dr. Chad Gestson. “With an emphasis on an integrated, rigorous curriculum while incorporating science, technology, engineering, and math, Dr. Batsell has successfully focused on increasing ACT scores and increasing student enrollment and retention. She has high expectations for herself and her staff.” Dr. Gestson continued, “these expectations have translated into a positive and supportive school culture. This, in turn, consistently promotes student success. Bioscience students receive hundreds of thousands of dollars in scholarships each year and many go on to successful STEM careers. The honor of being named a National Blue Ribbon School is a reflection of the hard work and dedication of all Bioscience staff.”​<br></p> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-10-01T07:00:00ZCity of Phoenix
SINGLE-CELL RNA SEQUENCING REVEALS DETAILS ABOUT INDIVIDUAL CELLS IN PANCREATIC TUMORSSINGLE-CELL RNA SEQUENCING REVEALS DETAILS ABOUT INDIVIDUAL CELLS IN PANCREATIC TUMORS<div class="ExternalClassC5788228BE4A4D53B31356F7F1C02CD4"><html> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">​Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Tuesday September 29, 2020</li></ul> <br> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen and HonorHealth investigators suggest this granular analysis could lead to better treatments for pancreatic cancer patients</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">SCOTTSDALE, Ariz. — Sept. 29, 2020 —</span> Led by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, and by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth Research and Innovation Institute</a><span style="box-sizing:border-box;border-radius:0px;">, </span>an international team of researchers have described in detail the individual cells that comprise the pancreatic cancer microenvironment, a critical step in devising new treatment options for patients with this aggressive and difficult-to-treat disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study results were published today in the scientific journal <em style="box-sizing:border-box;border-radius:0px;">Genome Medicine</em>, a publication of <em style="box-sizing:border-box;border-radius:0px;">Springer</em> <em style="box-sizing:border-box;border-radius:0px;">Nature</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Researchers used a relatively new technique known as single-cell sequencing to genetically identify cell types, and subtypes, that occur in pancreatic tumors, and identify the various cells in the tumor’s stroma, a substance surrounding the tumor that can hide the cancer from the body’s immune system.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While single-cell transcriptomics has been used previously to study the cellular composition of primary tumor tissues of pancreatic ductal adenocarcinoma (PDAC), this study also used the technology to profile individual cells from dissociated primary tumors and biopsies of metastatic tissues, those cancerous lesions that have spread throughout the body from the primary tumor.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This study was carried out in collaboration with investigators from <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.samsunghospital.com/gb/language/english/main/index.do" target="_blank">Samsung Medical Center</a> and City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. Primary tumors and core needle biopsies of metastatic lesions from PDAC patients were sequenced using the Chromium single cell RNA-Seq platform.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Single-cell transcriptome analysis can offer important clinical insights on individual cell subpopulations and provide clues for developing novel therapeutic strategies for both targeted therapies and immunotherapies,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/haiyong-han/" target="_blank">Haiyong Han</a>, Ph.D., a professor in TGen’s Molecular Medicine Division and head of the institute’s Pancreatic Cancer Research Laboratory.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Understanding the diversity and complexity of the PDAC tumor and stromal compartments in individual tumors may help identify unique intervention points and potentially inform treatment and maintenance strategies for patients with advanced disease,” said Dr. Han, the study’s senior author.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Distinct cell types and subtypes were identified in the analysis, including tumor cells, endothelial cells, cancer associated fibroblasts, and immune cells, and the expression levels of various genes in the individual cell populations correlated with patient clinical outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Working with our partners and colleagues by utilizing the technology of singe cell sequencing, we can continue to learn more about the biology of pancreas cancer.  These insights may potentially help us determine more treatment options for our patients,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/physicians/erkut-borazanci" target="_blank">Erkut Borazanci</a>, M.D., M.S., a medical oncologist and physician-investigator at HonorHealth Research and Innovation Institute, a clinical associate professor at TGen, and one of the paper’s authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Pancreatic cancer is an aggressive disease that carries a high mortality rate. It is the third-leading cause of cancer death in the U.S., following lung and colorectal cancers. In 2020, the five-year survival rate for pancreatic cancer is only about 10%, though that represents progress from the dismal 6% rate in 2014.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Next, researchers plan to use more advanced single-cell spatial transcriptomics analysis to further investigate the cellular relationships related to survival rates using real-time methods. Broader use of this technology could potentially guide the search for new agents to treat pancreatic cancer. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">For more information about pancreatic cancer research studies at HonorHealth Research and Innovation Institute, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/company/research-institute" target="_blank">HonorHealth.com/research</a>, call 480-323-1364 or email <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:clinicaltrials@honorhealth.com" target="_blank">clinicaltrials@honorhealth.com</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This research was supported by: the National Foundation for Cancer Research; SU2C-CRUK-Lustgarten Foundation Pancreatic Dream Team Research Grant (SU2C-AACR-DT-20-16); Baylor Scott & White Research Institute (BSWRI) and Translational Genomics Research Institute (TGen) Collaboration in Oncology Research; and the Korean Health Technology R&D Project  (HI14C2640).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study — <em style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-020-00776-9" target="_blank">Single-Cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions</a> — </em>was published in the scientific journal <em style="box-sizing:border-box;border-radius:0px;">Genome Medicine</em>.</p> <br> <br> </div> </div> <p> <br> </p> </html></div>2020-09-29T07:00:00ZTGen
TGEN LAUNCHES VIDIUM ANIMAL HEALTHTGEN LAUNCHES VIDIUM ANIMAL HEALTH<div class="ExternalClassE31BAFC3FABC460DA9375CB91D510B3B"><html> ​ <span id="ms-rterangepaste-start"></span> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;"> <ul class="list-inline posted-info" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span class="uBlogsy_author_name" style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" title="Steve Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Monday September 28, 2020</li></ul> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen subsidiary offers genomic diagnostics in support of veterinary oncologists and pet parents treating canine cancer</em> </p> </div> </div> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — Sept. (28), 2020 —</span> After more than a decade of pioneering the study of naturally occurring cancer in pet dogs, the <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a target="_blank" href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">City of Hope</a>, announced today the commercial launch of <a target="_blank" href="http://vidiumah.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Vidium Animal Health</a>, providing genomic-based precision-medicine to veterinary oncologists and pet parents.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">As a veterinarian, Vidium President Dr. David Haworth has seen first-hand the pain and concern that veterinarians and pet parents experience when a dog is diagnosed with cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Vidium is built around the human-animal bond, and the fact that the majority of pet owners feel their pet is part of their family,” Dr. Haworth said. “When a pet is diagnosed with cancer, it can be a really scary time for everyone, so we want to offer the very best information, and hope, that science can offer.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To increase a pets’ chance of survival, Vidium created <em style="box-sizing:border-box;border-radius:0px;">SearchLight DNA™</em>, a test designed specifically to identify any of the nearly 120 known cancer-associated genetic mutations in dogs, and use the molecular profile of misbehaving genes to help guide diagnosis and treatment.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Vidium Founder and Chief Science Officer Dr. Will Hendricks, an Assistant Professor in TGen’s Integrated Cancer Genomics Division, has spent much of the past decade dedicated to the pursuit of <a target="_blank" href="https://ccr.cancer.gov/comparative-oncology-program" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">comparative oncology</a>, the study of naturally occurring cancers in animals to better understand human cancers and vice versa.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“It’s clearly a two-way street, with both humans and dogs benefiting from the exchange,” he said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">As a prime example, Dr. Hendricks points to <a target="_blank" href="https://www.tgen.org/news/2019/august/20/tgen-and-ohio-state-link-gene-to-canine-lung-cancer/?search=canine" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">a landmark 2019 study</a> conducted by TGen and The Ohio State University, which found that — like many women who develop a particular type of breast cancer — the same gene, HER2, also appears to play an important role in lung cancer in many dogs.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Vidium was born from our finding that the genetic underpinnings of canine cancers reflected the same fundamental science that allowed us to apply precision medicine toward treating human cancers,” Dr. Hendricks said. “Cancer gene mutations that have clinical importance in canine oncology are abundant, and with <em style="box-sizing:border-box;border-radius:0px;">SearchLight DNA</em> our goal is to equip veterinarians with the best information possible to help guide the clinical management of the dogs in their care.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Katie Banovich, Vidium’s Director of Operations, said the absence of genomic technology in the care of pets is a tremendous void that Vidium hopes to fill, but only with the participation of veterinarians and pet parents.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Through application of multi-disciplinary genomic science, we want to position Vidium as a partner in the veterinary care team,” Banovich said. “We want to be a guide. We want to work with veterinarians.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">SearchLight DNA</em> reports will be customized with technical language designed for clinicians and easier-to-understand lay language for pet parents that fully communicates the details of their pet’s condition.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While Vidium’s efforts will initially be put toward canine cancer, its goal is to expand its genomic analysis to the treatment of other diseases, and other animals.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Beyond assisting with the diagnosis, prognosis and treatment of dogs with cancer, Vidium will play a continuing role in the discovery of new associations between gene mutations, specific types of cancers in specific breeds of dogs, and clinical outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We are going to play an active role in changing the landscape of veterinary care, both through expanding our understanding of genetic biomarkers, and by facilitating access to targeted therapeutics that may make a difference in specific genetic settings,” Dr. Hendricks said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Vidium Animal Health is a subsidiary of TGen. Learn more at: <a target="_blank" href="http://vidiumah.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">vidiumah.com</a>.​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-09-28T07:00:00ZTGen
Genetic Sleuthing Reveals Multiple Introductions Of Coronavirus To ArizonaGenetic Sleuthing Reveals Multiple Introductions Of Coronavirus To Arizona<div class="ExternalClass840E64380487488DB78CAE3B569438B3"><html> <p>​<span class="submitted" style="box-sizing:border-box;color:rgb(119, 119, 119);font-size:0.75em;line-height:1.25;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;letter-spacing:0.08px;word-spacing:0.4px;"><span class="submitted-label" style="box-sizing:border-box;">By</span> <span class="name" style="box-sizing:border-box;text-transform:uppercase;"><a target="_blank" href="https://www.knau.org/people/melissa-sevigny" rel="author" style="box-sizing:border-box;color:rgb(61, 61, 61);line-height:inherit;background:transparent;">MELISSA SEVIGNY</a></span></span><span style="color:rgb(61, 61, 61);font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;"> </span>​<br></p> <p> <span style="color:rgb(61, 61, 61);font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;">A</span><a style="box-sizing:border-box;color:rgb(22, 141, 217);line-height:inherit;background:transparent;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;" target="_blank" href="https://mbio.asm.org/content/11/5/e02107-20"> new study</a><span style="color:rgb(61, 61, 61);font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;letter-spacing:0.08px;word-spacing:0.4px;"> shows the virus that causes COVID-19 arrived in Arizona in at least eleven separate introductions in February and March. That’s the result of genetic detective work done by scientists at Arizona’s three state universities and the Translational Genomics Research Institute in Flagstaff. KNAU’s Melissa Sevigny spoke with Jolene Bowers of TGen North about how sequencing the genome of the coronavirus can help public health professionals track the disease through time and space.</span><br> </p><span id="ms-rterangepaste-start"></span><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">What can you learn from looking at the genetic material of the coronavirus?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">What we’re doing is we’re sequencing a whole bunch of virus genomes to try to understand how the virus is spreading in and around Arizona. The way we do that is we’re sequencing these genomes and looking for these small mutations that will tell us who is related to whom. These mutations are constantly happening. They’re being passed down from generation to generation. So when we see two viruses that share a certain mutation, then we can be confident that they’re related.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">So you sequenced the genome of the very first case in Arizona, and what did you learn from that?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">Actually the CDC sequenced that first case… This was in late January. A young man was returning from travel and he presented to a health care center with mild symptoms…. He was very quickly diagnosed and quarantined… We were able to show that none of the viruses that we sampled in Arizona were related to that virus genome at all… So public health response efforts really work.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">So you’ve sequenced many more genomes since that first case happened in January. What have you learned since then?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">What we were able to show is a lot of our viruses in Arizona are most closely related to other viruses that are circulating in other states in the United States…. And we determined that very likely the virus was introduced into Arizona probably in mid to late February, but we didn’t start seeing it until cases starting coming to light in early and mid-March…. This was when the virus really started taking off in Arizona, and it probably all arrived here through domestic travel. Probably not surprising because that was when some of the travel restrictions were put in place and international travel was being discouraged.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">One of the things your team discovered was that there were at least 11 separate introductions of the virus to Arizona. I’m curious, did that surprise you or were you expecting that?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">It’s not surprising at all that we had that many virus introductions into Arizona. Arizona’s not in a bubble and people are still moving around. What did surprise me is we were able to detect at least 11 different introductions to the virus. Because the way we’re doing that, we’re comparing the genomes of the virus, so these genomes have to be different enough to detect these differences in the virus, so we can trace these lineages or these variants of these viruses back to different ancestors. That’s how we determined there were probably at least 11 introductions. We think that’s probably an underestimate really.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">What are the next steps, or questions you still want to answer?</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">We definitely want to take another big picture look now that we have thousands of genomes sequenced and see how the pandemic has evolved in Arizona, Do we see any of these super spreader events? One of our major goals is really to demonstrate the value of this genomic epidemiology and make it routine, so that it becomes an everyday thing.</p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;"><span style="box-sizing:border-box;font-weight:700;line-height:inherit;">Jolene Bowers, thank you for speaking with me today.</span></p><p style="box-sizing:border-box;margin:0px 0px 1.5625rem;padding:0px;font-family:lato, "helvetica neue", helvetica, helvetica, arial, sans-serif;font-size:16px;line-height:1.75em;text-rendering:optimizelegibility;color:rgb(61, 61, 61);letter-spacing:0.08px;word-spacing:0.4px;">Thank you for having me.​<br></p><span id="ms-rterangepaste-end"></span><p><br></p> </html></div>2020-09-25T07:00:00ZNAU
Women in Medicine Fighting COVID-19: Drs. Hale, Herbst-Kralovetz and MahnertWomen in Medicine Fighting COVID-19: Drs. Hale, Herbst-Kralovetz and Mahnert<div class="ExternalClass3FD55060215B483CB856C46289507452"><html>​<span id="ms-rterangepaste-start"></span><h5 style="box-sizing:border-box;margin-top:0px;margin-bottom:0px !important;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:normal;line-height:18px;color:rgb(155, 155, 155);font-size:15px;margin-right:0.5rem !important;text-transform:uppercase !important;font-style:normal;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field_title text-uppercase mb-0 mr-2"><span style="box-sizing:border-box;" class="field field--name-title field--type-string field--label-hidden">TERESA JOSEPH</span></h5><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><span id="ms-rterangecursor-start"></span><span id="ms-rterangecursor-end"></span>​<br></h4><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><div style="box-sizing:border-box;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(33, 33, 33) !important;font-size:1.25rem;font-style:normal;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item">Collaborative Research Analyzes Impact of Stress, Pregnancy and COVID-19</div></h4><div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:15px;line-height:20px;margin-bottom:3rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><em>In honor of this year’s <a href="https://phoenixmed.arizona.edu/diversity/wims" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Women in Medicine and Science</a> month, the University of Arizona College of Medicine – Phoenix has asked a few faculty to share their inspiring stories and work that is helping our community through the <a href="https://phoenixmed.arizona.edu/covid-19" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">coronavirus pandemic</a>.</em></p></h4><h2 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);">Meet Drs. Hale, Herbst-Kralovetz and Mahnert</h2><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Three faculty members at the University of Arizona College of Medicine – Phoenix are working on a highly collaborative research project related to the COVID-19 pandemic, stress and pregnancy.</p><figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:250px;height:auto;background-color:rgb(232, 237, 243) !important;"><div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"><img data-entity-type="file" data-entity-uuid="ce39543b-ef6e-4b31-a7ff-6009b25382a9" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/hale-story_0.jpg" alt="Taben Hale, PhD" style="margin:5px;border:0px;width:142px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Taben Hale, PhD" /></div><figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"><em style="box-sizing:border-box;">Taben Hale, PhD</em></figcaption></figure><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The research is being conducted by Melissa Herbst-Kralovetz, PhD, an associate professor in<span> </span><a href="https://phoenixmed.arizona.edu/bms" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Basic Medical Sciences</a><span> </span>and<span> </span><a href="https://phoenixmed.arizona.edu/obgyn" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Obstetrics and Gynecology</a>, Taben Hale, PhD, an associate professor in<span> </span><a href="https://phoenixmed.arizona.edu/bms" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Basic Medical Sciences</a>, and Nichole Mahnert, MD, a clinical assistant professor in<span> </span><a href="https://phoenixmed.arizona.edu/obgyn" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;" target="_blank">Obstetrics and Gynecology</a>.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The collaborative study began from a graduate medical education project. Obstetrics and Gynecology residents complete a research project over the course of their four-year training. First-year resident Dr. Bryan Grover’s interest in maternal-fetal medicine and translational science inspired this project. He asked how COVID-19 infections affect a woman’s pregnancy and fetus. To tackle this question, a highly collaborative team was assembled with an infectious disease/ reproductive immunologist (Dr. Herbst-Kralovetz), maternal stress/cardiovascular researcher (Dr. Hale), OB/GYN and surgeon (Dr. Mahnert) and Dr. Grover.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">Describe the research in layman’s terms.</strong></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">We are interested in studying the impact of maternal stress, SARS-CoV-2 infection on pregnancy and newborn outcomes. We know that maternal stress can have a negative health impact on fetal development and future disease risk in adulthood. In this study, we are interested in evaluating how the COVID-19 pandemic impacts pregnant moms and their babies. As we have learned over the past several months, SARS-CoV-2 infection affects multiple organ systems including cardiovascular function and can have long-term health effects. Stress also causes global health effects and can exacerbate underlying health issues by increasing inflammation. In this study, we aim to evaluate the impact of pandemic stress and SARS-CoV-2 infection on maternal health and newborn offspring by measuring signatures of stress and inflammation.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Even in the absence of SARS CoV-2 infection, there is a significant degree of added stress due to the pandemic. The stress associated with fear of contracting the virus, added pressures of working from home, and managing remote learning for other children all result in an increased burden on the mother and associated risk to fetal development and long-term health.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;"></strong></p><figure class="bg-light figure img-fluid align-left" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 1rem 1rem 0px;float:left;max-width:250px;height:auto;background-color:rgb(232, 237, 243) !important;"><strong style="box-sizing:border-box;font-weight:bolder;"><div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"><img data-entity-type="file" data-entity-uuid="bef0696e-a3d3-4714-9f02-f1d0fea3416b" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/herbst-kralovetz-story_0.jpg" alt="Melissa Herbst-Kralovetz, PhD" style="margin:5px;border:0px;width:226px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Melissa Herbst-Kralovetz, PhD" /></div><figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"><em style="box-sizing:border-box;">Melissa Herbst-Kralovetz, PhD</em></figcaption></strong></figure><strong style="box-sizing:border-box;font-weight:bolder;">Why is this research important?</strong><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">This has potential long-term impact on women and their babies. It is important that we study how the pandemic stress and SARS-CoV-2 infection impacts health outcomes during pregnancy and beyond. The health outcomes we are interested in studying touch on some of those organ systems, including indicators of stress and inflammation, as well as cardiovascular outcomes.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">There is ample evidence that the in utero environment can have long-term consequences on cardiovascular function and future disease risk. We know that prenatal stress can lead to altered blood pressure and heart rate regulation, as well as increased risk of depression and anxiety in adults. Understanding the impact of COVID on maternal stress and fetal development will lead to improved care of the maternal-fetal dyad.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">What is the research goal?</strong></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">We are interested in understanding the level to which pandemic stress and/or SARS-CoV-2 infection increases inflammation or stress markers in pregnant moms and their newborns. Inflammation and markers of stress could be a driver for adverse effects on women and their offspring.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">What do you want our community to know about this?</strong></p><figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:250px;height:auto;background-color:rgb(232, 237, 243) !important;"><strong style="box-sizing:border-box;font-weight:bolder;"><div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"><img data-entity-type="file" data-entity-uuid="96b25183-92ff-4a1d-99c0-c79469f9172b" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/mahnert-story.jpg" alt="Nichole Mahnert, MD" style="margin:5px;border:0px;width:166px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Nichole Mahnert, MD" /></div><figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"><em style="box-sizing:border-box;">Nichole Mahnert, MD</em></figcaption></strong></figure><strong style="box-sizing:border-box;font-weight:bolder;"></strong><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Studies have shown that women are experiencing elevated symptoms of anxiety and depression during the COVID-19 pandemic relative to pre-pandemic pregnancy cohorts. As such, these stress levels could have long-term health impacts on their children. Healthy lifestyle factors could help to mitigate these negative effects and include social support and exercise.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Mindfulness, yoga and other stress reduction techniques are more important than ever. Thus far, the risk of transmission of COVID-19 from mom to fetus is unlikely, but further research on this topic is so important, which is part of why we are doing this study.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"><strong style="box-sizing:border-box;font-weight:bolder;">Why did you want to study this?</strong></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">We know women are bearing the burden of caregiving stress and are disproportionately impacted during pandemics over the course of history. That stress could be having a negative impact on women’s health, including during pregnancy. There are so many unknowns with COVID-19 pandemic and we would like to contribute to expanding our knowledge base and the impact it is having on women’s health.</p></h4></div><h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"><br><br></h4><p><br></p></html></div>https://biomedicalphoenix.com/Lists/News/Attachments/83/hale-feature.jpg2020-09-18T07:00:00ZUA
Celebrating Life & Science in ArizonaCelebrating Life & Science in Arizona<div class="ExternalClassBA1ACB881CD54EDEAAF0AA6E6E6F9EFC"><html> <p>​Watch <span style="color:#444444;">Celebrating Life & Science for inspiring stories of Arizonans working together and using science to make life better before, during and after the COVID-19 emergency. </span><a href="https://www.youtube.com/AZBio1" target="_blank">https://www.youtube.com/AZBio1</a> <span style="color:#444444;">​</span></p> <p><br></p></html></div>2020-09-17T07:00:00ZArizona BioIndustry Assoc
NCI FUNDS RESEARCH INTO WHY GLIOBLASTOMA HITS MALES HARDER THAN FEMALESNCI FUNDS RESEARCH INTO WHY GLIOBLASTOMA HITS MALES HARDER THAN FEMALES<div class="ExternalClass3D6E76197F37431295ACCB487936F28B"><html> <p>​</p> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span> </span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a href="https://www.tgen.org/news/?author=Steve+Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Steve Yozwiak" target="_blank"> <span style="box-sizing:border-box;border-radius:0px;">Steve Yozwiak</span> </a> </span> </div> </li> <span> </span> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Thursday September 17, 2020</li> </ul> </h4> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">​<span id="ms-rterangecursor-start"></span><span id="ms-rterangecursor-end"></span>TGen technology is key to brain cancer research consortium led by Cleveland Clinic and Case Western Reserve University</em> </p> </h4> </div> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — Sept. 17, 2020 —</strong> <span> </span>The<span> </span><a href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of<span> </span><a href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">City of Hope</a>, will employ two relatively new technologies in a study led by Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine into why men are stricken with glioblastoma brain cancer far more often than women, and why women survive the disease almost twice as long as men.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">As part of a five-year $10.4 million grant announced today from the National Cancer Institute (NCI), researchers will delve into the molecular-level biology of glioblastoma — the most common and deadliest adult brain tumor — seeking new therapies against the disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We’ve known for some time that glioblastoma multiforme (GBM) affects men more than women,” said<span> </span><a href="https://www.tgen.org/faculty-profiles/michael-berens/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Dr. Michael Berens</a>, a TGen Deputy Director and Head of the institute’s Glioma Research Lab. “It’s been in front of us all along. We just haven’t taken a deep enough dive to appreciate in what ways they are different, and — more significantly from a precision-medicine perspective — how the sex of the patient might inform tailored treatment strategies.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr. Berens will study the tumor microenvironment, and the effect of immune cells on the tumor. A major goal of the study is to find out how to make the normal host cells in the brain more resilient against the tumor; specifically how women respond to the disease, and how to apply those findings to provide better treatment outcomes for men.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">First, TGen will employ “single-cell transcriptomics,” which will enable researchers to genetically identify every type of cell that occurs in the tumor, and identify all of the various normal brain cells that surround the tumor.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Then, for the first time in GBM, TGen will use a new technology called “spatial transcriptomics,” which will show the locations of the various cells and how they interact with each other.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We will be able to see who is there, who is misbehaving, who is next to who and, hopefully, who is influencing who,” Dr. Berens said of the various cellular interactions his team will investigate.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Two specific questions Dr. Berens wants to answer are: Why brain tumor cells connect with neurons, the functioning cells of the brain that determine memory and action; and why brain tumor cells appear to recruit special blood cells from bone marrow known as Myeloid Derived Suppressor Cells (MDSCs), which suppress the body’s immune system.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Previous research, including pioneering work at TGen, has shown that glioblastoma occurs at a rate 60 percent higher in males than in females. And, females have a significant survival advantage over males with a median improved survival of up to 10 months. However, while these sex differences are known, they are poorly understood and are not yet considered when treating glioblastoma.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Glioblastomas are aggressive and rare: fewer than 4 per 100,000 in the U.S. from 2012-16, according to the most recent data available from the<span> </span><a href="https://cbtrus.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Central Brain Tumor Registry</a><span> </span>of the United States (CBTRUS). The median survival time is 12 to 14 months, and only about 5% of patients survive more than five years.   </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">Leaders of the study</strong> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The research team is led by co-principal investigators Justin Lathia, Ph.D., of Cleveland Clinic’s Lerner Research Institute, and Jill Barnholtz-Sloan, Ph.D., of Case Western Reserve University School of Medicine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We have the molecular profiling technology and the computing and analytical strength to lead in this effort to better understand the role of sex differences in cancer, particularly for glioblastoma,” said Dr.<span> </span><a href="https://case.edu/cancer/members/member-directory/jill-s-barnholtz-sloan" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Barnholtz-Sloan</a>, the Sally S. Morley Designated Professor in Brain Tumor Research and associate director of Data Sciences at the Case Comprehensive Cancer Center, Case Western Reserve School of Medicine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“This next phase of research relies on vast, varied, and complex datasets — in animals and humans — and promises to be a game-changer in how we understand the role of sex in tumor formation and disease outcomes. This comprehensive approach has applications to all forms of cancer, as well as other diseases,” Dr. Barnholtz-Sloan said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Dr.<span> </span><a href="https://www.lerner.ccf.org/cms/lathia/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Lathia</a><span> </span>is the vice chair of the Department of Cardiovascular and Metabolic Sciences and co-director of the Brain Tumor Research & Therapeutic Development Center of Excellence at Lerner Research Institute, and co-leader of the Molecular Oncology Program at the Case Comprehensive Cancer Center.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Sex differences are inherent drivers of glioblastoma incidence and survival and we are taking a multidimensional approach to uncover a better understanding of this differentiation,” Dr. Lathia said. “We are incorporating data from tumor cells and their surrounding micro-environment, as well as genetic programs responsible for tumor growth, and underlying epigenetic differences that may be responsible for sex differences. We aim to gain a better understanding of how these variables interrelate to better understand disease mechanism, which in turn defines better diagnostics and more personalized therapies for patients.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The multi-disciplinary project involves established investigators with complementary expertise and a strong collaborative history. Along with Dr. Lathia and Dr. Barnholtz-Sloan, participating principal investigators include: Dr. Berens of TGen; Joshua Rubin, M.D., Ph.D. of<span> </span><span style="box-sizing:border-box;border-radius:0px;">Washington University School of Medicine in St. Louis</span>; and James Connor, Ph.D., of Penn State College of Medicine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The study’s three related research projects will delve into the basic biology and cellular mechanisms that drive sex differences in glioblastoma formation and progression. These related research projects will inform, synergize and depend on each other. Findings from the labs based on their animal models will then be queried against data from human clinical samples across multiple institutions. The vast amount of data generated from these studies requires robust data management and sophisticated data analysis for a comprehensive view of sex differences across these diverse but related inquiries.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Comprehensive findings will inform future clinical research design, the search for targets for new therapeutics, or the use of existing therapeutics that may be applied differently depending on a patient’s sex.   </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This NCI grant —<span> </span><em style="box-sizing:border-box;border-radius:0px;">Sex-based Differences in Glioma</em><span> </span>— was awarded under number 1P01CA245705.</p> </div> </div> <br> <br> </h4> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/82/dr_michael_berens.jpg2020-09-17T07:00:00ZTGen
Women in Medicine Fighting COVID-19: Denege Ward-Wright, MDWomen in Medicine Fighting COVID-19: Denege Ward-Wright, MD<div class="ExternalClass2BBCC94ADDF24203A1E00A742FAF37DA"><html> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:16px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field field--name-field-news-media-contact-ref field--type-entity-reference field--label-hidden field__item"><article class="node node--type-media-contact node--promoted node--view-mode-default" role="article" style="box-sizing:border-box;display:block;"><div style="margin-bottom:1.5rem !important;display:flex;box-sizing:border-box;flex-wrap:nowrap !important;align-items:center !important;" class="d-flex flex-nowrap align-items-center mb-4"> <h5 style="box-sizing:border-box;margin-top:0px;margin-bottom:0px !important;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:normal;line-height:18px;color:rgb(155, 155, 155);font-size:15px;margin-right:0.5rem !important;text-transform:uppercase !important;" class="field_title text-uppercase mb-0 mr-2"><span style="box-sizing:border-box;" class="field field--name-title field--type-string field--label-hidden">TERESA JOSEPH</span> </h5> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <a target="_blank" href="https://twitter.com/uazmedphx/" style="box-sizing:border-box;background-color:transparent;color:rgb(1, 28, 72);text-decoration:none;" class="field_media_contact_twitter_url"> <em></em> </a> </h4> </div> </article> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;margin-bottom:1rem !important;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(33, 33, 33) !important;font-size:1.25rem;font-style:normal;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item">Hospitalist Helped Develop Inpatient COVID Tele-Visits to Reduce Physician Exposure</div> </h4> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:17px;line-height:23px;margin-bottom:3rem;padding-bottom:1rem;border-bottom:1px solid rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <em>In honor of this year’s <a target="_blank" href="https://phoenixmed.arizona.edu/diversity/wims" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;">Women in Medicine and Science</a> month, the University of Arizona College of Medicine – Phoenix has asked a few faculty to share their inspiring stories and work that is helping our community through the <a target="_blank" href="https://phoenixmed.arizona.edu/covid-19" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration:underline;transition:all 0.3s ease 0s;">coronavirus pandemic</a>.</em> </p> </h4> <h2 style="box-sizing:border-box;margin-top:0px;margin-bottom:0.5rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;color:rgb(30, 82, 136);font-size:2.1875rem;"> <figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:0px;height:auto;background-color:rgb(232, 237, 243) !important;"> <div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"> <img data-entity-type="file" data-entity-uuid="01f5a41d-2f5b-4a42-9598-a99d6480d4ed" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/wright-story.jpg" alt="Denege Ward-Wright, MD" style="margin:5px;border:0px;width:0px;vertical-align:middle;max-width:100%;box-sizing:border-box;" class="img-fluid" title="Denege Ward-Wright, MD" /> </div> <figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;display:block;font-size:14px;color:rgb(96, 96, 96);margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;line-height:20px;"> <em style="box-sizing:border-box;">Denege Ward-Wright, MD</em> </figcaption> </figure>Denege Ward-Wright, MD</h2> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">During the pandemic, Denege Ward-Wright, MD, has led the way in helping the hospital set-up telehealth and video conferences for inpatient COVID cases, which is designed to decrease physician exposure while still providing quality patient care.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Ward-Wright is a clinical associate professor in the Division of Hospital Medicine at the University of Arizona College of Medicine – Phoenix. She has been affiliated with the medical school since 2018.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">Describe your experience working during the pandemic</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Personally, I have been practicing for about 30 years and during my residency, HIV and AIDS were just being discovered and treated. So, I was experienced in managing patients with unknown pathology and disease process, as well as the anxiety it brings for patients and health care workers treating patients with high rates of fatality and little known treatment options. As an attending in internal medicine, I was also treating patients during the H1N1 pandemic, the threat of SARS-COV1 and MERS possible pandemics and then most recently preparing for the possible Ebola pandemic that fortunately did not materialize.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">I had some anxiety and fear during those times, but I think my curiosity for infectious disease and treating patients superseded my fears. I’ve learned that you must respect diseases and take the most appropriate precautions to mitigate infections and to follow the science. During this pandemic with COVID-19, I was fortunate to have expert pulmonologists, infectious disease specialists and cardiologists who supported and educated the hospitalist in management. Our hospitalist teams were organized and we disseminated information in a controlled and precise manner to alleviate misinformation and help develop standards of care and algorithms for this population of patients. There was daily support in our management. The most amazing experience is working with nurses, nurse practitioners, physician assistants, dieticians, clerks and environmental services who worked with these patients and provided 24-hour care with no visible anxiety and comforted these patients daily.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Working with COVID-19 patients has helped me accept the mitigation practices all of us need to take to prevent the spread. The constant politicizing of this disease has made it difficult as there are still some patients and families that cannot accept the measures needed to ensure public safety and that has also been challenging.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">What advice or words of encouragement do you have for other physicians during this time of uncertainty?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Paying attention to the science and public health policies is a pathway of understanding, and that is helpful in trying to protect each other’s safety. I think if we respect this disease and accept that lifestyles have changed then it helps to move forward. Try to look at the positives that have come out of this, prioritizing what is important in our happiness such as the closeness that we developed or rediscovered in our families and communities. Also, to be mindful of our feelings and take steps to our own wellness — whether it be reading, exercising, listening to music or tapping in to whatever creative talents you may have.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">What would you like the community to know about your work during this time as a woman in medicine and science?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">I feel anxious at times; I am sometimes fearful of what the future may bring. However, paying attention to how patients have recovered and watching the trends improve in our cities and states brings about promise. I think women in medicine are mothers and daughters and have the same concerns for their family and communities. Also, we follow the science and public health experts to deliver the best care possible.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">What does your day-to-day look like right now?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Usually, I begin my day earlier to review charts and before I do my rounds, I put on all my PPE and see my patients. Not much has changed in my rounding with patients. I’ve gotten used to talking through masks and a face shield, and I notice patients have, as well. This pandemic has made it to where I can no longer give a patient a hug. I also find myself no longer going back and forth to the patient rooms as much as before to limit exposure.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <strong style="box-sizing:border-box;font-weight:bolder;">Can you describe the inpatient telehealth system you helped set-up?</strong> </p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Banner has been using telehealth in the ambulatory setting to facilitate patient appointments. In the inpatient setting, we have some designated rooms where there is a camera attached to the TV and physicians can communicate with those patients who are able through a secure program at a hospital workstation or website for a tele-visit. This currently operates only while in the hospital with the goal to limit exposure to COVID positive patients. It has limitations, as the patient needs to be able to communicate and is only present in designated rooms.</p> </h4> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <br>​<br></h4> <p> <br> </p> </html></div>2020-09-16T07:00:00ZUA
Ashion Analytics announces innovative cancer treatment partnership with Elevation OncologyAshion Analytics announces innovative cancer treatment partnership with Elevation Oncology<div class="ExternalClassDA589023AF34469082BC9DF9D4102CB6"><html> <p></p><span id="ms-rterangepaste-start"></span><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"><span style="box-sizing:border-box;" class="xn-location">PHOENIX</span>,<span> </span><span style="box-sizing:border-box;" class="xn-chron">Sept. 16, 2020</span><span> </span>/PRNewswire/ -- <a rel="nofollow" target="_blank" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Ashion Analytics LLC</a><span> </span>today announced a partnership with<span> </span><span style="text-decoration:underline;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=2236143105&u=http://www.elevationoncology.com/&a=Elevation+Oncology" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Elevation Oncology</a></span>, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion's proprietary GEM ExTra® test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">NRG1 gene fusions are a rare genomic alteration implicated as a driver of tumorigenesis and growth across many types of solid tumors, including lung, breast, pancreatic, ovarian, and colorectal cancers.<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=2157809113&u=https://nrg1fusion.com/&a=CRESTONE" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">CRESTONE</a><span> </span>— or<span> </span><span style="text-decoration:underline;">C</span>linical study of<span> </span><span style="text-decoration:underline;">RE</span>sponse to<span> </span><span style="text-decoration:underline;">S</span>eribantumab in<span> </span><span style="text-decoration:underline;">T</span>um<span style="text-decoration:underline;">O</span>rs with<span> </span><span style="text-decoration:underline;">NE</span>uregulin 1 (NRG1) fusions — provides an investigational treatment opportunity for patients with any advanced solid tumor who have not responded or are no longer responding to standard cancer treatment, and whose tumor has tested positive for an<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=802101388&u=https://nrg1fusion.com/wp-content/uploads/2020/07/EO0003-001-000_NRG1-fusion-1-pager.pdf&a=NRG1" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">NRG1</a><span> </span>fusion.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This partnership creates a new dynamic in the way cancer patients can be matched to precision medicine therapeutics. By first identifying a genetic driver that has an available targeted therapy option, in this case an NRG1 fusion and the investigational therapy seribantumab, the diagnostic technology, data insights, and network reach at Ashion Analytics can be leveraged to efficiently identify and directly match eligible patients to the CRESTONE trial using test results that are already available today, while also maximizing the value of every additional test.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">"The comprehensive nature of the GEM ExTra test means that its value grows directly with each new genomic driver that is identified and each new precision therapy under development," said<span> </span><span style="box-sizing:border-box;" class="xn-person">Laurie Goodman</span>, Ph.D., Ashion Analytics Director of Business Development and Medical Affairs. "Partnerships like this enable us to continuously facilitate the ability for our patients to receive the most up-to-date information about the emerging treatment opportunities available to them today."</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=862518699&u=https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/&a=Ashion+Analytics+recently+announced" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Ashion Analytics recently announced</a><span> </span>that Medicare has approved coverage of its proprietary cancer profiling test,<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=638858039&u=http://ashion.com/physicians-2/&a=GEM+ExTra" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">GEM ExTra</a>®, one of the nation's most comprehensive genomic cancer analysis tests. Medicare coverage enables potentially 44 million more patients to afford this test, which aims to match patients with best available treatments for their disease.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=915260637&u=https://www.tgen.org/news/2020/june/11/tgen-s-ashion-certified-for-nci-match/&a=GEM+ExTra" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">GEM ExTra</a><span> </span>detects tumor-specific mutations in both DNA and RNA, allowing physicians to make the best-available treatment recommendations for patients with advanced solid tumors. An Ashion study poster presented at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=3353191598&u=https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u%3D6b0e128788a10661a1fb2d549%26id%3D80cc45bf65%26e%3Dbcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOToaeHqm$&a=Employing+RNA+Sequencing+to+Enhance+Treatment+Options+for+Cancer+Patients" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</a>.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This leading-edge test provides treating physicians with vital interpreted information needed to understand changes to a patient's genomic profile. It outlines a therapeutic treatment plan best suited for each patient. Conditions that may benefit from this approach include treatment of refractory, rare or aggressive cancers.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">"We are partnering with Ashion Analytics because we recognize the sensitivity and continuing potential of their GEM ExTra cancer profiling test," said<span> </span><span style="box-sizing:border-box;" class="xn-person">Shawn Leland</span>, PharmD, RPh, Founder and Chief Business Officer of Elevation Oncology. "Elevation Oncology is committed to expanding the benefit of precision medicine to all patients with cancer by developing therapies that make results from tests like GEM ExTra clinically actionable, no matter how rare the finding. Close collaboration between diagnostic and therapeutic developers is critical to re-thinking our approach to clinical trial enrollment as an industry and finding more efficient ways to bring the right treatment opportunities to the patients that need them."</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">For more information about seribantumab and the CRESTONE study, please visit<span> </span><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=1504483846&u=http://www.nrg1fusion.com/&a=www.NRG1fusion.com" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">www.NRG1fusion.com</a>.</p><p style="box-sizing:border-box;margin:0px 0px 35px;font-size:16px;line-height:1.8;color:rgb(55, 55, 55);font-family:montserrat, helvetica, arial, sans-serif;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Ashion Analytics is a clinical laboratory of the<span> </span><span style="text-decoration:underline;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=4084671636&u=https://www.tgen.org/&a=Translational+Genomics+Research+Institute+%28TGen%29" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">Translational Genomics Research Institute (TGen)</a></span>, an affiliate of<span> </span><span style="text-decoration:underline;"><a rel="nofollow" target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2917086-1&h=4122051859&u=https://www.cityofhope.org/homepage&a=City+of+Hope" style="box-sizing:border-box;background-color:transparent;color:rgb(0, 131, 126);text-decoration:none;word-break:break-word;">City of Hope</a></span>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.​<br></p><span id="ms-rterangepaste-end"></span><p>​​<br></p> </html></div>2020-09-16T07:00:00ZAshion Analytics
Discovering New Medicines in Arizona: 2nd Annual Drug Discovery and Development Summit Watch on DemandDiscovering New Medicines in Arizona: 2nd Annual Drug Discovery and Development Summit Watch on Demand<div class="ExternalClassC32C90E66DBF4EF28C0D5A79EF8BCBC6"><html> <p>​<span style="color:#333333;">Presented by the <a href="https://www.pharmacy.arizona.edu/centers/arizona-center-drug-discovery" target="_blank"><strong><span style="color:#ab0520;text-transform:uppercase;">ARIZONA CENTER FOR DRUG DISCOVERY</span></strong></a> and the <a href="https://cancercenter.arizona.edu/" target="_blank"><strong><span style="color:#ab0520;text-transform:uppercase;">UNIVERSITY OF ARIZONA CANCER CENTER</span></strong></a>. The Discovering New Medicines in Arizona Summit will highlight key areas of research in discovering effective drug candidates in prevalent diseases in Arizona while establishing collaborations that enable success in these key areas. Speakers include leaders from Bristol Myers Squibb, TGen, University of Arizona Cancer Center, Arizona State University <span style="background:white;">Center for Immunotherapy, Vaccines and Virotherapy.</span></span><span style="color:black;background:white;"> Watch it <a href="https://www.pharmacy.arizona.edu/event/2020/discovering-new-medicines-arizona-2nd-annual-drug-discovery-and-development-summit" target="_blank">here</a>. </span><span style="color:#333333;"> ​</span></p> <p><br></p></html></div>2020-09-15T07:00:00ZUA
ARIZONA COVID-19 GENOMICS UNION TRACKS STRAINS OF SARS-COV-2ARIZONA COVID-19 GENOMICS UNION TRACKS STRAINS OF SARS-COV-2<div class="ExternalClassDF28E954B8354AFABD2C361F544659DC"><html> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span> </span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Steve Yozwiak"> <span style="box-sizing:border-box;border-radius:0px;">Steve Yozwiak</span> </a> </span> </div> </li> <span> </span> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;"></li> </ul> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;">Posted Tuesday September 15, 2020<br></li> </ul> </h4> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Molecular clock analysis showed no widespread ‘community’ distribution of the highly contagious coronavirus disease in Arizona until mid-February</em> </p> </h4> </div> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">FLAGSTAFF, Ariz. — Sept. 15, 2020 —</strong> <span> </span>Initial findings reported by the Arizona COVID-19 Genomics Union (ACGU) suggest that following Arizona’s first reported case of COVID-19 in late January, the state experienced no cases that went undetected and was COVID-free until at least 11 distinct incursions occurred between mid-February and early April.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The published results appear in the scientific journal<span> </span><em style="box-sizing:border-box;border-radius:0px;">mBio</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Faculty at the<span> </span><a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Translational Genomics Research Institute (TGen)</a>, an affiliate of<span> </span><a target="_blank" href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">City of Hope</a>, Northern Arizona University (NAU), University of Arizona (UArizona) and Arizona State University (ASU) launched the ACGU in April with the express purpose of tracking the causative agent of COVID-19, SARS-CoV-2: how it evolves and how it spreads into, within and out of Arizona.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The ACGU sequenced the SARS-CoV-2 genomes in as many virus-positive patient samples in Arizona as possible, and working with Arizona’s public health officials, applied the results toward statewide efforts to test and track patients, as well as provide guidance for Arizona public policy makers.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Quick action by ASU and Maricopa County public health officials, ACGU scientists agree, likely kept the first identified COVID-19 patient in Arizona — a student who had just returned from Hubei, the Chinese province where the disease originated — from igniting an outbreak, and prevented Arizona from becoming an early epicenter for the contagion.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“This is a great example of how a rapid and thorough public health response can be successful in preventing the spread of this disease,” said ACGU Director<span> </span><a target="_blank" href="https://www.tgen.org/faculty-profiles/paul-keim/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. Paul Keim</a>, Regents’ Professor of Biological Sciences and Cowden Endowed Chair in Microbiology at NAU and Executive Director of NAU’s Pathogen and Microbiome Institute.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“Similar steps could be taken when shaping future efforts to reopen businesses and schools, even though the virus continues to circulate and people remain susceptible,” added Keim, who is also a Distinguished Professor and Co-Director of TGen’s Pathogen and Microbiome Division.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://profiles.arizona.edu/person/worobey" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. Michael Worobey</a>, an ACGU co-founder and the head of University of Arizona’s Department of Ecology and Evolutionary Biology, agrees.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“It’s a combination of the patient doing the right things to isolate himself and be aware that he possibly had this disease, and public health officials doing all the right things. Stopping an incursion of COVID-19 was a victory for the state of Arizona,” Dr. Worobey said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This bought Arizona valuable time for preparedness efforts. The first reported case of “community” transmission occurred in Arizona in early March descended from the Washington state outbreak that was discovered in February. More than 80% of the SARS-CoV-2 genome sequences from Arizona COVID-19 cases descended from at least 11 separate lineages that were initially circulating widely in Europe, and by travel have since dominated the outbreak throughout the U.S. None of the observed transmission clusters are epidemiologically linked to the original travel-related case in the Arizona, suggesting successful early isolation and quarantine.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The ACGU uses state-of-the-art sequencers, custom computational analysis workflows, and supercomputers to determine the sequence of the virus’s RNA genome, which is just under 30,000 bases long. In contrast, there are nearly 3 billion bases in the human genome, which determine traits as simple as eye and hair color, and as complex as an individual’s propensity for cancer and other disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">TGen has so far sequenced SARS-CoV-2 genomes from nearly 3,000 COVID-19 positive samples for the ACGU, and additional sequencing was performed at ASU and UArizona, from among the more than 200,000 positive cases in Arizona, making it one of the most robust such efforts in the nation. ACGU receives Arizona samples collected by state, county, tribal and private healthcare systems.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">ACGU scientists take advantage of small changes or mutations in the virus’ genome, which naturally occur over time as the virus reproduces, to track the spread of the virus. By comparing mutations observed in Arizona to those present in strains circulating across the globe, they can determine when and from where the virus has been introduced to Arizona.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Using molecular clock analyses, researchers found that the majority of Arizona sequences are represented by two lineages — and several sub-lineages — most of which were likely introduced through domestic travel, but with some evidence for international importation.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“Through the ACGU, we are harnessing expertise in virology, genomics, evolution and bioinformatics from throughout Arizona in order to rapidly distill these genomic data into actionable insights that can complement the state’s public health response,” Dr. Keim said. “These results demonstrate the power of public health contact tracing and self-isolation following a positive test for stemming the tide of infections moving forward.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://www.tgen.org/faculty-profiles/david-engelthaler/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. David Engelthaler</a>, Director of TGen North in Flagstaff, which includes the institute’s infectious disease branch, said the initial ACGU findings show how each community, each state is writing its own story for what is happening in the COVID-19 pandemic.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“We need to understand all of those plot lines that have led to where we are now,” said Dr. Engelthaler, another of the co-founders of the ACGU. “Once this disease was detected in Arizona on Jan. 26, public health immediately jumped in to make sure that all contacts were identified, samples were collected and the patient was watched very closely for the next couple of weeks to make sure there were not any more cases.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">In the coming months, he said, it will be necessary to track COVID-19 outbreaks and build epidemiological walls around each case, especially for those most at risk: persons older than 65, those in long-term care facilities, prisons, and those with pre-existing health problems.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“When you don’t have eyes on this, when you don’t have contact tracing, then it can really easily move from person-to-person,” Dr. Engelthaler said. “It’s really useful for public policy makers to be making locally-informed decisions.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://biodesign.asu.edu/efrem-lim" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;">Dr. Efrem Lim</a>, a virologist who leads the ASU team, said the SARS-CoV-2 genome sequence data can give health care providers and public policy makers an edge in fighting the pandemic.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">“Tracking the transmission of the virus and its mutations ensures that therapeutics and vaccines being developed are on the right course,” said Dr. Lim, an assistant professor at ASU’s Biodesign Institute. “We now have a handle on what the SARS-CoV-2 virus in our communities looks like at the sequence level.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">This study —<span> </span><a target="_blank" href="https://mbio.asm.org/content/11/5/e02107-20" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;"><em style="box-sizing:border-box;border-radius:0px;">An Early Pandemic Analysis of SARS-CoV-2 Population Structure and Dynamics in Arizona</em></a><span> </span>— was supported by: The NARBHA Institute, Flinn Foundation, The Virginia G. Piper Charitable Trust, Blue Cross and Blue Shield of Arizona, the National Institutes of Health, the David and Lucile Packard Foundation, the University of Arizona College of Science and Office of Research Innovation and Impact, and BIO5 Institute.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">The authors acknowledge the critical role the Arizona Department of Health Services and multiple county and tribal health departments play in directing samples to the ACGU to be sequenced. Computational analyses were run on Northern Arizona University’s Monsoon computing cluster, funded by Arizona’s Technology and Research Initiative Fund (TRIF), administered by the Arizona Board of Regents. Additional analysis efforts also were funded by TRIF. Software development efforts were funded in part by the Chan-Zuckerberg Initiative and the Alfred P. Sloan Foundation. The Cowden Endowment for Microbiology provided funds to support salaries.</p> <br class="Apple-interchange-newline"> </div> </div> <br>​<br></h4> <span id="ms-rterangepaste-end"></span> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;font-weight:400;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;font-style:normal;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <a target="_blank" href="https://www.tgen.org/news/2020/september/15/acgu-initial-findings-of-the-pandemic/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Arizona COVID-19 Genomics Union tracks strains of SARS-CoV-2"> <span style="box-sizing:border-box;border-radius:0px;"></span> </a> </h2> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <br>​<br></h4> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/81/download (1).jpg2020-09-15T07:00:00ZTGen
TGEN AND MAYO CLINIC RESEARCHERS ID POTENTIAL TARGETS FOR THE MOST-DEADLY FORM OF PANCREATIC CANCERTGEN AND MAYO CLINIC RESEARCHERS ID POTENTIAL TARGETS FOR THE MOST-DEADLY FORM OF PANCREATIC CANCER<div class="ExternalClass2F585DFEE9694C8983894C91757DDC12"><html> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">​Written by</span> <span> </span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a href="https://www.tgen.org/news/?author=Steve+Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);text-decoration:none;outline:0px !important;" title="Steve Yozwiak" target="_blank"> <span style="box-sizing:border-box;border-radius:0px;">Steve Yozwiak</span> </a> </span> </div> <span id="ms-rterangecursor-start"></span> <span id="ms-rterangecursor-end"></span> <br> </li> <li style="border-radius:0px;color:rgb(85, 85, 85);padding-right:5px;padding-left:5px;font-style:italic;display:inline-block;box-sizing:border-box;">Posted Monday September 14, 2020<br><br></li> </ul> </h4> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Multi-year study published today tees-up clinical trials using patient-specific therapies</em> </p> </h4> </div> </div> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <strong style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX and SCOTTSDALE, Ariz. — Sept. 14, 2020 —</strong> <span> </span>A team of researchers led by<span> </span><a href="https://www.mayoclinic.org/about-mayo-clinic?_ga=2.193260206.246406646.1597880436-433202803.1558387184" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Mayo Clinic</a><span> </span>and the<span> </span><a href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of<span> </span><a href="https://www.cityofhope.org/homepage" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">City of Hope</a>, has identified specific potential therapeutic targets for the most aggressive and lethal form of pancreatic cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In what is believed to be the most comprehensive analysis of<span> </span><em style="box-sizing:border-box;border-radius:0px;">adenosquamous cancer of the pancreas</em><span> </span>(ASCP), the Mayo Clinic and TGen team identified, in preclinical models, therapeutic targets for this extremely fast-moving and deadly form of pancreatic cancer, and identified already available cancer inhibitors originally designed for other types of cancer, according to a study published today in<span> </span><em style="box-sizing:border-box;border-radius:0px;">Cancer Research</em>, a journal of the American Association for Cancer Research (AACR). </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“The rarity of ASCP, the scarcity of tissue samples suitable for high resolution genomic analyses, and the lack of validated preclinical models, has limited the study of this particularly deadly subtype of pancreatic cancer,” said<span> </span><a href="https://www.tgen.org/faculty-profiles/daniel-von-hoff/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Dr. Daniel Von Hoff</a>, Distinguished Professor and TGen’s Physician-In-Chief, considered one of the nation’s foremost authorities on pancreatic cancer, and one of the study’s authors. “We need entirely new possible approaches for our patients with ASCP.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Pancreatic ductal adenocarcinoma</em> <span> </span>(PDAC) is the most common form of pancreatic cancer, which this year is projected to kill nearly 57,600 Americans, making it the nation’s third leading cause of cancer-related death, according to the American Cancer Society. Among pancreatic cancer patients, a small percentage (less than 4%) are diagnosed with ASCP, a particularly aggressive form of pancreatic cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“ASCP currently has no effective therapies. Unlike PDAC, ASCP is defined by the presence of more than 30% squamous (skin-like) epithelial cells in the tumor. The normal pancreas does not contain squamous cells,” said the study’s senior author,<span> </span><a href="https://www.mayo.edu/research/faculty/barrett-michael-t-ph-d/bio-20178838" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank">Michael Barrett, Ph.D., who holds a joint research appointment at Mayo Clinic and TGEN.</a></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Our study has shown that ASCPs have novel ‘hits’ (mutations and deletions) in genes that regulate tissue development and growth superimposed on the common mutational ‘landscape’ of a typical PDAC. As a consequence, cells within the tumor have the ability to revert to a stem-cell-like state that includes changes in cell types and appearance, and the activation of signaling pathways that drive the aggressive nature of ASCP,’ said Dr. Barrett.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">While this activated aggressive stem-cell-like state is very resistant to current therapies for pancreatic cancer, Dr. Barrett said, the study has shown that ASCP can be targeted by drugs currently in clinical use for other cancers as well as non-cancer related conditions.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using multiple cancer analysis methods and platforms — including: flow cytometry, copy number analysis, whole exome sequencing, variant calling and annotation, ATAC-seq, immunofluorescence, immunohistochemistry, single cell sequencing, and organoid cultures and treatments — the Mayo Clinic and TGen research team conducted what is believed to be the most in-depth analysis of ASCP tissue samples.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Researchers identified multiple mutations and genomic variants that are common to both PDAC and the more aggressive ASCP. “Of significant interest,” the study says, the team also identified two potential therapeutic targets unique to ASCP genomes: FGFR signaling, including an<span> </span><em style="box-sizing:border-box;border-radius:0px;">FGFR1-ERLIN2</em><span> </span>gene fusion, and a pancreatic cancer stem cell regulator known as<span> </span><em style="box-sizing:border-box;border-radius:0px;">RORC</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">These data provide a unique description of the ASCP genomic and epigenomic landscape and identify candidate therapeutic targets for this lethal cancer, the study says.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using organoids, which are laboratory cultures derived from samples of patient tumors, researchers tested the activity and functional significance of candidate therapeutic targets. According to the study: “Specifically, organoids carrying the<span> </span><em style="box-sizing:border-box;border-radius:0px;">FGFR1-ERLIN2</em><span> </span>fusion show a significant response to pharmacological FGFR inhibition,” providing new candidate targets for developing therapies for patients with ASCP.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition, the study says, “To our knowledge, this is the first study to apply DNA content sorting to the genomic analysis of ASCP,” a method that purifies the cancer DNA from other cells and parts of cells, thereby eliminating any biological “noise” that might impede the precision of the analysis.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using an interrogation tool known as ATAC-seq, researchers also identified<span> </span><em style="box-sizing:border-box;border-radius:0px;">RORC</em><span> </span>as another distinguishing feature of ASCP.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Of significant interest will be clinical trials with<span> </span><em style="box-sizing:border-box;border-radius:0px;">FGFR</em><span> </span>and<span> </span><em style="box-sizing:border-box;border-radius:0px;">RORC</em><span> </span>inhibitors that include correlative studies of genomic and epigenomic lesions in both ASCP and PDAC,” the study concludes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Also contributing to this study —<span> </span><a href="https://cancerres.aacrjournals.org/content/early/2020/09/12/0008-5472.CAN-20-0078" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);text-decoration:none;outline:0px !important;" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas</em></a><span> </span>— were: Virginia G Piper Cancer Center at HonorHealth; University of California, San Diego School of Medicine; Salk Institute for Biological Studies; Memorial Sloan Kettering Institute; and University of Nebraska Medical Center (UNMC). </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Funding for this study was provided by: the Lee Hanley Foundation; TGen’s annual<span> </span><em style="box-sizing:border-box;border-radius:0px;">stepNout</em><span> </span>pancreatic cancer fundraising; a Pancreatic Cancer Dream Team Research Grant through Stand Up to Cancer (SU2C) and Lustgarten-Cancer Research UK (CRUK); Damon Runyon Cancer Research Foundation; the National Institutes of Health (NIH); the Pancreatic Cancer Collective New Therapies Challenge; and a fellowship through the Tobacco Related Disease Research Program.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition, Mayo Clinic Cancer Center is supported by a Cancer Center Support Grant from the National Institute of Cancer (NCI).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The UNMC Tissue Bank Rapid Autopsy Program for Pancreas is supported by the following:<span> </span><span style="box-sizing:border-box;border-radius:0px;">Specialized Program of Research Excellence (</span>SPORE) in Pancreatic Cancer; Pancreatic Cancer Detection Consortium; an NCI Cancer Center Support Grant; and an NCI Research Specialist.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The authors declare no conflicts of interest.</p> </div> </div> <br> <br> </h4> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/79/dr_daniel_von_hoff (1).jpg2020-09-14T07:00:00ZTGen
Phoenix Invests Big in Health Care and Biosciences, Hoping to Boost Economy and Add JobsPhoenix Invests Big in Health Care and Biosciences, Hoping to Boost Economy and Add Jobs<div class="ExternalClass472800B53D104192AA9A2774F7E386BD"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;">Claudia Whitehead turns from her computer screen and picks up her phone. The caller is the CEO of a Phoenix-based biosciences company calling to tell the program manager in the Phoenix Community and Economic Development Department that it landed $1 million in seed money to advance its contribution in the search to cure cancer. The company needs help in expanding its workforce. ​​​​</em> <br style="box-sizing:border-box;"> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;"></em> <img style="margin:5px;border:0px;width:200px;vertical-align:baseline;max-width:100%;box-sizing:border-box;" alt="Photo, Claudia Whitehead, program manager" src="https://www.phoenix.gov/econdevsite/MediaAssets/STAFF-20180222-Whitehead-Claudia-450PX.jpg" /> <em style="box-sizing:border-box;">To get the ball rolling, Whitehead will confer with a teammate at the Phoenix Business and Workforce Development Center, part of the city's Arizona@Work career program. A representative from GateWay Community College’s LabForce will be swept into that conversation. Within a matter of hours, work begins to set up a custom training program to help the company grow out of its incubator. It's just another service from city of Phoenix to the growing bioscience healthcare industry sector in the city.</em> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;">"Bioscience healthcare has become one of our core industry sectors," said Whitehead. "When we started talking with Amanda Morris, bioscience reporter for The Arizona Republic, it became apparent that Phoenix is a major global center for life-changing bioscience achievements. The work being accomplished with precision medicine and cancer research is like something from science fiction. In Phoenix, we have the ecosystem in bioscience to take the future of medicine from discovery to delivery."</em> <br style="box-sizing:border-box;"> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;"> <em style="box-sizing:border-box;">Amanda Morris, the bioscience reporter for the The Arizona Republic, pulls back the curtain and unveils how 7,000 new jobs in bioscience healthcare are to be dispersed around the growth in the sector.</em> <br style="box-sizing:border-box;"> </p> </h4> <h3 style="margin-top:3px;margin-right:0px;margin-bottom:10px !important;margin-left:0px;font-weight:600;font-family:montserrat, "open sans", sans-serif !important;color:rgb(0, 0, 0);font-size:26px;display:block;letter-spacing:-0.4px;line-height:28px !important;box-sizing:border-box;font-style:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Companies are investing billions in Phoenix's bioscience and health care industries, which is expected to bring 7,000 new jobs.<br style="box-sizing:border-box;"></h3> <h4 class="n_gEPV1NTWQkXX0HDg_0 ap_gEPV1NTWQkXX0HDg_0 inheritFontFamily"> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;text-align:center;"> <em style="box-sizing:border-box;">By Amanda Morris for The Arizona Republic</em> </p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Phoenix recovered more slowly than the rest of the nation after the Great Recession, taking years to recoup lost jobs. <br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">But this time around, the region might see faster recovery from the COVID-19 recession.<br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">One big reason is the city’s changing economic landscape, which has begun to rely less on construction and focus increasingly on sectors like health care and bioscience.<br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">Those industries are more resilient in the face of economic changes, said Christine Mackay, community and economic development director for the city of Phoenix. She said the city has seen significant growth in health care and bioscience over the past few years.<br style="box-sizing:border-box;"></p> <p style="margin-bottom:14px;display:block;font-family:hind, "open sans", sans-serif !important;font-size:16px;line-height:18px !important;box-sizing:border-box;color:rgb(0, 0, 0);font-style:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;background-color:rgb(255, 255, 255);text-decoration-style:initial;text-decoration-color:initial;">​Read the full story in<span> </span><a style="color:rgb(32, 173, 149);text-decoration:none;background:transparent;font-family:hind, sans-serif;transition:all 0.2s ease-in-out 0s;box-sizing:border-box;" href="https://www.azcentral.com/in-depth/news/local/arizona-science/2020/09/13/bioscience-and-health-care-industries-expand-and-add-jobs-phoenix/3392691001/" target="_blank">The Arizona Republic</a>.</p> <br>​<span id="ms-rterangecursor-start"></span><span id="ms-rterangecursor-end"></span><br></h4> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/85/Newsroom_CED_0057.jpg2020-09-14T07:00:00ZCity of Phoenix
CITY OF HOPE, TGEN RESEARCHERS FIND LINK BETWEEN GUT MICROBIOME AND CANCER TREATMENT OUTCOMESCITY OF HOPE, TGEN RESEARCHERS FIND LINK BETWEEN GUT MICROBIOME AND CANCER TREATMENT OUTCOMES<div class="ExternalClass75E1D49F7BFA49A5AAEE69D41DA3CD37"><html> <p style="text-align:left;"><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span><span class="uBlogsy_author_name" style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;"><a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" title="Steve Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">Steve Yozwiak</a></span></p> <p style="text-align:center;"><br></p> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"><div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"><em style="box-sizing:border-box;border-radius:0px;">​Study highlights positive impact of microbial diversity on immunotherapy response and suggests that cancer patients should eat a high-fiber diet with fruits, vegetables and grains with resistant starches</em></p></div></div><div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"><div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:855px;" class="col-md-12"><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">FLAGSTAFF, Ariz. and </span><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">DUARTE, Calif. — Aug. 19, 2020 —</span> Physicians at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, working in collaboration with scientists at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens. Their findings are outlined in a study published today in the journal <em style="box-sizing:border-box;border-radius:0px;">European Urology.</em></p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We also reported the changes over time in the gut microbiome that occur during the course of therapy — the cumulative findings from our report open the door to therapies directed at the microbiome,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/people/pal-sumanta" target="_blank">Sumanta Pal</a>, M.D., one of the study’s senior authors and co-director of the Kidney Cancer Program at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The gut microbiome is composed of microbes like bacteria and viruses that reside in the gastrointestinal tract. In recent years, an increase in knowledge about the microbiome in relation to general health has led to deeper explorations of its role in disease states, as well as how the organisms may interact with treatments.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Previous studies have suggested a relationship between the gut microbiome and response to immunotherapy in solid tumors, including metastatic kidney cancer,” said Nicholas Salgia, B.Sc., a clinical research assistant at City of Hope and the paper’s lead author. “The results from our study build on earlier findings and reaffirm that the diversity and composition of patients’ microbiomes are associated with clinical responses to anti-cancer therapies.”</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study, which collected data from 31 people with metastatic kidney cancer, features the first reports of comparing microbiome sequencing at different time points in cancer patients. Participants were asked to provide up to three stool samples: at baseline, four weeks into therapy and 12 weeks into therapy.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Using the clinical trial results, the team was able to identify changes in the microbiome over time in kidney cancer patients receiving immunotherapy. The findings found that a greater variety of organisms was associated with a benefit to the patients, and also suggested that modulating the gut microbiome during the course of treatment may impact responses to therapy.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The patients with the highest benefit from cancer treatment were those with more microbial diversity, but also those with a higher abundance of a specific bacterium known as <em style="box-sizing:border-box;border-radius:0px;">Akkermansia muciniphila</em>,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/sarah-highlander/" target="_blank">Sarah Highlander</a>, Ph.D., a research professor in TGen’s Pathogen and Microbiome Division and one of the study’s senior authors. “This organism has been associated with benefit in other immunotherapy studies.”</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Highlander says one potential takeaway is that oncologists might encourage patients to pay attention to their gut microbiome by eating a high-fiber diet, including fruits and vegetables high in fructo-oligosaccharides such as bananas, dried fruit, onions, leeks, garlic, asparagus and artichokes, as well as grains with resistant starches such as barley or uncooked potato starch, for example.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Highlander says that next steps should include expanding the relatively small study to a much larger group of patients that are followed over a longer time period. At City of Hope, researchers have already embarked on a clinical trial to further explore the idea that modulating the microbiome during therapy could have an impact on clinical outcomes.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We have randomized patients with metastatic kidney cancer to receive a probiotic supplement in addition to an FDA-approved immunotherapy regimen or the immunotherapy alone,” explained Salgia. “This work provided a strong framework for such a study.” </p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The collaborations between clinical experts at City of Hope and basic science colleagues at TGen have contributed to advancements in the understanding of not just the microbiome, but also in cancer biology and clinical outcomes at large.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Our strong relationship with the microbiome team at TGen has fruitfully produced novel insights into the clinical implications of the microbiome in kidney cancer, among other cancer types,” said Pal, who is an internationally recognized leader in the area of genitourinary cancers.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Just last month, City of Hope and TGen <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/breakthroughs/creating-personalized-roadmaps-to-treat-kidney-cancer" target="_blank">launched a project</a> to use one of the world’s most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“This current study is a further testament to the collaborative research structure we’ve developed between the affiliate institutions,” said Pal. “Through these collaborations we can implement both a bench-to-bedside and bedside-to-bench research model that will lead to better patient care at City of Hope through access to clinical trials and precision medicine approaches.”</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The paper, titled “<a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.europeanurology.com/article/S0302-2838%2820%2930543-1/fulltext" target="_blank">Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors</a>,” features additional City of Hope and TGen authors, along with a researcher from the Centro de Oncologia do Paraná in Curitiba, Brazil. Portions of the work were supported by a grant from Bristol-Myers Squibb.</p>​<br><br></div></div><p><br></p> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/77/dr-sarah-highlander.jpg2020-08-19T07:00:00ZTGen
Medical Students Explore Efficacy of Potential COVID-19 TherapeuticMedical Students Explore Efficacy of Potential COVID-19 Therapeutic<div class="ExternalClassEC9C84727A7247D0919F22C1470F7407"><html> <p style="text-align:center;">​​<span style="font-size:12px;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";background-color:window;">Medical Students Ryan Farhat, Mohammad Mousa and Eshaan Daas</span></p> <div style="box-sizing:border-box;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;font-size:1.25rem;margin-bottom:1rem !important;color:rgb(33, 33, 33) !important;" class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item">Perspective Analyzes the Clinical and Historical Information Available on Convalescent Plasma Transfusion</div> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:17px;line-height:23px;margin-bottom:3rem;padding-bottom:1rem;border-bottom:1px solid rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Three medical students at the University of Arizona College of Medicine – Phoenix are trying to improve clinical decisions for <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/covid-19" target="_blank">COVID-19</a> by consolidating the clinical and historical information available on a treatment known as Convalescent Plasma (CP) Transfusion.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">This study was led by fourth-year medical students Ryan Farhat, Mohammad Mousa and Eshaan Daas, along with their mentor <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/about/news/inaugural-division-chief-pulmonary-medicine-critical-care-and-sleep-medicine-named" target="_blank">Marilyn Glassberg, MD</a>, chief of the Division of Pulmonary Critical Care and Sleep Medicine. Findings were published on July 28, 2020, in <em><a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://www.frontiersin.org/articles/10.3389/fmed.2020.00435/full" target="_blank">Frontiers in Medicine</a></em>.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p> <figure class="bg-light figure img-fluid align-right" role="group" style="box-sizing:border-box;display:inline-block;margin:0px 0px 1rem 1rem;float:right;max-width:0px;height:auto;background-color:rgb(232, 237, 243) !important;"> <div style="box-sizing:border-box;margin-bottom:0.5rem;line-height:1;" class="figure-img"> <img style="box-sizing:border-box;border-width:0px;vertical-align:middle;max-width:100%;margin:5px;width:0px;" title="Marilyn Glassberg, MD" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/glassberg-story.jpg" data-entity-uuid="ac0e786d-522b-4a93-aafa-f6982ba9719d" data-entity-type="file" class="img-fluid" alt="Marilyn Glassberg, MD" /> </div> <figcaption class="figure-caption mb-1 px-2 text-right" style="box-sizing:border-box;font-size:14px;line-height:20px;margin-bottom:0.25rem !important;padding-right:0.5rem !important;padding-left:0.5rem !important;text-align:right !important;"> <em style="box-sizing:border-box;">Marilyn Glassberg, MD</em> </figcaption> </figure>There are more than 10 million cases and 500,000 deaths reported worldwide caused by COVID-19, with no effective treatment regimen. Historically, CP has been utilized in the treatment of viral respiratory pathogens. This study explored the efficacy of CP to facilitate an informed decision regarding the use of CP for COVID-19.<p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"></p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“With the rising mortality of COVID-19 and the lack of successful therapy, every possible treatment must be properly explored,” said Mousa. “CP is plasma with COVID antibodies from patients who have recovered from the virus. It has been used historically in previous virus outbreaks and a few early case reports have demonstrated that it may be beneficial for patients with active infections. CP is already being used in many hospitals around the world for those who are failing current treatment regimens. The need for a large randomized control trial is extremely necessary to determine if CP is effective.”</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">This project started during the initial phase of the current pandemic when the early studies in China were published. Mousa said that they were fortunate to work with Dr. Glassberg, who provided excellent mentorship and strong support during this project.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“There were a few potential therapies for COVID-19 when we started this project,” said Farhat. “We heard about hydroxychloroquine, remdesivir, azithromyocin and dexamethasone being effective in treating symptomatic patients. Convalescent plasma has been historically used to treat SARS and MERS, making us curious about its effectiveness in treating our current pandemic. We hope that the completed clinical trials can lead to an improvement in the morbidity and mortality worldwide.”</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The perspective looked at the advantages of CP against COVID-19 by analyzing studies using CP during SARS, influenza pandemic and MERS, which demonstrate potential for clinical efficacy during the COVID-19 pandemic. The perspective also highlighted the limitations of CP implementation — such as transfusion of blood products, specifically plasma, being associated with a few rare adverse effects.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">"Perspectives help direct future studies by identifying data that is needed to provide efficacy," Dr. Glassberg said. “Ryan, Mohammad and Eshaan had a specific question: 'Would CP be efficacious?' Our perspective suggested that more studies needed to be done, with the most recent trial suggesting that the timing and titer of neutralizing antibodies make a difference in outcome."</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">After evaluating the advantages and limitations of CP, the study said that there is promise in this treatment option for patients with COVID-19. They added that there are currently multiple randomized trials in progress evaluating the effectiveness of CP.</p><p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“We hope our work contributes to the advancement of our understanding of this virus and results in positive health care outcomes,” Daas said. “Lastly, while novel treatment options are explored by researchers around the world, it is still a collective duty to keep our community healthy with measures such as social distancing, wearing a mask and hand washing.”<br></p></div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/76/covid-therapy-header.jpg2020-08-18T07:00:00ZUA
New Jersey couple welcomes quadruplets at Banner hospital in PhoenixNew Jersey couple welcomes quadruplets at Banner hospital in Phoenix<div class="ExternalClassECA73AE07D5A477FBD7CB9A22B2ED5D8"><html> <p>​</p><span id="ms-rterangepaste-start"></span><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">PHOENIX (August 12, 2020) – First-time parents from New Jersey, Jennifer and Nicholas Stepenosky, welcomed four new babies into the world on June 16 at Banner – University Medical Center Phoenix, in spite of a global pandemic and other major health challenges.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">The Stepenoskys welcomed three baby girls and a baby boy – Caitlin, Addison, Emilia, and Elliott – at 27 weeks and 3 days.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">"After finding out we were going to have a high-order multiple pregnancy in early January, we knew this wasn't a normal pregnancy," said Jennifer. "It's high risk, and there is a lot more at stake since we would need more care to make sure the babies and myself were safe."</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Jennifer was first admitted to a hospital in Pennsylvania at just 16 weeks gestation after losing one of the five babies due to an incompetent cervix. This prompted the couple to start looking for alternative options for enhanced prenatal care.</p><h4 style="box-sizing:border-box;font-family:kyrialsanspro;line-height:1.1;color:rgb(34, 39, 72);margin-top:10px;margin-bottom:1em;font-size:18px;"><span style="box-sizing:border-box;font-weight:700;">Video: </span><a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="http://bannerhealth.mediaroom.com/nj_quadruplets_broll" target="_blank">Interviews and B-Roll of the Stepenoskys</a></h4><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">"Most doctors would say, 'You need to set up an appointment with Dr. Elliott,' [but] I was able to get his cell phone number from my support group and just called him directly," said Jennifer. "He was on the phone with me for 45 minutes without even knowing who I was or what my pregnancy looked like. He went through all the details of what we needed to do… I knew that we needed to come out here [to Phoenix] for treatment."</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">The Stepenoskys faced a very complicated pregnancy, but Dr. John Elliott, a perinatologist at <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.bannerhealth.com/locations/phoenix/banner-university-medical-center-phoenix" target="_blank">Banner – University Medical Center Phoenix</a> and Valley Perinatal Services – who assumed care of Jennifer and the babies while in utero – saw this as an opportunity to help the New Jersey couple to make their lifelong dreams of starting a family finally come true.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Jennifer made her first trip to Phoenix in March, shortly after she was discharged from a nearby hospital back home. During her first visit to Banner – University Medical Center Phoenix, Dr. Elliott performed a cerclage, also known as a cervical stitch. This is a treatment for cervical weakness, when the cervix starts to shorten and open too early during pregnancy, usually causing either a late miscarriage or preterm birth.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Jennifer was able to go home to New Jersey for several weeks following the cerclage. She returned to Phoenix at 23 weeks in her pregnancy and remained hospitalized at Banner – University Medical Center Phoenix until the birth of the quadruplets.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Dr. Elliott has extensive knowledge and experience in managing and delivering high-order multiplies. He first delivered a set of quadruplets in 1984 and has since delivered 110 quadruplets and 25 quintuplets. To Dr. Elliott’s knowledge, this was also the first case of a delayed internal delivery for a set of quintuplets in the world.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">After spending nearly three months in Phoenix, the Stepenoskys will be returning home today back to the East Coast. The four babies will be medically transported to a children’s hospital in Delaware. All four babies have made quick and successful progress with their development where each one has now doubled in size.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">“We are really looking forward to being back home with our family and friends,” said Jennifer. “It’s been a long yet rewarding journey and we can’t wait for them to meet the four new little additions to our family.”</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">The Stepenosky family will continue to post updates on the progress of each baby on their <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.facebook.com/FiveStepsForUs/" target="_blank">Facebook</a> and <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.instagram.com/fivestepsforus/" target="_blank">Instagram</a> accounts (@FiveStepsForUs) for those interested in following their story as a family of high-order multiples.</p><p style="box-sizing:border-box;margin:0px 0px 2em;font-size:1.188em;line-height:1.5em;color:rgb(51, 51, 51);font-family:kyrialsanspro;">Banner – University Medical Center Phoenix is a large teaching hospital that has provided medical care to Arizona and the Southwest since 1911. It is part of Banner – University Medicine, a premier academic medical network. The institution, which has trained thousands of doctors over decades as a teaching hospital, is the academic medical center for The University of Arizona College of Medicine – Phoenix. The hospital, recognized by U.S. News and World Report as one of the nation’s best hospitals, specializes in heart care, cancer care, high-risk obstetrics, neurosciences, organ transplants, medical toxicology and emergency care, including a Level I trauma center. Banner – University Medical Center Phoenix is part of Banner Health, a nonprofit health care system with 28 hospitals in six states. For more information, visit <a style="box-sizing:border-box;background-color:transparent;color:rgb(0, 137, 208);" href="https://www.bannerhealth.com/universityphoenix" target="_blank">bannerhealth.com/universityphoenix</a>.​<br></p><span id="ms-rterangepaste-end"></span><p><br></p></html></div>https://biomedicalphoenix.com/Lists/News/Attachments/65/Stepenosky_Quadruplets_2-medium.jpg2020-08-12T07:00:00ZUA
COMBAT STUDY PRELIMINARY RESULTS SHOW RESPONSE OF 32% IN TREATMENT OF PANCREATIC TUMORSCOMBAT STUDY PRELIMINARY RESULTS SHOW RESPONSE OF 32% IN TREATMENT OF PANCREATIC TUMORS<div class="ExternalClassADEF8C8F38B9487D8D35A7066FBE35C1"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Tuesday August 11, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="COMBAT study preliminary results show response of 32% in treatment of pancreatic tumors " href="https://www.tgen.org/news/2020/august/11/tgen-honorhealth-combat-fights-pancreatic-cancer/" target="_blank">COMBAT STUDY PRELIMINARY RESULTS SHOW RESPONSE OF 32% IN TREATMENT OF PANCREATIC TUMORS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen and HonorHealth investigators are encouraged with results and hope to show patient benefit in larger studies</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">SCOTTSDALE, Ariz. — Aug 11, 2020 —</span> Working with an international team of researchers, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth Research Institute</a> and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, <em style="box-sizing:border-box;border-radius:0px;">Nature Medicine</em>. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The “COMBAT trial” (NCT02826486) is a prospective, open label, phase IIa clinical trial for patients with metastatic pancreatic cancer, meaning their cancer had spread to other parts of the body. Patients were given pembrolizumab, an immune therapy drug, in combination with BL-8040, an agent that makes the tumor microenvironment more receptive to immune therapy. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study was conducted in Arizona at the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth Research Institute</a> and at 30 other locations in the U.S. and across the globe, including Spain, Israel and South Korea. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The two-part clinical trial began in September 2016: </p> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;"> <li style="box-sizing:border-box;border-radius:0px;">Cohort 1, a group of 37 patients whose cancer had already progressed on other therapies, were treated with pembrolizumab and BL-8040. Importantly, it appeared this combination therapy made pancreatic cancer more “hot,” meaning it could work in tandem with the body’s own immune system. Previous studies have shown pancreatic tumors to be “cold,” meaning immune therapies like pembrolizumab were not able to act on the cancer.</li> </ul> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;"> <li style="box-sizing:border-box;border-radius:0px;">Preliminary results of Cohort 2 were reported in the manuscript on a group of 22 patients (out of approximately 40 patients in total expected in the cohort), who had previously received one line of chemotherapy. These patients received pembrolizumab and BL-8040, as well as chemotherapy drugs 5-fluorouracil and nano-liposomal irinotecan.</li> </ul> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The percentage of meaningful tumor shrinkage was 32% in Cohort 2, which is double what is available for individuals with pancreatic cancer with traditional chemotherapy. While the study is small, these preliminary results are encouraging and there is hope that we will be able to do larger trials to see if the response to therapy is high and if it is better in comparison to traditional treatment,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/physicians/erkut-borazanci" target="_blank">Erkut Borazanci</a>, M.D., M.S., a medical oncologist and physician-investigator at HonorHealth Research Institute, a clinical associate professor at TGen, and one of the paper’s authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This clinical trial is currently in a follow-up phase of the study. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Pancreatic cancer is an aggressive disease that carries a high mortality rate. It is the third-leading cause of cancer death in the U.S., following lung and colorectal cancers. In 2020, the five-year survival rate for pancreatic cancer is 10%, which has increased from 6% in 2014.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Next steps for this research would be to compare this COMBAT combination therapy in future studies to other treatment options, such 5-fluorouracil, leucovorin and nano-liposomal irinotecan.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">COMBAT derives its name from letters in one of the study’s descriptions: <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">Com</span></span>bination of <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">B</span></span>L-8040 and Pembrolizum<span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">a</span></span>b in Patients with Metastatic Pancrea<span style="box-sizing:border-box;border-radius:0px;font-weight:700;"><span style="text-decoration:underline;">t</span></span>ic Cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The COMBAT treatment continues at the HonorHealth Research Institute. For more information, please go to <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/company/research-institute" target="_blank">HonorHealth.com/research</a>, call 480-323-1339 or email <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:clinicaltrials@honorhealth.com" target="_blank">clinicaltrials@honorhealth.com</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This research is supported by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.biolinerx.com/about" target="_blank">BioLineRx Ltd</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study – <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.nature.com/articles/s41591-020-0880-x" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial</em></a> – was published May 25, 2020, in <em style="box-sizing:border-box;border-radius:0px;">Nature Medicine</em>. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # # </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/74/dr_daniel_von_hoff.jpg2020-08-11T07:00:00ZTGen
25-YEAR DOLPHIN STUDY REVEALS FACTORS CONTRIBUTING TO AGING RATES IN LONG-LIVED MAMMALS25-YEAR DOLPHIN STUDY REVEALS FACTORS CONTRIBUTING TO AGING RATES IN LONG-LIVED MAMMALS<div class="ExternalClass2D3FBC4144364893A8D0DA3367F87064"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Monday August 10, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="25-year dolphin study reveals factors contributing to aging rates in long-lived mammals" href="https://www.tgen.org/news/2020/august/10/tgen-finds-dolphin-data-could-extend-human-longevity/" target="_blank">25-YEAR DOLPHIN STUDY REVEALS FACTORS CONTRIBUTING TO AGING RATES IN LONG-LIVED MAMMALS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">TGen-Epitracker analysis of U.S. Navy data uncovers groundbreaking science that may help delay aging in dolphins and humans</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. and SAN DIEGO, Calif. — Aug. 10, 2020 — </span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.epitracker.com/" target="_blank">Epitracker Inc.</a> and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, today announced the results from a groundbreaking, 25-year study of bottlenose dolphins that identified factors differentiating individuals with slow and accelerated aging rates.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study results, which will be published this week in the <em style="box-sizing:border-box;border-radius:0px;">Proceedings of the National Academy of Sciences</em>, highlights how biological differences between dolphins, living in the same natural ocean environment and receiving routine medical examinations under the care of the U.S. Navy, may inform new approaches to slow degradative processes associated with aging. </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Epitracker, a life sciences company applying metabolomics and other advanced omic technologies to discover therapeutics targeting aging-associated diseases, and TGen, a non-profit biomedical research institute, leveraged archived health data on 144 dolphins receiving meticulous care throughout their lives. These health data included 44 clinically relevant measurements on 5,889 biological routine samples collected throughout the dolphins’ lifetimes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Amazingly, this work all started with the sole intent of continually improving the health and welfare of dolphins,” said Stephanie Venn-Watson, D.V.M., M.P.H., co-founder and CEO of Epitracker Inc. and Seraphina Therapeutics, and the study’s lead author. “The fact that our work is resulting in groundbreaking approaches to delay aging and improve health for both dolphins and humans is a dream come true.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Navy dolphins, which on average live 50 percent longer than wild dolphins, consumed a controlled and well-maintained fish diet and received ongoing health monitoring and medical care. The routine health data and 44 measures collected over time were analyzed to determine aging rates and establish aging rate-related biomarkers that could also be studied in humans.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">TGen and Epitracker discovered four key biomarkers in dolphins associated with an accelerated aging rate. Two of these biomarkers, which already are used in assessing older people, decreased linearly with age: hemoglobin, used to detect anemia; and lymphocytes, used to detect immunosenescence, or weakened immunity. Importantly, while some dolphins had declines in these clinical biomarkers as they aged, including declines leading to clinical anemia and immunosenescence, others had no declines during the same aging timeframe.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While it has long been believed that there are factors influencing why some humans and mammals age faster than others, identifying those factors requires a data set that has been difficult to develop in species closely related to humans — one that is sufficiently large, robust, longitudinal in nature, and collected in a well-controlled population over lifetimes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The nature of the Navy dolphins’ shared environment created a perfect setting to generate unparalleled longitudinal health data using easily measured biomarkers that identified slow and accelerated aging in dolphins,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/nik-schork/" target="_blank">Nicholas Schork</a>, Ph.D., a TGen Distinguished Professor, Scientific Director for the National Institute on Aging’s Longevity Consortium, and the study’s senior author.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The results from the analysis of the dolphin population are directly translatable into human biology and will now empower us to identify how aging rates vary in humans and what we might be able do to slow the rates down for all,” said Dr. Schork, who also is Director of TGen’s Quantitative Medicine & Systems Biology Division.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This study is one of three recently published peer-reviewed scientific articles from Epitracker and its spin-out health and wellness company, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.seraphinatherapeutics.com/" target="_blank">Seraphina Therapeutics</a>, demonstrating the promise of applying advanced technologies to delay aging in dolphins and humans.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In April 2020, Epitracker reported in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230769" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">PLOS ONE</em></a> the discovery of shifted dolphin serum metabolomes and improved health resulting from a wild-type fish diet. Specifically, increased dietary intake of pentadecanoic acid (C15:0), a trace dietary odd-chain saturated fatty acid present in some fish as well as dairy fat, independently predicted raised hemoglobin and alleviated chronic anemia in dolphins. A subsequent series of controlled laboratory studies demonstrated evidence of repeated, broad health benefits of C15:0 related to healthy aging, including attenuated anemia and fibrosis, lowered inflammation and cholesterol, and improved cellular stability and mitochondrial function. The growing body of evidence supporting C15:0 as the first essential fatty acid to be discovered in 90 years, was published by Epitracker and Seraphina in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.nature.com/articles/s41598-020-64960-y" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Scientific Reports</em></a>, a <em style="box-sizing:border-box;border-radius:0px;">Nature</em> publication, in May 2020.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Our discovery of slow and accelerated aging dolphins are now enabling us to compare thousands of small molecules in the archived serum of individuals with and without aging-related conditions and help find which molecules have the greatest promise of protecting the health of aging mammals,” Venn-Watson said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Seraphina Therapeutics is currently advancing C15:0 as a once daily dietary supplement, food fortifier and nutritional intervention to protect against aging-associated breakdown and as a potential treatment of C15:0 deficiency disorders in humans. Seraphina aims to have C15:0 available for purchase as a supplement during Fall 2020 and as a food ingredient in January 2021.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In addition to developing C15:0 supplements for Navy dolphins, Epitracker is working cooperatively with the U.S. Navy to study additional serum metabolites that may help prevent and treat chronic aging-associated conditions present in both dolphins and humans, including pulmonary, hepatic, and neurogenerative diseases, including Alzheimer’s disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">For more information on Epitracker Inc. and the research discoveries made, please read the full published paper — <em style="box-sizing:border-box;border-radius:0px;">25-Year Longitudinal Dolphin Cohort Supports that Long-Lived Individuals in Same Environment Exhibit Variation in Aging Rates</em> — in the <em style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.pnas.org/cgi/doi/10.1073/pnas.1918755117" target="_blank">Proceedings of the National Academy of Sciences</a></em>, or visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.epitracker.com/" target="_blank">www.epitracker.com</a>. To learn more about Seraphina Therapeutics, its science-based approach to advancing global health or the discovery of C15:0, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.seraphinatherapeutics.com/" target="_blank">www.seraphinatherapeutics.com</a>.<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> <br style="box-sizing:border-box;border-radius:0px;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">City of Hope</a>, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" target="_blank">Twitter @TGen</a>.<span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> </span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/73/us-navy-dolphin.jpg2020-08-10T07:00:00ZTGen
Researchers to Develop Device to Accurately and Quickly Detect COVID-19Researchers to Develop Device to Accurately and Quickly Detect COVID-19<div class="ExternalClass32993B30DBF04D19867D1E038F2EC274"><html> <div style="text-align:center;">​TERESA JOSEPH</div> <p> <br> </p> <div class="field field--name-field-subtitle field--type-string field--label-hidden h5 mb-lg-3 text-dark field__item" style="box-sizing:border-box;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-weight:700;line-height:1.2;font-size:1.25rem;margin-bottom:1rem !important;color:rgb(33, 33, 33) !important;">The Center for Applied NanoBioscience and Medicine Awarded Grant from NASA to Develop Prototype by September 2020</div> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item" style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:17px;line-height:23px;margin-bottom:3rem;padding-bottom:1rem;border-bottom:1px solid rgb(96, 96, 96);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Amid the <a target="_blank" href="https://phoenixmed.arizona.edu/covid-19" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">coronavirus pandemic</a>, a team of researchers at the University of Arizona College of Medicine – Phoenix are developing a device that will easily and accurately detect COVID-19 in a matter of minutes.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <a target="_blank" href="https://phoenixmed.arizona.edu/anbm" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">The Center for Applied NanoBioscience and Medicine</a>, directed by <a target="_blank" href="https://phoenixmed.arizona.edu/anbm/zenhausern" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">Frederic Zenhausern, PhD</a>, has received a grant to extend the development of its current space-based health monitoring system to build a prototype for COVID-19 testing by September 2020. The grant for $150,000 is from <a target="_blank" href="https://www.bcm.edu/academic-centers/space-medicine/translational-research-institute" style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;">the Translational Research Institute (TRISH)</a> through NASA Cooperative Agreement NNX16AO69A. Dr. Zenhausern’s lab is working on the project with Dr. Pierre Cosson at the University of Geneva in Switzerland, and Dr. David Aucoin at the University of Nevada in Reno.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“As cases of the virus continue to increase across the globe, specifically in Arizona, the need for a rapid diagnostic test for the COVID-19 virus is crucial,” Dr. Zenhausern said.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“TRISH is pleased to see progress on the technology Dr. Zenhausern and his team are making for fast and accurate COVID-19 detection,” Kristin Fabre, PhD, chief scientist at TRISH. “This demonstrates how tools developed for deep space missions, designed specifically to address unknown medical needs, are being applied to address the COVID pandemic.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Currently, the test on market takes several days to get results, due to the requirement for being processed with large automated instrument at centralized laboratories, like Sonora Quest or LabCorp.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Zenhausern’s lab is developing a Vertical Flow Assay diagnostic system that can combine genes and antibodies directed to specific viral components of the SARS-Cov-2 onto a paper membrane through which biological fluids can flow and antigen interactions can be detected by the light scattering from gold nanoparticles whose imaging is directly interfaced with a smartphone. A user will self-collect a small finger-prick of blood or a spit of saliva, and then the liquid will be pushed through the paper membrane. Essentially, the device will take a picture of the array of spots from multiplex molecules onto the paper, which then can be analyzed by an algorithm on a cloud server prior to being sent back to the users in less than 15 minutes, telling them if they’ve been exposed to the virus.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Our goal is to get a more accurate, comprehensive and faster test out there,” Dr. Zenhausern said. “Testing is extremely important. If we had this kind of device, we would have the capability to test for SARS-COV-2 infection sooner and faster, and we could provide more information moving forward in guiding medical countermeasures for reducing fatalities, better managing health care resources, while bringing people back to safer work environments.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">At present, polymerase chain reaction (PCR) and antibody testing are the two major ways that health care systems are testing for COVID-19, and a majority of tests use the gold standard PCR — which detects genetic information of the virus (the RNA) at high sensitivity with less than 200 copies of the virus in a sample; but PCR can only detect if someone is actively infected with the virus, and cannot detect post exposure to the infection. PCR testing for the virus typically includes a nasal swab, which involves a soft brush going up the nose for a few seconds to collect cells and fluids along the passageway.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Unlike PCR, antibody tests can detect proteins if someone has been previously infected, but recovered from the virus. However, the sensitivity and specificity are limited. The team is using recombinant antigen production technology, which provides a synthetic alternative to the long inoculation of animal models over several months to generate antibodies against the virus. Dr. Zenhausern’s team, comprised of Jerome Lacombe, PhD, and Jian Gu, PhD, partnered with researchers in Geneva who are working to design and validate a pipeline of antibodies against the various proteins of the viral components.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">For example, the spike proteins (S) on the surface of the SARS-COV-2, its membrane protein (M), the nucleo-capsid (N) and the envelope (E) proteins. The team also designed smaller antibody fragments or “nanobodies,” which can be very stable and specific. These reagents have been made available as open source for research and the team has already reported in the literature over a dozen antibodies against COVID N, S, E or M proteins. These biomarkers from the different domains of the virus are typically printed into arrays of spots onto the vertical flow assay membrane, so the biological fluid can be flown through the thickness of the paper and provide enhanced limit of detection by more than 100 times over standard lateral flow immunoassay, such as the common tests commercially available for other health conditions.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Through our device, we are combining the benefit of both platforms by increasing capabilities of looking at a much broader panel of disease signatures while significantly increasing the test sensitivity by orders of magnitude,” Dr. Zenhausern said.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">A vertical flow assay test is when the biofluids go toward and through the thickness of the paper, not by capillarity along the length of the test strip. This changes the mechanisms of fluidics and physics, which allows testing to look at multiple biomarkers for a wider range of pathogens, instead of just looking at one target biomarker. “It’s much faster and more sensitive,” Dr. Zenhausern said, “while the volume of the samples can be tuned from a small droplet of blood to a large volume of saliva or urine allowing us to detect low abundance target pathogens without the need for pre-concentrating the specimen prior to run a test.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Already in Arizona and other parts of the world, scientists have discovered a mutated strain of the coronavirus. Mutations can impact diagnostics, but a unique aspect of this platform is the ability to add or modify biomarkers to the test with a high-quality control and fast turn-around-time for production. As more antibodies against coronavirus are detected and as scientists continue to find mutated strains of the virus, researchers can add these markers to the platform and turn it into a large-scale production in the matter of a few weeks.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">According to Dr. Zenhausern, due to the current health crisis, we will need to have rapid testing everywhere that is less invasive and readily deployable at home for more personalized diagnostics.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Through this technology, we could deliver point of care diagnostics in a parking lot, hospital emergency room, in an outpatient clinic and at a pharmacy, or even at home, that could run the test in several minutes while delivering secure results,” Dr. Zenhausern said.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Zenhausern hopes that this platform improves diagnostics not only for COVID-19, but for other viruses and conditions. His team is using a similar technology platform to detect pathogens and Tier 1 biothreats in the Armed Forces, and has worked with NASA TRISH to improve diagnostics for radiation exposure in deep space mission to Mars. Any kind of biological signature, this device could potentially detect. Besides diagnostics, there is also significant potential for building viral nanoparticles as future therapeutic treatment and vaccines.<br></p> </div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/75/zenhausern-photo.jpg2020-08-05T07:00:00ZUA
UARIZONA-TGEN LED TEAM IDENTIFIES NEW BIOMARKERS TO DIAGNOSE AND MONITOR BRAIN INJURIESUARIZONA-TGEN LED TEAM IDENTIFIES NEW BIOMARKERS TO DIAGNOSE AND MONITOR BRAIN INJURIES<div class="ExternalClass969950D0EE1C4C8BBCCA6CDE205A78F4"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Friday July 31, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="UArizona-TGen led team identifies new biomarkers to diagnose and monitor brain injuries" href="https://www.tgen.org/news/2020/july/31/proteomic-analysis-reveals-new-brain-injury-biomarkers/" target="_blank">UARIZONA-TGEN LED TEAM IDENTIFIES NEW BIOMARKERS TO DIAGNOSE AND MONITOR BRAIN INJURIES</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">Integrated protein and metabolite analysis open the door to more precise ways of guiding treatment for the nearly 70 million people worldwide who annually suffer traumatic brain injuries</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 31, 2020 —</span> A scientific team led by the University of Arizona and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, identified a robust set of biomarkers through proteomics and metabolomic analysis that could help guide treatment for tens of millions of patients who each year sustain brain injuries, potentially preventing severe long-term disabilities.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The team’s findings were reported in a study published today in the <em style="box-sizing:border-box;border-radius:0px;">Nature</em> journal: <em style="box-sizing:border-box;border-radius:0px;">Scientific Reports</em>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">An estimated 69 million people worldwide annually sustain traumatic brain injury (TBI). That includes at least 3 million in the U.S., resulting in nearly 288,000 hospitalizations, 56,800 deaths and more than 90,000 with permanent disabilities.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">One of the practical applications of the study was to show the effectiveness of a treatment for brain injuries known as RIC (Remote Ischemic Conditioning). RIC involves, for example, using a tourniquet to restrict, then release, the flow of blood in one of the head-injury patient’s arms or legs. Scientists still don’t know why, but circulating molecules in the bloodstream are produced that could help the brain minimize or repair the injury through this seemingly unrelated technique of on-again, off-again flow of oxygen and nutrients to a patient’s limb.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The molecules released by alternately restricting and releasing the blood flow seem to have a neuro-protective effect,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/patrick-pirrotte/" target="_blank">Dr. Patrick Pirrotte</a>, Director of TGen’s Collaborative Center for Translational Mass Spectrometry and one of the study’s senior authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Using mice models and TGen’s state-of-the-art mass spectrometry facility to analyze proteins and metabolites, Dr. Pirrotte’s team identified biomarkers that showed the effectiveness of RIC, and additional biomarkers that could be used to measure the presence of the injury.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Premature return to normal or strenuous activities can worsen the (TBI) condition and induce chronic health-related issues, the study says, further exacerbating the onset of neurodegenerative diseases.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The biomarkers we identified allow us to measure the extent of the injury, and monitor RIC-aided recovery from brain injury,” said Dr. Khyati Pathak, a member of Dr. Pirrotte’s team and one of the study’s authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The newly-identified biomarkers can provide a more exacting, molecular-level diagnosis of TBI.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Traumatic brain injury, particularly in its less severe form, may not seemingly require hospitalization or an emergency room visit,” said Dr. Jonathan Lifshitz, Director of the UArizona’s Translational Neurotrauma Research Program: a joint venture between the UArizona College of Medicine-Phoenix; a branch of Barrow Neurological Institute at Phoenix Children’s Hospital; and the Phoenix VA Health Care System.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“For millions of individuals, there often is no health care access immediately after TBI events, whether it be organized sports, recreational activities, occupational hazards, military service, or domestic violence,” said Dr. Lifshitz, one of the study’s senior authors.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The use of RIC — the alternating restriction and release of blood flow to an arm or leg — has been shown in clinical studies to be effective in other emergency medical situations, including cardiac arrest, organ transplantation, and lung injury.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“RIC is an easy to teach, practical intervention for a brain injury outside of the hospital setting. It allows for immediate care to the patient with the intent to reduce brain injury pathology,” said Dr. Maha Saber, who is affiliated with Barrow and UArizona and is the study’s lead author.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">This research study — <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.nature.com/articles/s41598-020-69865-4" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Proteomic analysis identifies plasma correlates of remote ischemic conditioning in the context of experimental traumatic brain injury</em></a> — was funded by grants from the National Institutes of Health (NIH-R21-NS096515, F31-NS090921, and T32-AG044402).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/72/patrick-pirrotte.jpg2020-07-31T07:00:00ZTGen
UArizona Aims to Provide Rapid Tests for Individuals Exposed to Biothreats and Pathogens, Such as COVID-19UArizona Aims to Provide Rapid Tests for Individuals Exposed to Biothreats and Pathogens, Such as COVID-19<div class="ExternalClassB8A82FB060624E5FA321BCE44452036E"><html> <p style="text-align:center;">​<span style="color:rgb(155, 155, 155);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:15px;text-transform:uppercase;background-color:window;">TERESA JOSEPH</span></p> <div> <div> <span style="box-sizing:border-box;" class="field field--name-title field--type-string field--label-hidden"> <br> </span> </div> <a style="box-sizing:border-box;color:rgb(1, 28, 72);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:16px;" href="https://twitter.com/uazmedphx/" target="_blank" class="field_media_contact_twitter_url"></a> <br> </div> <p> <span style="color:rgb(33, 33, 33);font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:1.25rem;font-weight:700;background-color:window;">​Thanks to a U.S. Department of Defense Contract for as Much as $9.5 Million, College of Medicine – Phoenix and Partners Aim to Develop a Portable Device to Easily and Accurately Detect Biological Threats</span> </p> <div style="box-sizing:border-box;color:rgb(96, 96, 96);font-size:15px;line-height:20px;margin-bottom:3rem;font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";" class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">To better protect individuals serving on battlefields or dealing with an event, such as the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/covid-19" target="_blank">COVID-19 global pandemic</a>, as well as potential future pandemics, scientists at the University of Arizona College of Medicine – Phoenix are leading an effort to develop a device for easy, quick and accurate detection of pathogens and biological threats.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/anbm" target="_blank">The Center for Applied Nanobioscience and Medicine</a> (ANBM) at the UArizona College of Medicine – Phoenix is heading the effort, under an Other Transaction Agreement (OTA) with the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://www.dtra.mil/" target="_blank">Defense Threat Reduction Agency</a> (DTRA), an agency within the U.S. Department of Defense. The agreement is a $9.5 million ceiling contract for three years, to provide about 3,000 devices.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;"> <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/anbm/zenhausern" target="_blank">Frederic Zenhausern, PhD</a>, ANBM director and interim co-chair of the <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://phoenixmed.arizona.edu/bms" target="_blank">Department of Basic Medical Sciences</a>, and his team members, including associate professor Jian Gu, PhD, are creating the device, in collaboration with scientists from the University of Nevada, Arizona State University, Duke University and Whitespace Enterprise — an Arizona-based startup founded by Dr. Zenhausern. The group is responsible for mass production of the technology.<img style="box-sizing:border-box;border-width:0px;vertical-align:middle;float:right;max-width:100%;margin:5px;width:0px;" title="" src="https://phoenixmed.arizona.edu/sites/default/files/inline-images/zenhausern-story_0.jpg" data-entity-uuid="8296785b-4bb8-4af1-859d-35b8cd92735a" data-entity-type="file" class="img-fluid align-right" alt="Frederic Zenhausern, PhD" /></p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“An individual in a combat zone or a first responder in the field could know within minutes if they have — or were exposed to — a serious pathogen or biothreat,” Dr. Zenhausern said. “We want the brave individuals serving on the front lines to be safe, and this device potentially could prevent a next pandemic by providing rapid diagnostic testing for a broad range of threats, including coronaviruses.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The team is developing a vertical flow immunoassay (VFI) diagnostic test that interfaces with a smartphone, as the only system component requiring battery power. Users would take a small finger prick of blood, or a syringe of urine, and then push the liquid onto a test strip. Essentially the device would take a picture of that paper membrane, which would be analyzed and sent back to the users, telling them if they have been exposed to pathogens, such as anthrax or Y. pestis, which can cause the plague or possibly other bacteria and viruses.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Two major platforms for microbial diagnostics are available, including polymerase chain reaction (PCR) tests, which look at the nucleic acid molecules of the organism, and antibody or immunoassay testing. The immunoassay test typically is color-coded, like a pregnancy test, and uses a lateral flow immunoassay method that involves a piece of paper upon which biofluid, such as blood or urine, is placed.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The biofluid would migrate along the paper and meet different antibodies to determine if an individual’s body has produced an immune response to the virus, or if antigens could be detected. Then an interaction occurs, signaling the individual has been exposed to the biothreat, like a line appearing through the paper.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Lateral flow immunoassay tests are limited to only a few antibodies and are not very sensitive or fast, but they are inexpensive and safe, which has made it a popular option in the past,” Dr. Zenhausern said. “Through our device, we are combining the benefit of both platforms by increasing capabilities of looking at a much broader panel of disease signatures while significantly increasing the test sensitivity by orders of magnitude.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">A vertical flow immunoassay test is when biofluids go toward and through the paper, not by capillarity, along surface of the test strip. This changes the mechanisms of fluidics and physics, which allows testing to look at multiple biomarkers for a wider range of pathogens, instead of just looking at one target biomarker.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“It’s much faster and more sensitive,” Dr. Zenhausern explained, adding this device would have more capabilities than technology currently available and could be applied to illnesses, such as influenza, Ebola or the COVID-19 threat — or any other biological signature.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">“Dr. Zenhausern’s team at the University of Arizona Health Sciences and additional collaborators have worked tirelessly to take this idea from concept to production, and I am grateful for their dedication,” said University of Arizona President <a style="box-sizing:border-box;background-color:transparent;color:rgb(171, 5, 32);text-decoration-line:underline;transition:all 0.3s ease 0s;" href="https://president.arizona.edu/dr-robert-c-robbins-biography" target="_blank">Robert C. Robbins, MD</a>. “This research is an incredible example of how university research directly serves the community. By protecting first responders and others who have an increased likelihood of pathogen exposure, including those serving in combat zones, we can improve public health and prevent future outbreaks. I am immensely proud of our faculty who are spearheading this vital work, and I am eager to see its impact.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">Dr. Zenhausern said, due to the pandemic, a change in the health care delivery system will occur. “We will need to have rapid testing that is less invasive and more personalized.”</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">A previously DTRA-sponsored program successfully established design rules of the proposed VFI platform technology, which will be scaled up for this product-development project. This increase would encompass the U.S. Food and Drug Administration regulatory filing and delivery of thousands of devices. The OTA contract also includes a subsequent production option for future commercialization and possible stockpiling through the Department of Defense.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The OTA program is a partnership among several investigators and their teams, which have been collaborating for many years. These teams are led by world-renowned scientists such as David Aucoin, PhD (University of Nevada Reno); Tuan Vo-Dinh, PhD (Duke University); and Doug Montgomery, PhD (Arizona State University); as well as many industry partners.</p> <p style="box-sizing:border-box;margin-top:0px;margin-bottom:1rem;">The collaboration among most of these institutions began in 2016 after receiving about $2 million in a DTRA contract to study this technology and determine how it could be applied for the detection of Tier-1 bioagents in defense operations.<br></p> </div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/64/zenhauern-dod.jpg2020-07-23T07:00:00ZUA
TGEN CENTER FOR RARE CHILDHOOD DISORDERS PATIENT IS HEADED TO MARSTGEN CENTER FOR RARE CHILDHOOD DISORDERS PATIENT IS HEADED TO MARS<div class="ExternalClass90032E1993CB473C8C426119C64CC951"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Thursday July 23, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="TGen Center for Rare Childhood Disorders patient is headed to Mars" href="https://www.tgen.org/news/2020/july/23/tgen-c4rcd-patient-is-headed-to-mars/" target="_blank">TGEN CENTER FOR RARE CHILDHOOD DISORDERS PATIENT IS HEADED TO MARS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">Alex Yiu, whose rare neurological disorder was diagnosed by TGen, will celebrate a combination birthday and ‘Perseverance’ pre-launch party and fundraiser on July 25</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 23, 2020 —</span> Alex Yiu, whose once-mysterious and debilitating disease was eventually diagnosed by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, turns 15 years old this week.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">And to celebrate his birthday, NASA is sending Alex to Mars.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex, who has been a space enthusiast since he was a young child, couldn’t be happier about it.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">His name is etched on a microchip embedded on the newest and most sophisticated Mars rover called <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://mars.nasa.gov/mars2020/" target="_blank">Perseverance</a>. It is set to launch from Florida sometime between July 30 and Aug. 15, and land on Mars in February inside the 30-mile-wide Jezero Crater, which scientists — including those at ASU and UofA — think was once a large water-filled lake. The Perseverance rover will collect rock and soil samples, seeking signs of ancient life. Aboard the rover will be the Mars Helicopter, the first drone ever deployed on the Red Planet.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex’s mother, Caroline Cheung-Yiu, says her teenage son is looking forward to the launch. To celebrate, his family is hosting a virtual combination birthday and prelaunch party as a fundraiser for TGen’s Center for Rare Childhood Disorders.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex has always been fascinated about space. He helped build a model of the solar system in middle school, loves Star Wars movies, and even dressed as Darth Vader for Halloween.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“When he was younger and we took him to science centers, he was always interested in space,” Caroline said. Alex still loves watching the NASA channel on TV. As a gift from one of his special education teachers, Alex's name is one of 10.9 million names etched on the microchips on board Perseverance.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Once healthy child now has debilitating condition</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Born healthy with no complications, Alex was an active, social and happy boy. Today, he is entirely dependent on his family for his care and activities of daily living. He is fed via a tube, cannot walk, cannot talk and relies on a non-invasive ventilator to breathe. He communicates by blinking his eyes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">At age 3, Alex walked with an unusual gait. His motor skills and coordination became awkward. Gradually he became increasingly clumsy on his feet, requiring increasing support to walk safely. He could no longer walk by age 6. Progressively, his speech slowed and slurred and by age 7 his family could no longer understand him. Eating and drinking became challenging.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Family life for Alex revolved around a multitude of doctor consults for health issues, traveling for appointments with neurologists at leading institutions, a slew of tests and applications to programs dedicated to undiagnosed patients. His initial visits to TGen nearly a decade ago yielded no significant findings.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We held onto the hope that once we found the cause, we could find treatments,” Caroline said. “We reached out to researchers, specialists, and other parents already lighting the way.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Accidental discovery of diagnosis by TGen</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In the fall of 2018, by what his mother called a “miraculous intervention,” Alex was a cold case revisited at TGen’s Center for Rare Childhood Disorders. A mutation in a gene called IRF2BPL  had just been discovered earlier that year.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Keri Ramsey, a nurse and Clinical Co-Director of TGen’s Center, was searching for another patient when she accidentally came across Alex’s file. Using a new computer diagnostic tool, and having recently seen two new scientific studies about IRF2BPL, Ramsey found that Alex had this same mutation.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Immediately, I saw this mutation in this gene,” Ramsey said. “It was perfect timing.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">After 12 years of relentlessly searching for answers to Alex’s progressive neurodegenerative condition, Alex’s family finally had a diagnosis: NEDAMSS (Neurodevelopmental disorder with regression, abnormal movements, loss of speech and seizures).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Unfortunately, there are as yet no treatments for NEDAMSS. Still, while Alex’s family waits for a breakthrough, they are raising funds so that other TGen patients and their families can receive a diagnosis.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“What’s amazing about Alex’s mom is that she continues to fight for other families who still don’t have a diagnosis. To her, it’s still so important, and that’s why she continues to reach out to us because she knows the value of having that diagnosis and because for so many years they didn’t have it,” Ramsey said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Our hearts ache knowing that there are other families struggling and feeling alone with no diagnosis,” Caroline said. “We shall never give up, we forever hold onto hope, and just like the Mars Rover Perseverance, our perseverance continues.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To contribute to a fund in Alex’s name to TGen’s Center for Rare Childhood Disorders, please go to: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/alex" target="_blank">https://www.tgen.org/alex</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Alex’s combined birthday and pre-launch party starts at 1 p.m. Arizona and California time this coming Saturday, July 25, and will feature a country love song written by Alex. To join the party, please <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://docs.google.com/forms/d/e/1FAIpQLSe_ihS1WitY1pC4J70C0WWKba4tAX-YvpC5QzYpJYR4FuMRxA/viewform" target="_blank">RSVP here</a> to get your Zoom boarding pass.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To see a story about Alex produced by National Public Radio, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.npr.org/sections/health-shots/2019/10/16/769462793/a-boys-mysterious-illness-leads-his-family-on-a-diagnostic-odyssey" target="_blank">click here</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">To see Alex’s Countdown to Mars on Vimeo, go to: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://vimeo.com/439803390" target="_blank">https://vimeo.com/439803390</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/71/alex-yiu.jpg2020-07-23T07:00:00ZTGen
TGEN’S ASHION ANALYTICS® AND HONORHEALTH SHOW HOW ‘ORGANOIDS’ CAN HELP PINPOINT THE RIGHT THERAPIES FOR CANCER PATIENTSTGEN’S ASHION ANALYTICS® AND HONORHEALTH SHOW HOW ‘ORGANOIDS’ CAN HELP PINPOINT THE RIGHT THERAPIES FOR CANCER PATIENTS<div class="ExternalClass71754A0ACB574D3BAF61A3A87600FB30"><html> <p style="text-align:center;"> <span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span> <span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span> <span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a> </span> </p> <p style="text-align:left;"></p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:667.5px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">New PATRIOT analysis unveiled at this week’s AACR meeting; builds on Ashion’s GEM-ExTra program, providing unprecedented accuracy in prescribing anti-cancer treatments</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;float:left;width:667.5px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — June 22, 2020 —</span> Precision medicine, using the power of the human genome to diagnose and treat patients, is about to get even more precise.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">A new program called PATRIOT, developed by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, is using organoids — laboratory cultures derived from samples of patient tumors — to provide a whole new level of accuracy in prescribing anti-cancer treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">PATRIOT builds on other precision medicine programs devised by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics</a>, a TGen clinical laboratory, which uses its <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank">GEM ExTra</a><span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">® </span>proprietary test to match each patient’s unique cancer to the best available cancer treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">PATRIOT, which stands for <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.abstractsonline.com/pp8/#%21/9045/presentation/3954" target="_blank"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PAT</span>hway based <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">R</span>NA and DNA <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">I</span>ntegration with tumor <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">O</span>rganoid <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">T</span>esting for clinical therapeutics</a>, will be showcased in a study presentation June 22-24 at the second 2020 virtual annual meeting of the American Association for Cancer Research (AACR).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Cancer tumors are complicated,” said Dr. Sunil Sharma, Deputy Director of TGen Clinical Sciences and Chief of Translational Oncology and Drug Development at the HonorHealth Research Institute. “PATRIOT is a very powerful platform that will make GEM ExTra even more powerful. This will expand the use of RNA analysis in a way that has never been used before.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In this system, organoids — which can mimic the reactions of solid tumors in patients’ bodies —are grown in a laboratory and then used to test different anti-cancer therapies.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“It’s a way of conducting clinical trials on a laboratory plate,” said Dr. Sharma, who also is a Professor and Director of TGen’s Applied Cancer Research and Drug Discovery Division.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The study being presented at AACR shows how Dr. Sharma’s TGen lab, using melanoma tumor samples provided by HonorHealth, used the new PATRIOT system to identify potential therapeutic targets by focusing on molecular pathways within tumor cells, a level of analysis that goes beyond searching for mutations in DNA, and even builds on top of the intricate analysis of RNA-expression provided by Ashion’s GEM ExTra.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“These druggable targets were validated on the tumor organoids,” said Dr. Sharma, who hails the system as a whole new way to provide therapeutic benefit to patients. “This allows for a holistic assessment of a patient’s tumor for improving therapy recommendations and expanding personalized therapy options.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition, he said, PATRIOT analysis of organoids gives investigators the ability to test immunotherapy options in the laboratory.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion’s GEM ExTra platform already has expanded the therapeutic potential of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Fact-Sheet" target="_blank">genomic sequencing</a> by using RNA sequencing to identify novel fusions and alternate transcripts, providing additional tumor profiling data in addition to that identified by DNA sequencing.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Unlike many other genomic sequencing tests, which use panels of dozens or even hundreds of known cancer-causing genomic variants, Ashion’s GEM ExTra screens cancer patients for <em style="box-sizing:border-box;border-radius:0px;">all</em> of the nearly 3 billion nucleotides, or letters, in human DNA, which includes more than 19,000 genes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The next step, Dr. Sharma said, is to test the predictions from PATRIOT and GEM ExTra analysis of patient organoids in the laboratory to see if they might work in a larger clinical trial.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This study was supported by funding from Flinn Foundation grant #2193.<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics<br style="box-sizing:border-box;border-radius:0px;"></span>At Ashion, our goal is to accelerate the adoption of genomic analysis for clinical decision support to improve the treatment of patients with refractory, rare or aggressive disease. We are experts at Next-Generation Sequencing-based clinical laboratory services, deriving our pedigree from the pioneering precision medicine work at the Translational Genomics Research Institute (TGen) in Phoenix. Ashion Analytics’ mission is to develop and deliver the premier personalized medicine diagnostic, data analytic, and clinical coordination services, which assist healthcare providers in offering their patients individualized treatment options, and which improve outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About HonorHealth <br style="box-sizing:border-box;border-radius:0px;"></span>HonorHealth is a non-profit, local community healthcare system serving an area of 1.6 million people in the greater Phoenix area. The network encompasses five acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer care network, clinical research, medical education, a foundation and community services with approximately 12,300 employees, 3,700 affiliated physicians and 3,100 volunteers. HonorHealth was formed by a merger between Scottsdale Healthcare and John C. Lincoln Health Network. HonorHealth’s mission is to improve the health and well-being of those we serve. Learn more at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://honorhealth.com/" target="_blank">HonorHealth.com</a></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About HonorHealth Research Institute<br style="box-sizing:border-box;border-radius:0px;"></span>HonorHealth Research Institute is helping shape the future of medicine. We're finding cures and improving treatments in areas like gene therapy, early drug/device development, early detection and prevention of disease. Through our clinical trials and applied research, we’ve given hope and improved the lives of patients from all 50 states and 28 different countries around the globe. Our advanced technologies and cutting-edge treatment options are introducing tomorrow’s cures, today. For more information on oncology clinical trials for cancer contact HonorHealth Research Institute Nurse Navigators (480) 323-1364 or email <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:clinicaltrials@honorhealth.com" target="_blank">clinicaltrials@honorhealth.com</a> or learn more at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.honorhealth.com/research" target="_blank">HonorHealth.com/research</a>.  Follow HonorHealth Research Institute on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/HonorHealthcares" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/honorhealth" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/HRInstitute_AZ" target="_blank">Twitter @HRInstitute_AZ. </a> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_tag_container"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;" class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50"></ul> </div> <div style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_label_container"> <div style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_labels_container"></div> </div> </aside>​<br></div> </div> <span id="ms-rterangepaste-end"></span> <p style="text-align:left;"> <br> </p> <p style="text-align:center;"> <br> </p> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="text-align:center;"> <br> <br> <br> </div> </li> </ul> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/59/dr_sunil_sharma.jpg2020-07-22T07:00:00ZAshion Analytics
TGEN, CITY OF HOPE LOOKING TO CREATE PERSONALIZED ROADMAPS FOR THE TREATMENT OF KIDNEY CANCERTGEN, CITY OF HOPE LOOKING TO CREATE PERSONALIZED ROADMAPS FOR THE TREATMENT OF KIDNEY CANCER<div class="ExternalClass8B5C1DB374104E0C8252D76950F8F08D"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Wednesday July 22, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="TGen, City of Hope looking to create personalized roadmaps for the treatment of kidney cancer" href="https://www.tgen.org/news/2020/july/22/tgen-city-of-hope-roadmaps-to-treat-kidney-cancer/" target="_blank">TGEN, CITY OF HOPE LOOKING TO CREATE PERSONALIZED ROADMAPS FOR THE TREATMENT OF KIDNEY CANCER</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">Physician-scientists are using one of the world’s most comprehensive genomic analysis tools to determine whether targeted therapy or immunotherapy has the best chance of working for each individual patient</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz., and DUARTE, Calif. — July 22, 2020 —</span> Experts at <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/" target="_blank">City of Hope</a> and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a> are using one of the world’s most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">While the physician-scientists are at the beginning of this long journey, they believe they’re on the right path. They recently published a study in the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://jitc.bmj.com/content/8/2/e000953" target="_blank">Journal of Immunotherapy of Cancer</a> that suggests mutations in the TERT gene predicts that a patient may not be receptive to immune checkpoint inhibitors such as nivolumab or pembrolizumab.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The hope is to one day identify patients who will benefit from immunotherapy and those who will not. Eventually we may be able to distinguish which patient is better suited for other treatments, like targeted therapy,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/people/pal-sumanta" target="_blank">Sumanta Pal</a>, M.D., one of the study’s senior authors and co-director of the Kidney Cancer Program at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. Examples of targeted therapy include vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors like cabozantinib.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Nearly 74,000 new cases of kidney cancer will be diagnosed this year, and about 14,800 people will die from the disease, according to the American Cancer Society. Ironically, experts know patients who have certain genetic mutations are more susceptible to specific drugs, but most doctors are not genetically sequencing each kidney cancer patient’s tumors, Pal said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“It’s a paradox: We don’t use targeted therapy in a targeted fashion,” he added. “At City of Hope, we have begun to provide comprehensive genome and exome sequencing for all patients with Stage 4 cancer, regardless of their cancer site.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">City of Hope is on pace to be the only major cancer center in the United States to genetically profile the tumors of every single patient, regardless of cancer type. The goal is to enable patients to receive effective targeted therapies or to enroll people in innovative clinical trials as early as possible so that they can fight their disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In the study, Pal and his colleagues sent samples of 91 patients’ tumors to TGen’s clinical laboratory, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics</a>, so that the specimens could be sequenced by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank">GEM ExTra</a> a leading-edge tool that features tumor-normal whole exome sequencing and tumor whole transcriptome sequencing. These are molecular-level analyses of each patient’s entire protein-coding DNA and RNA.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“The goal was to identify genomic alterations that correlated with therapy response,” said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/sara-byron/" target="_blank">Sara Byron</a>, Ph.D., assistant professor in TGen’s Integrated Cancer Genomics Division and co-senior author of the study. “We wanted to use this ‘real-world evidence’ to explore potential molecular and genomic features associated with response.” (<a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/" target="_blank">Ashion Analytics recently announced</a> that Medicare has approved coverage of GEM ExTra, potentially providing 44 million more patients access to this test, which aims to match patients with the best available treatments for their disease.)</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Kidney cancer treatment regimens involving either targeted therapy or immunotherapy have burgeoned since 2015. Because new treatments sprouted so rapidly, scientists have not yet discovered the ideal strategy to sequence regimens for optimal outcomes. Moreover, the current way treatment risk is assessed tends to be subjective with ingrained bias, the study reported. City of Hope and TGen are working to develop objective laboratory-based biomarkers for kidney cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Only patients whose genomic profiling was performed prior to systemic treatment were included in the study. Patients received either targeted therapy known as VEGF tyrosine kinase inhibitors (sunitinib, cabozantib, lenvatinib/everolimus) or immunotherapy (nivolumab, ipilimumab, pembrolizumab). They were divided into those who received no clinical benefit, meaning their disease progressed, or those who received clinical benefit, meaning the disease shrunk or stabilized for more than six months. Some 19,396 genes and nucleic sequences were analyzed to tease out a therapeutic treatment plan that would have best suited each patient based on their specific tumor mutations. More research in larger sample sizes are needed, but the scientists are off to a good start.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Stage 4 cancer is often considered incurable, but that doesn’t always have to be the case,” Pal said. “By sequencing all protein-coding DNA, that is by sequencing the whole exome, we may be able to identify new therapeutic targets, and that’s a very exciting prospect.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/tests-and-treatments/bone-marrow-and-blood-stem-cell-transplants" target="_blank">bone marrow transplantation</a> and immunotherapy such as <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/research/car-t-cell-therapy" target="_blank">CAR T cell therapy</a>. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.cityofhope.org/research/beckman-research-institute/about-beckman-research-institute/beckman-research-institute-milestones" target="_blank">numerous breakthrough cancer drugs</a> are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Report’s Best Hospitals: Specialty Ranking. Its main campus is located near Los Angeles, with <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/about-city-of-hope/locations" target="_blank">additional locations</a> throughout Southern California. For more information about City of Hope, follow us on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/cityofhope/" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/cityofhope" target="_blank">Twitter</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.youtube.com/user/cityofhopeonline" target="_blank">YouTube</a> or <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.instagram.com/cityofhope/" target="_blank">Instagram</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact<br style="box-sizing:border-box;border-radius:0px;"></span>Zen Vuong<br style="box-sizing:border-box;border-radius:0px;">City of Hope<br style="box-sizing:border-box;border-radius:0px;">626-409-9367<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:zvuong@coh.org" target="_blank">zvuong@coh.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/69/sara-byron.jpg2020-07-22T07:00:00ZTGen
ASHION ANALYTICS ANNOUNCES INNOVATIVE CANCER TREATMENT PARTNERSHIP WITH ELEVATION ONCOLOGYASHION ANALYTICS ANNOUNCES INNOVATIVE CANCER TREATMENT PARTNERSHIP WITH ELEVATION ONCOLOGY<div class="ExternalClassCE5BA87BAD024C64B7290E33B0785836"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Wednesday July 22, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Ashion Analytics announces innovative cancer treatment partnership with Elevation Oncology" href="https://www.tgen.org/news/2020/july/22/ashion-analytics-teams-with-elevation-oncology/" target="_blank">ASHION ANALYTICS ANNOUNCES INNOVATIVE CANCER TREATMENT PARTNERSHIP WITH ELEVATION ONCOLOGY</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;">Ashison Analytics GEMExTra test detects rare NRG1 gene fusions in patients whose cancer is driven by this genomic alteration for potential matching to a clinical trial</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 22, 2020 —</span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics LLC</a> today announced a partnership with <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.elevationoncology.com/" target="_blank">Elevation Oncology</a>, a clinical stage biopharmaceutical company, focused on the matching of patients with tumors harboring an NRG1 gene fusion identified using Ashion’s proprietary GEM ExTra® test with CRESTONE, a registration-directed Phase 2 study sponsored by Elevation Oncology.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">NRG1 gene fusions are a rare genomic alteration implicated as a driver of tumorigenesis and growth across many types of solid tumors, including lung, breast, pancreatic, ovarian, and colorectal cancers. <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://nrg1fusion.com/" target="_blank">CRESTONE</a> — or <span style="text-decoration:underline;">C</span>linical study of <span style="text-decoration:underline;">RE</span>sponse to <span style="text-decoration:underline;">S</span>eribantumab in <span style="text-decoration:underline;">T</span>um<span style="text-decoration:underline;">O</span>rs with <span style="text-decoration:underline;">NE</span>uregulin 1 (NRG1) fusions — provides an investigational treatment opportunity for patients with any advanced solid tumor who have not responded or are no longer responding to standard cancer treatment, and whose tumor has tested positive for an <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://nrg1fusion.com/wp-content/uploads/2020/07/EO0003-001-000_NRG1-fusion-1-pager.pdf" target="_blank">NRG1</a> fusion.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This partnership creates a new dynamic in the way cancer patients can be matched to precision medicine therapeutics. By first identifying a genetic driver that has an available targeted therapy option, in this case an NRG1 fusion and the investigational therapy seribantumab, the diagnostic technology, data insights, and network reach at Ashion Analytics can be leveraged to efficiently identify and directly match eligible patients to the CRESTONE trial using test results that are already available today, while also maximizing the value of every additional test.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“The comprehensive nature of the GEM ExTra test means that its value grows directly with each new genomic driver that is identified and each new precision therapy under development,” said Laurie Goodman, Ph.D., Ashion Analytics Director of Business Development and Medical Affairs. “Partnerships like this enable us to continuously facilitate the ability for our patients to receive the most up-to-date information about the emerging treatment opportunities available to them today.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/" target="_blank">Ashion Analytics recently announced</a> that Medicare has approved coverage of its proprietary cancer profiling test, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank">GEM ExTra</a>®, one of the nation’s most comprehensive genomic cancer analysis tests. Medicare coverage enables potentially 44 million more patients to afford this test, which aims to match patients with best available treatments for their disease.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2020/june/11/tgen-s-ashion-certified-for-nci-match/" target="_blank">GEM ExTra</a> detects tumor-specific mutations in both DNA and RNA, allowing physicians to make the best-available treatment recommendations for patients with advanced solid tumors. An Ashion study poster presented at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=80cc45bf65&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOToaeHqm$" target="_blank">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</a><span style="box-sizing:border-box;border-radius:0px;">.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This leading-edge test provides treating physicians with vital interpreted information needed to understand changes to a patient’s genomic profile. It outlines a therapeutic treatment plan best suited for each patient. Conditions that may benefit from this approach include treatment of refractory, rare or aggressive cancers.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We are partnering with Ashion Analytics because we recognize the sensitivity and continuing potential of their GEM ExTra cancer profiling test,” said Shawn Leland, PharmD, RPh, Founder and Chief Business Officer of Elevation Oncology. “Elevation Oncology is committed to expanding the benefit of precision medicine to all patients with cancer by developing therapies that make results from tests like GEM ExTra clinically actionable, no matter how rare the finding. Close collaboration between diagnostic and therapeutic developers is critical to re-thinking our approach to clinical trial enrollment as an industry and finding more efficient ways to bring the right treatment opportunities to the patients that need them.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">For more information about seribantumab and the CRESTONE study, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.nrg1fusion.com/" target="_blank">www.NRG1fusion.com</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion Analytics is a clinical laboratory of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics LLC<br style="box-sizing:border-box;border-radius:0px;"></span>Ashion Analytics LLC is a CLIA-certified and CAP-accredited clinical laboratory that uses advanced genomic technologies to offer a wide range of testing capabilities to assist physicians, health systems, research and commercial partners to provide precision cancer treatments. Ashion was developed and launched by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute</a> (TGen), an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/impact?gclsrc=aw.ds&&gclid=EAIaIQobChMIyu7l0Jit6gIVHz2tBh02oA0BEAAYASAAEgIbkPD_BwE" target="_blank">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About GEM ExTra<br style="box-sizing:border-box;border-radius:0px;"></span>To achieve complete analytic coverage of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=792e518cba&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOelLUM2E$" target="_blank">human genome</a>, Ashion uses a proprietary test called <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=7881a18cf6&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOZeMLcKW$" target="_blank">GEM ExTra</a>, which covers all protein coding regions of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=ca7762bff4&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOXhojeuo$" target="_blank">exome</a>), <em style="box-sizing:border-box;border-radius:0px;">and</em> an analysis of all RNA, the messengers of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=05dc9ef049&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOfQbE1cu$" target="_blank">transcriptome</a>). <em style="box-sizing:border-box;border-radius:0px;">GEM</em> stands for <span style="text-decoration:underline;">G</span>enomic <span style="text-decoration:underline;">E</span>nabled <span style="text-decoration:underline;">M</span>edicine, and <em style="box-sizing:border-box;border-radius:0px;">ExTra</em> stands for <span style="text-decoration:underline;">Ex</span>ome and <span style="text-decoration:underline;">Tra</span>nscriptome. Ashion’s GEM ExTra sequences both the individual patient’s normal genome and the patient’s cancer genome. Then the two sets of genomic data are compared to find gene changes, known as mutations, that are specific to the tumor and that may be potentially driving the patient’s cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. <span style="box-sizing:border-box;border-radius:0px;">Follow TGen on </span><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a><span style="box-sizing:border-box;border-radius:0px;">, </span><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a><span style="box-sizing:border-box;border-radius:0px;"> and </span><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a><span style="box-sizing:border-box;border-radius:0px;">.</span><br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Ashion Analytics Contact<br style="box-sizing:border-box;border-radius:0px;"></span>Laurie Goodman, Ph.D.<br style="box-sizing:border-box;border-radius:0px;">Director, Business Development and Medical Affairs<br style="box-sizing:border-box;border-radius:0px;">Ashion Analytics LLC<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:lgoodman@ashion.com" target="_blank">lgoodman@ashion.com<br style="box-sizing:border-box;border-radius:0px;"></a>650-245-8410<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://www.ashion.com/" target="_blank">www.Ashion.com</a></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">TGen Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_tag_container"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;" class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50"></ul> </div> <div style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_label_container"> <div style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_labels_container"></div> </div> </aside>​<br></div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/70/laurie-goodman.jpg2020-07-22T07:00:00ZAshion Analytics
ASHION ANALYTICS RECEIVES MEDICARE COVERAGE FOR GEM EXTRA® ASSAY FOR PATIENTS WITH ADVANCED SOLID TUMORSASHION ANALYTICS RECEIVES MEDICARE COVERAGE FOR GEM EXTRA® ASSAY FOR PATIENTS WITH ADVANCED SOLID TUMORS<div class="ExternalClass8B2D62744E3942B6913FFD39BD36A32B"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;"> <ul class="list-inline posted-info" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;"> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span class="uBlogsy_author_name" style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="https://www.tgen.org/news/?author=Steve+Yozwiak" title="Steve Yozwiak" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Tuesday July 14, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a target="_blank" href="https://www.tgen.org/news/2020/july/14/medicare-covers-tgen-ashions-gem-extra-cancer-test/" title="Ashion Analytics receives Medicare coverage for GEM ExTra® assay for patients with advanced solid tumors " style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;">ASHION ANALYTICS RECEIVES MEDICARE COVERAGE FOR GEM EXTRA® ASSAY FOR PATIENTS WITH ADVANCED SOLID TUMORS</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <em style="box-sizing:border-box;border-radius:0px;"></em> </p> </div> </div> <div class="row" style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;"> <div class="col-md-12" style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 14, 2020 —</span> <a target="_blank" href="http://ashion.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Ashion Analytics LLC</a> announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostic Services Program (MolDX), has awarded coverage to its proprietary cancer profiling test, <a target="_blank" href="http://ashion.com/physicians-2/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">GEM ExTra</a>®, one of the nation’s most comprehensive genomic cancer analysis tests.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <a target="_blank" href="https://www.tgen.org/news/2020/june/11/tgen-s-ashion-certified-for-nci-match/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">GEM ExTra</a>, Ashion’s flagship clinical assay, detects tumor-specific mutations, allowing physicians to make the best-available treatment recommendations for patients with advanced solid tumors. The leading-edge test provides treating physicians with vital interpreted information that they need to understand changes to a patient’s genomic profile. It outlines a therapeutic treatment plan best suited for each patient. Conditions that may benefit from this approach include treatment of refractory, rare or aggressive cancers.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“GEM ExTra was designed to be fast and accurate, and now with Medicare coverage, it is also more affordable for a larger set of patients,” said Ashion Medical Director Janine LoBello, D.O. “GEM ExTra differs from other genomic tests on the market due to its versatility, breadth and depth, including the power to sensitively detect mutations with low tumor purity.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">GEM ExTra features whole <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=ca7762bff4&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOXhojeuo$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">exome</a> sequencing, a molecular-level analysis of each patient’s entire protein-coding DNA. The proprietary test identifies point mutations, amplifications, deletions, translocations and transcriptome sequencing. It flags the expression of both rare and common fusion genes and alternatively spliced transcripts (ARv7, EGFRvIII and others). Positive findings in this data may guide patient treatment, leading to more targeted, effective therapies. As an example, the test includes reporting on immuno-oncology markers, providing clinicians with important information on the potential utility of powerful immune checkpoint treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">GEM ExTra is available for use with a variety of biological sample types, including formalin-fixed paraffin-embedded (<span style="box-sizing:border-box;border-radius:0px;">FFPE) tissue specimens and </span>fresh-frozen tissue for solid tumors<span style="box-sizing:border-box;border-radius:0px;">. Results are reported back to physicians within 14 calendar days.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Medicare coverage of GEM ExTra allows Ashion to offer a test to the broader market that is optimized for detection of common and rare mutations and is able to identify more actionable cancer mutations than most other commercially available tests,” said Audrey Ozols, Ashion’s head of market access. “The company is well positioned for growth with payers and physicians alike by offering 44 million more patients access to a best-in-class comprehensive genomic cancer test.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion Analytics was founded by the <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Translational Genomics Research Institute</a> (TGen), an affiliate of <a target="_blank" href="https://www.cityofhope.org/impact?gclsrc=aw.ds&&gclid=EAIaIQobChMIyu7l0Jit6gIVHz2tBh02oA0BEAAYASAAEgIbkPD_BwE" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“City of Hope patients have had access to GEM ExTra’s comprehensive exome sequencing for more than two years,” said Michael Caligiuri, M.D., president of City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. “This sequencing tool often enables clinical teams to offer precision medicine so that patients are given the care most likely to put them into long-term cancer remission and improve their quality of life.”<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"># # #</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About GEM ExTra<br style="box-sizing:border-box;border-radius:0px;"></span>To achieve complete analytic coverage of the <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=792e518cba&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOelLUM2E$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">human genome</a>, Ashion uses a proprietary test called <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=7881a18cf6&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOZeMLcKW$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">GEM ExTra</a>, which covers all protein coding regions of DNA (known as the <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=ca7762bff4&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOXhojeuo$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">exome</a>), <em style="box-sizing:border-box;border-radius:0px;">and</em> an analysis of all RNA, the messengers of DNA (known as the <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=05dc9ef049&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOfQbE1cu$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">transcriptome</a>). <em style="box-sizing:border-box;border-radius:0px;">GEM</em> stands for <span style="text-decoration:underline;">G</span>enomic <span style="text-decoration:underline;">E</span>nabled <span style="text-decoration:underline;">M</span>edicine, and <em style="box-sizing:border-box;border-radius:0px;">ExTra</em> stands for <span style="text-decoration:underline;">Ex</span>ome and <span style="text-decoration:underline;">Tra</span>nscriptome. Ashion’s <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em> sequences both the individual patient’s normal genome and the patient’s cancer genome. Then the two sets of genomic data are compared to find gene changes, known as mutations, that are specific to the tumor and that may be potentially driving the patient’s cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Study highlighting RNA role presented at recent ASCO meeting<br style="box-sizing:border-box;border-radius:0px;"></span>An Ashion study poster presented at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a target="_blank" href="https://urldefense.com/v3/__https:/tgen.us10.list-manage.com/track/click?u=6b0e128788a10661a1fb2d549&id=80cc45bf65&e=bcd23e9d1a__%3b%21%21Fou38LsQmgU%215is31ALaqgPXIWwf0RCLxSUwenylXnIgeVfTtWnkZc7oP1oqRiYeOToaeHqm$" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</a><span style="box-sizing:border-box;border-radius:0px;">.</span></p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics, LLC<br style="box-sizing:border-box;border-radius:0px;"></span>Ashion Analytics, LLC, is a CLIA-certified and CAP-accredited clinical laboratory that uses advanced genomic technologies to offer a wide range of testing capabilities to assist physicians, health systems, research and commercial partners to provide precision cancer treatments. Ashion was developed and launched by the <a target="_blank" href="https://www.tgen.org/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">Translational Genomics Research Institute</a> (TGen), an affiliate of <a target="_blank" href="https://www.cityofhope.org/impact?gclsrc=aw.ds&&gclid=EAIaIQobChMIyu7l0Jit6gIVHz2tBh02oA0BEAAYASAAEgIbkPD_BwE" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">City of Hope</a>. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Contact<br style="box-sizing:border-box;border-radius:0px;"></span>Laurie Goodman, Ph.D.<br style="box-sizing:border-box;border-radius:0px;">Director, Business Development and Medical Affairs<br style="box-sizing:border-box;border-radius:0px;">Ashion Analytics, LLC<br style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="mailto:lgoodman@ashion.com" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">lgoodman@ashion.com<br style="box-sizing:border-box;border-radius:0px;"></a>650-245-8410<br style="box-sizing:border-box;border-radius:0px;"><a target="_blank" href="http://www.ashion.com/" style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;">www.Ashion.com</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div class="uBlogsy_tag_container" style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <ul class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50" style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;"></ul> </div> <div class="uBlogsy_label_container" style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <div class="uBlogsy_labels_container" style="box-sizing:border-box;border-radius:0px;"></div> </div> </aside>​<br></div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>2020-07-14T07:00:00ZAshion Analytics
TGEN’S ASHION ANALYTICS CERTIFIED FOR NCI’S MATCH CANCER CLINICAL TRIALSTGEN’S ASHION ANALYTICS CERTIFIED FOR NCI’S MATCH CANCER CLINICAL TRIALS<div class="ExternalClass5F8DAADB97B14A0092D5EC15B5354F62"><html> <p style="text-align:center;">​<span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></p> <p style="text-align:left;"></p> <span id="ms-rterangepaste-start"></span> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — June 11, 2020 —</span> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">Ashion Analytics</a>, a clinical laboratory of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, is now part of the National Cancer Institute’s MATCH program, which provides patients who have rare or difficult-to-treat cancers with access to unique clinical trials nationwide that might give them the best therapeutic treatments and outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Ashion is one of the nation’s few dozen institutes participating in <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match" target="_blank">MATCH</a>, which stands for <span style="text-decoration:underline;">M</span>olecular <span style="text-decoration:underline;">A</span>nalysis for <span style="text-decoration:underline;">T</span>herapy <span style="text-decoration:underline;">CH</span>oice.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Unlike other MATCH participants, which screen patients with panels consisting of a few hundred known gene variants associated with various cancers, Ashion screens cancer patients for <em style="box-sizing:border-box;border-radius:0px;">all</em> of the nearly 3 billion nucleotides, or letters, in human DNA, which includes more than 19,000 genes. Ashion accomplishes this by performing <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Fact-Sheet" target="_blank">genomic sequencing</a> — a molecular-level analysis of each patient’s entire genome. Ashion scientists then <em style="box-sizing:border-box;border-radius:0px;">match</em> each patient’s unique cancer to the best available cancer treatments.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Our genomic cancer analysis is one of the nation’s most comprehensive tests, not only for the MATCH program, but for any cancer patient whose treating physician, or medical team, requires our precision-medicine guidance,” said Dr. Janine LoBello, Ashion’s Medical Director.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">One of the biggest perks for patients who become eligible to enroll in MATCH clinical trials is that the federal government covers the cost of their drugs, which can be substantial, often reaching six figures. MATCH patients, or their medical insurance providers, usually pick up other clinical costs.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em> </span> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;"> analyzes complete patient genome</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">To achieve this complete analytic coverage of the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets" target="_blank">human genome</a>, Ashion uses a proprietary test called <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/physicians-2/" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em></a>, which covers all protein coding regions of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.broadinstitute.org/blog/what-exome-sequencing" target="_blank">Exome</a>), <em style="box-sizing:border-box;border-radius:0px;">and</em> an analysis of all RNA, the messengers of DNA (known as the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.genome.gov/about-genomics/fact-sheets/Transcriptome-Fact-Sheet" target="_blank">Transcriptome</a>). <em style="box-sizing:border-box;border-radius:0px;">GEM</em> stands for <span style="text-decoration:underline;">G</span>enomic <span style="text-decoration:underline;">E</span>nabled <span style="text-decoration:underline;">M</span>edicine, and <em style="box-sizing:border-box;border-radius:0px;">ExTra</em> stands for <span style="text-decoration:underline;">Ex</span>ome and <span style="text-decoration:underline;">Tra</span>nscriptome.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em>, Ashion sequences both the individual patient’s normal genome and the patient’s cancer genome. Then the two sets of genomic data are compared to find the gene changes, known as mutations, that are specific to the tumor and may be potentially driving that patient’s cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Study highlighting RNA role presented at recent ASCO meeting</span> </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">An Ashion study poster presented May 29-31 at the 2020 annual meeting of the American Society for Clinical Oncology (ASCO) details the importance of using RNA as part of the analysis to give cancer physicians the best possible options for treating their patients: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3628" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">Employing RNA Sequencing to Enhance Treatment Options for Cancer Patients</em></a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“As you can imagine, this requires billions of precise data points to understand each patient’s molecular makeup; to understand which genes are the likely culprits involved in the patient’s cancer, and what therapeutic drug, or drugs, may be best to counter the patient’s disease,” Dr. LoBello explained.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This could include new therapeutics, as well as existing drugs already approved by the U.S. Food and Drug Administration (FDA) for a particular cancer. These FDA-approved drugs could be repurposed to fight a different cancer through any of the more than 1,100 sites nationwide that are conducting NCI-MATCH clinical trials. Clinical trials are most often the first tests of drugs in human patients, after the drugs have undergone substantial computer and laboratory testing to ensure they are safe and effective.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“We are excited to be selected by the National Cancer Institute to participate in the NCI’s MATCH program, and we hope that more patients will benefit from this program as a result of our <em style="box-sizing:border-box;border-radius:0px;">GEM ExTra</em> testing,” said Thomas Royce, Executive Director of Ashion.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">For more information, please visit <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="http://ashion.com/" target="_blank">ashion.com</a> or call 844-539-3309.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);text-align:center;"># # #</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About Ashion Analytics<br style="box-sizing:border-box;border-radius:0px;"></span>At Ashion, our goal is to accelerate the adoption of genomic analysis for clinical decision support to improve the treatment of patients with refractory, rare or aggressive disease. We are experts at Next-Generation Sequencing-based clinical laboratory services, deriving our pedigree from the pioneering precision medicine work at the Translational Genomics Research Institute (TGen) in Phoenix. Ashion Analytics’ mission is to develop and deliver the premier personalized medicine diagnostic, data analytic, and clinical coordination services, which assist healthcare providers in offering their patients individualized treatment options, and which improve outcomes.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a></p> <aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"> <div style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_tag_container"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;" class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50"></ul> </div> <div style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_label_container"> <div style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_labels_container"></div> </div> </aside>​<span id="ms-rterangepaste-end"></span><p style="text-align:left;"><br></p><ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="list-inline posted-info"><li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"><div><br><br></div></li></ul><p><br></p></html></div>https://biomedicalphoenix.com/Lists/News/Attachments/60/janine-lobello.jpg2020-07-11T07:00:00ZAshion Analytics
TGEN IDENTIFIES IMMUNE EFFECTS OF A DRUG IN AGGRESSIVE OVARIAN CANCER THAT STRIKES YOUNG WOMENTGEN IDENTIFIES IMMUNE EFFECTS OF A DRUG IN AGGRESSIVE OVARIAN CANCER THAT STRIKES YOUNG WOMEN<div class="ExternalClass3CF041C7829E46FDBFC6457C0CD849E1"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div style="box-sizing:border-box;border-radius:0px;"> <span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div> </li> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Friday July 10, 2020</li></ul> <h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="TGen identifies immune effects of a drug in aggressive ovarian cancer that strikes young women" href="https://www.tgen.org/news/2020/july/10/tgen-drug-could-enable-immune-attack-on-ovarian-cancer/" target="_blank">TGEN IDENTIFIES IMMUNE EFFECTS OF A DRUG IN AGGRESSIVE OVARIAN CANCER THAT STRIKES YOUNG WOMEN</a> </h2> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <em style="box-sizing:border-box;border-radius:0px;">SP-2577 could enable the immune system to attack ovarian cancer; clinical trials for patients expected soon</em> </p> </div> </div> <div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="row"> <div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 10, 2020 —</span> A drug known as SP-2577 could help enable the body’s own immune system to attack ovarian cancer, according to a study led by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Published today in the scientific journal <em style="box-sizing:border-box;border-radius:0px;">PLOS ONE</em>, the study builds on years of research led by <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/jeffrey-trent/" target="_blank">Dr. Jeffrey Trent</a>, TGen President and Research Director, into a type of ovarian cancer known as Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), an aggressive and deadly cancer that usually strikes girls and young women.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Clinical trials already are on the horizon to test SP-2577 in combination with another proven immunotherapeutic compound for the first time in patients with SCCOHT.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“Immunotherapy is the future of cancer treatment. Our combination of drugs should promote an immune response in an ovarian cancer that usually does not respond well to immunotherapies,” said Dr. Raffaella Soldi, a TGen Research Associate Professor and the lead author of the study. “One drug opens a biological gate, while the other drug helps push immune cells through the gate to attack the cancer.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">SP-2577, also known as Seclidemstat, was developed in the laboratory of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/sunil-sharma/" target="_blank">Dr. Sunil Sharma</a>, TGen Deputy Director of Clinical Sciences, and senior author of the study. Seclidemstat has already shown to be a promising drug in clinical trials against a bone cancer known as Ewing sarcoma.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Dr. Sharma, who also is Director of TGen’s Applied Cancer Research and Drug Discovery Division, explained that Seclidemstat works by inhibiting LSD1, a protein that is abundant in SCCOHT ovarian cancer. LSD1 also is implicated in initiating and aggressively accelerating many other types of cancer.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">“We suggest in this paper that LSD1 inhibition should improve the immune-therapy response in these tumors,” Dr. Sharma said. “This treatment is exquisitely dependent on the mutation found by Dr. Trent and his group. Without that mutation, this treatment would not work.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In 2014, Dr. Trent led and international team of investigators who discovered that <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2014/march/23/tgen-study-discovers-genetic-cause-of-rare-type-of-ovarian-cancer/?search=SMARCA4" target="_blank">a single mutation in a gene called SMARCA4</a> triggered SCCOHT. The SMARCA4 gene — previously associated with lung, brain and pancreatic cancer — was the only recurrently mutated gene in the study's ovarian cancer samples, a finding that at the time Dr. Trent likened to “a genetic superhighway.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">"Many genetic anomalies can be like a one-lane road to cancer; difficult to negotiate. But these findings indicate a genetic superhighway that leads right to this highly aggressive disease," Dr. Trent said at the time of his team’s discovery. "The correlation between mutations in SMARCA4 and the development of SCCOHT is simply unmistakable."</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">The study published today in <em style="box-sizing:border-box;border-radius:0px;">PLOS ONE</em> — <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235705" target="_blank"><em style="box-sizing:border-box;border-radius:0px;">The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer</em></a> — is based on TGen laboratory findings.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">In an upcoming clinical trial for those with SCCOHT ovarian cancer, patients will receive Seclidemstat plus another drug, Pembrolizumab, a proven immunotherapy treatment that prevents cancer from hiding from the body’s immune system. It uncloaks the tumor so immune cells can see the cancer and attack it.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Also contributing to this study were: the Lineberger Cancer Center at the University of North Carolina, HonorHealth Research Institute, and the Huntsman Cancer Institute at the University of Utah.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;">Seclidemstat was developed by Salarius Pharmaceuticals of Houston, which was established with the help of Dr. Sharma.<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"># # # <br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> </div> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/67/dr_sunil_sharma.jpg2020-07-10T07:00:00ZTGen
TGEN-LED STUDY IDENTIFIES UNIQUE CELLS THAT MAY DRIVE LUNG FIBROSISTGEN-LED STUDY IDENTIFIES UNIQUE CELLS THAT MAY DRIVE LUNG FIBROSIS<div class="ExternalClassAC8479D517B447C6A7DD906407E4BE29"><html> <span id="ms-rterangepaste-start"></span><div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"><div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"><ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;" class="list-inline posted-info"><li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"><div style="box-sizing:border-box;border-radius:0px;"><span style="box-sizing:border-box;border-radius:0px;">Written by</span> <span style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></div></li> <li style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;">Posted Wednesday July 8, 2020</li></ul><h2 style="box-sizing:border-box;border-radius:0px;font-family:"open sans", arial, sans-serif;line-height:33px;color:rgb(85, 85, 85);margin:0px 0px 20px;font-size:24px;text-shadow:none;text-transform:uppercase;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="TGen-led study identifies unique cells that may drive lung fibrosis" href="https://www.tgen.org/news/2020/july/08/tgen-study-identifies-cells-that-may-drive-lung-fibrosis/" target="_blank">TGEN-LED STUDY IDENTIFIES UNIQUE CELLS THAT MAY DRIVE LUNG FIBROSIS</a></h2><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"><em style="box-sizing:border-box;border-radius:0px;">Study with Vanderbilt University shows how the body’s attempts to repair damage may instead contribute to severe lung disease</em></p></div></div><div style="box-sizing:border-box;border-radius:0px;margin-right:-15px;margin-left:-15px;" class="row"><div style="box-sizing:border-box;border-radius:0px;min-height:1px;padding-right:15px;padding-left:15px;" class="col-md-12"><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">PHOENIX, Ariz. — July 8, 2020 —</span> A groundbreaking study published today and led by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, identifies unique lung cells that may drive Idiopathic Pulmonary Fibrosis (IPF), a deadly lung disease that affects hundreds of thousands of Americans, and for which there is no cure.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">This is one of the first comprehensive looks at lung cells using a technology called single-cell RNA sequencing. Instead of examining a mash-up of many cells from a tissue sample, single-cell sequencing allowed researchers in this study to closely examine the individual cells that make up the lungs; to identify their function, and ultimately understand the molecular changes that may be driving the disease.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Using this method, researchers identified five unique cells types associated with lung fibrosis, which could potentially lead to earlier diagnosis and therapeutic drug targets. </p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The study’s initial findings, published today as the cover story for the journal <em style="box-sizing:border-box;border-radius:0px;">Science Advances</em>, are the first under a combined <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/news/2019/march/27/nih-dod-grants-61-million-to-tgen-lung-research/?search=Banovich" target="_blank">$6.1 million in federal grants</a> aimed at uncovering the origins of lung disease, including IPF, the nation’s most common and severe form of fibrotic lung disease. An estimated 50,000 Americans, mostly middle-aged and older adults, are diagnosed each year with IPF. Most die from respiratory failure within five years.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In collaboration with <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.vumc.org/" target="_blank">Vanderbilt University Medical Center (VUMC)</a><span style="box-sizing:border-box;border-radius:0px;">, r</span>esearchers analyzed tissue samples from 20 lungs with pulmonary fibrosis provided by the Norton Thoracic Institute and VUMC, and tissue samples from 10 healthy lungs provided by the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.dnaz.org/" target="_blank">Donor Network of Arizona</a> and the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://tds.dcids.org/" target="_blank">Tennessee Donor Services</a>.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/nicholas-banovich/" target="_blank">Dr. Nicholas Banovich</a>, an Assistant Professor in TGen’s Integrated Cancer Genomics Division and co-senior author of the study, said the most interesting finding is the characterization of cells called <em style="box-sizing:border-box;border-radius:0px;">KRT5<span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">-</span>/KRT17<span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">+</span></em>, which appeared in the epithelium, or protective lining of the lungs, but only in individuals with pulmonary fibrosis.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“These cells are incredibly unique as they are clearly epithelial, but are also producing collagen and components of extra-cellular matrix (ECM), which make scar tissue,” Dr. Banovich said, “They are directly contributing to fibrosis.”  These cells also share characteristics of both the airway and alveolar epithelium, the respiratory membrane that allows the exchange of gases.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Another of the study’s most interesting findings is the high degree of plasticity, the ability of a cell to share characteristics with multiple classically defined cell types, in the lung epithelium.  </p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“Classically, the field used a small number of genes to determine cell types. With the single cell RNA sequencing approach, we find that it is often hard to draw a firm line between different types of cells,” Dr. Banovich said. “Instead of thinking of them as discrete cell types, we should think of them more along a continuum, and given the right stimulus, these cells can change their state.”</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">In addition to the <em style="box-sizing:border-box;border-radius:0px;">KRT5<span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">-</span>/KRT17<span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">+</span></em> cells, the study identified a cell type marked by the gene <em style="box-sizing:border-box;border-radius:0px;">SCGB3A2</em>. These cells are similar to club cells — an epithelial cell that lines the airways — yet are found almost exclusively in in pulmonary fibrosis. Unlike other airway epithelial cells, it appears these cells are able to transform into type 1 alveolar cells (AT1) — the cells where oxygen is taken into the body, and through which carbon dioxide is expelled — in an effort to repair damage to the lung.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">“In addition to becoming AT1 cells, our results suggest the <em style="box-sizing:border-box;border-radius:0px;">SCGB3A2<span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">+</span></em> cells can also become the  <em style="box-sizing:border-box;border-radius:0px;">KRT5<span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">-</span>/KRT17<span style="box-sizing:border-box;border-radius:0px;font-size:10.5px;line-height:0;vertical-align:baseline;top:-0.5em;">+</span></em> cells. It actually appears that, during the transformation into AT1 cells, the process is being hijacked and instead of helping repair the lungs these cells are pushed toward this weird pro-fibrotic epithelial cell that continues to drive fibrosis,” Dr. Banovich said.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Two other cells unveiled by the study are distinct subsets of fibroblasts, the cells that form normal connective tissue and scar tissue in the lungs, marked by high levels of the genes <em style="box-sizing:border-box;border-radius:0px;">PLIN2</em> or <em style="box-sizing:border-box;border-radius:0px;">HAS1</em>. These cells are also limited to pulmonary fibrosis.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">IPF is a progressive and irreversible disease characterized by a dry cough, fatigue, aching muscles and joints, and ever worsening shortness of breath. IPF and PF both scar and stiffen the interstitium — the delicate lace-like network that supports the lungs' tiny air sacs. IPF has both genetic and environmental risk, but the exact cause is unknown and current treatments short of a lung transplant only slow disease progression. Lung transplants are radical surgeries that usually require months of waiting for available organs, and often require a long and sometimes agonizing recovery.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The study acknowledges the help of: 10x Genomics and the Chan Zuckerberg Initiative in developing technology optimizations of the single-cell RNA sequencing; and the patients and organ donors who made this work possible.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">Also contributing to this study were co-first authors Austin Gutierrez and Dr. Linh Bui of TGen; and co-first author Arun Chris Habermann and co-senior author Dr. <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.kropskilab.org/" target="_blank">Jonathan Kropski</a> of VUMC.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);">The study — <em style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://advances.sciencemag.org/content/6/28/eaba1972?rss=1" target="_blank">Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis</a></em> — also was funded by grants from: the Doris Duke Charitable Foundation, the U.S. Department of Veterans Affairs, and Boehringer Ingelheim Pharmaceuticals.</p><div style="box-sizing:border-box;border-radius:0px;text-align:center;"># # #</div><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p><p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);"><span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a></p><aside class="uBlogsy_post_details" style="box-sizing:border-box;border-radius:0px;"><div style="box-sizing:border-box;border-radius:0px;overflow:hidden;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_tag_container"><ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:5px;list-style:none;font-size:11px;" class="margin-left-5 list-inline tags-v2 uBlogsy_font_style50"></ul></div><div style="box-sizing:border-box;border-radius:0px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="uBlogsy_label_container"><div style="box-sizing:border-box;border-radius:0px;" class="uBlogsy_labels_container"></div></div></aside>​<br></div></div><span id="ms-rterangepaste-end"></span><p><br></p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/66/dr_nicholas_banovich.jpg2020-07-08T07:00:00ZTGen
Project SOAR Participant on Her Way to Princeton UniversityProject SOAR Participant on Her Way to Princeton University<div class="ExternalClass2A646094C70042CE969ED46745E84650"><html> ​<span style="font-family:hind, "open sans", sans-serif;font-size:16px;background-color:window;color:windowtext;">​Melanie Delgado Santacruz is a participant in the city’s ROSS for Education program - also known as Project SOAR (Student + Opportunities + Achievements = Results). She is a recent Phoenix Union Bioscience High School graduate.</span><br><div class="news-item-text2 full-text" style="height:auto;overflow:hidden;padding:10px 0px;box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"><p style="margin-bottom:14px;box-sizing:border-box;font-family:hind, "open sans", sans-serif !important;line-height:18px !important;">She enrolled in Project SOAR in 2017 as a Sophomore with a 4.0 GPA, was a member of the National Honor Society and a participant with the Be A Leader Foundation. Be a Leader empowers students with leadership skills and support through high school.</p><p style="margin-bottom:14px;box-sizing:border-box;font-family:hind, "open sans", sans-serif !important;line-height:18px !important;">Upon enrollment in the city’s program, Melanie was self-sufficient, however, she gained additional support from her Education Navigator, Bethany Neal, who was always available to provide advice on navigating the education system and case management services. Melanie completed her Free Application for Federal Student Aid (FAFSA) in 2019 at the city’s College Depot. </p><p style="margin-bottom:14px;box-sizing:border-box;font-family:hind, "open sans", sans-serif !important;line-height:18px !important;">Not only has Melanie completed high school, but she was accepted to Princeton University with a full-ride scholarship. She is one of 50 students chosen for the Jack Kent Cooke Scholarship and the only recipient from Arizona.</p><p style="margin-bottom:14px;box-sizing:border-box;font-family:hind, "open sans", sans-serif !important;line-height:18px !important;">Melanie has started online classes with a summer bridge program for first-generation students and will officially start as a freshman at Princeton in the fall.</p><p style="margin-bottom:14px;box-sizing:border-box;font-family:hind, "open sans", sans-serif !important;line-height:18px !important;">Melanie plans to major in engineering. She is very honored and excited to be attending Princeton.</p><p style="margin-bottom:14px;box-sizing:border-box;font-family:hind, "open sans", sans-serif !important;line-height:18px !important;">CONGRATULATIONS Melanie!</p></div><div class="social-hashtags" style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"><label style="font-family:hind, "open sans", sans-serif;box-sizing:border-box;">Related Social Media Hashtags and Handles: </label><span style="font-weight:bold;box-sizing:border-box;"><a target="_blank" href="https://www.phoenix.gov/newsroom/search?k=social:%40Princeton" style="color:rgb(32, 173, 149);background:transparent;font-family:hind, sans-serif;transition:all 0.2s ease-in-out 0s;box-sizing:border-box;">@Princeton</a></span></div><div class="keywords-container" style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"><label style="font-family:hind, "open sans", sans-serif;box-sizing:border-box;">Keywords: </label><span style="font-weight:bold;box-sizing:border-box;"><a target="_blank" href="https://www.phoenix.gov/newsroom/search?k=kw:Project%20SOAR" style="color:rgb(32, 173, 149);background:transparent;font-family:hind, sans-serif;transition:all 0.2s ease-in-out 0s;box-sizing:border-box;">Project SOAR</a>, <a target="_blank" href="https://www.phoenix.gov/newsroom/search?k=kw:ROSS%20for%20Education" style="color:rgb(32, 173, 149);background:transparent;font-family:hind, sans-serif;transition:all 0.2s ease-in-out 0s;box-sizing:border-box;">ROSS for Education</a>, <a target="_blank" href="https://www.phoenix.gov/newsroom/search?k=kw:College%20Depot" style="color:rgb(32, 173, 149);background:transparent;font-family:hind, sans-serif;transition:all 0.2s ease-in-out 0s;box-sizing:border-box;">College Depot</a>​</span></div><span id="ms-rterangepaste-end"></span><p><br></p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/55/Newsroom_Housing_023.jpg2020-07-02T07:00:00ZPhoenix Bio News
TGEN TEAMS WITH POBA MEDICAL TO PRODUCE 10,000 COVID-19 TEST KITS PER MONTHTGEN TEAMS WITH POBA MEDICAL TO PRODUCE 10,000 COVID-19 TEST KITS PER MONTH<div class="ExternalClass1C5F4EADBBA94332BB8C1CE491751F56"><html> <p style="text-align:center;">​<span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;">Written by</span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;"> </span><span style="font-style:italic;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;background-color:window;box-sizing:border-box;border-radius:0px;" class="uBlogsy_author_name"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(85, 85, 85);outline:0px !important;" title="Steve Yozwiak" href="https://www.tgen.org/news/?author=Steve+Yozwiak" target="_blank">Steve Yozwiak</a></span></p> <p style="text-align:left;"></p> <span id="ms-rterangepaste-start"></span> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">FLAGSTAFF, Ariz. — July 2, 2020 —</span> In response to the continuing need for more COVID-19 diagnostic tests, the <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">Translational Genomics Research Institute (TGen)</a>, an affiliate of <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">City of Hope</a>, is working with Poba Medical in northern Arizona to produce 10,000 coronavirus test kits per month, it was announced today.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.pobamedical.com/" target="_blank">Poba Medical</a> is in the same industrial park near the Flagstaff airport as TGen’s Pathogen and Microbiome Division, the institute’s infectious disease branch, also known as TGen North, where TGen’s efforts against the new coronavirus is centered.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">This partnership is helping TGen North fill the gaps in Arizona’s testing systems by focusing on highly vulnerable and underserved groups across the state, including: tribal, indigent and psychiatric health services, county jails, front-line medical workers at community healthcare centers, and as needed for the Arizona Department of Health Services (ADHS).</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">A maker of specialized medical devices, Poba Medical’s large antiseptic cleanroom within its 20,000-square-foot facility is an ideal location for TGen’s COVID-19 test kit assembly line, said <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/faculty-profiles/david-engelthaler/" target="_blank">Dr. David Engelthaler</a>, Director of TGen North.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">“As part of TGen’s efforts to test, trace and treat patients with COVID-19, our partnership with Poba Medical is a logistical no-brainer. We can literally walk across a parking lot to get the kits as they are produced,” Dr. Engelthaler said. “We are fortunate to have such a strong partnership with another Flagstaff biomedical company.”</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">A maker of catheters and thermoplastic balloons for a variety of interventional devices and surgical applications, Poba Medical realized that they had extra capacity in their cleanroom to accommodate TGen’s test kit assembly, and without hindering any of their other ongoing medical equipment manufacturing.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">“Amidst the COVID-19 pandemic, our Poba Medical team became aware of TGen’s efforts to develop test kits in response to the pandemic, and we wanted to make sure that we contributed to the cause in the best way that our company could,” said Cristian Montanez, Poba Medical’s Senior Operations Manager.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">“Poba’s ability to assemble the test kits for TGen advances the overall effort to produce thousands of units quickly, and potentially save more lives,” Montanez said.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">TGen provides the contents of the test kits, including swabs, tubes and medium to stabilize the samples until they can be analyzed. They are then assembled into test kits in Poba Medical’s cleanroom assembly lines.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">“We are in constant contact with all of our partners across Arizona, and we can now ship these tests kits wherever needed, and whenever needed,” Dr. Engelthaler said. Couriers return boxes of completed test kits for TGen to analyze, and those boxes are then refilled by Poba Medical with new test kits so they can be sent out again to TGen’s medical service partners.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">To date, TGen has analyzed more than 15,000 COVID-19 samples, and continues to ramp up its testing capacities.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;">Poba Medical, which opened in Flagstaff in January 2019, serves a range of global customers, from startups to large multi-national companies. TGen is its only COVID-19 test kit assembly customer. Please see a video of test kits as they are assembled: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://youtu.be/qQV4Hu6JIPA" target="_blank">https://youtu.be/qQV4Hu6JIPA<br style="box-sizing:border-box;border-radius:0px;"><br style="box-sizing:border-box;border-radius:0px;"></a># # # </p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">About TGen, an affiliate of City of Hope<br style="box-sizing:border-box;border-radius:0px;"></span>Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.cityofhope.org/homepage" target="_blank">www.cityofhope.org</a>.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.tgen.org/" target="_blank">www.tgen.org</a>. Follow TGen on <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.facebook.com/helptgen" target="_blank">Facebook</a>, <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://www.linkedin.com/company/tgen/" target="_blank">LinkedIn</a> and <a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="https://twitter.com/TGen" target="_blank">Twitter @TGen</a>.</p> <p style="box-sizing:border-box;border-radius:0px;margin:0px 0px 20px;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;"> <span style="box-sizing:border-box;border-radius:0px;font-weight:700;">Media Contact:<br style="box-sizing:border-box;border-radius:0px;"></span>Steve Yozwiak<br style="box-sizing:border-box;border-radius:0px;">TGen Senior Science Writer<br style="box-sizing:border-box;border-radius:0px;">602-343-8704<br style="box-sizing:border-box;border-radius:0px;"><a style="box-sizing:border-box;border-radius:0px;background-color:transparent;color:rgb(12, 72, 135);outline:0px !important;" href="mailto:syozwiak@tgen.org" target="_blank">syozwiak@tgen.org</a>​<br></p> <span id="ms-rterangepaste-end"></span> <p style="text-align:left;"> <br> </p> <ul style="box-sizing:border-box;border-radius:0px;margin-top:0px;margin-bottom:10px;padding-left:0px;margin-left:-5px;list-style:none;color:rgb(85, 85, 85);font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14px;" class="list-inline posted-info"> <li style="box-sizing:border-box;border-radius:0px;display:inline-block;padding-right:5px;padding-left:5px;font-style:italic;"> <div> <br> <br> </div> </li> </ul> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/58/dave-engelthaler-horizontal.jpg2020-07-02T07:00:00ZTGen
Arizona and COVID-19: A Doctor on the Front LinesArizona and COVID-19: A Doctor on the Front Lines<div class="ExternalClass9D792BF8AC314BCFA7F706D6B7CBF994"><html> <p style="text-align:center;">​In this June 27, 2020, file photo, medical personnel prepare to test hundreds of people lined up in vehicles in Phoenix's western neighborhood of Maryvale for free COVID-19 tests.</p> <p style="text-align:center;">( AP Photo/Matt York, File )<br></p> <p style="text-align:left;"></p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:inherit;padding-left:0px;padding-right:0px;" class="story__details"> <div style="box-sizing:inherit;" class="ember-view"> <div style="box-sizing:inherit;" class="story__body"> <div style="box-sizing:inherit;" class="ember-view"> <div style="box-sizing:inherit;font-family:"open sans", "segoe ui", tahoma, sans-serif;font-size:18px;line-height:1.5;margin:0px auto 67px;width:800px;max-width:800px;" class="django-content"> <div style="box-sizing:inherit;"> <p style="box-sizing:inherit;line-height:1.5;">This past week, there has been an explosion of COVID-19 cases in Arizona. On Sunday, <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" href="https://www.npr.org/sections/coronavirus-live-updates/2020/06/29/885067257/arizona-issues-new-shutdown-order-as-coronavirus-cases-spike" target="_blank">nearly 4,000 people</a> tested positive for the virus in the state, nearly double the number of cases reported the previous week.<br></p> <p style="box-sizing:inherit;line-height:1.5;">Since the crisis began, <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" href="https://www.azdhs.gov/preparedness/epidemiology-disease-control/infectious-disease-epidemiology/covid-19/dashboards/index.php" target="_blank">nearly 75,000 people</a> have tested positive for the virus in Arizona and close to 1,600 people have died.</p> <p style="box-sizing:inherit;line-height:1.5;">Arizona is just one of the states that began to reopen businesses earlier than the <span style="box-sizing:inherit;">Centers for Disease Control and Prevention </span>recommended, only to see a surge in confirmed COVID-19 cases shortly thereafter. Similar spikes are being seen in California and Texas.</p> <p style="box-sizing:inherit;line-height:1.5;">On Monday, Arizona Governor Ducey announced the 30-day closure of bars, gyms, and other businesses.</p> <p style="box-sizing:inherit;line-height:1.5;">And as of today, more than 126,000 people have died overall in the U.S. from the pandemic.</p> <p style="box-sizing:inherit;line-height:1.5;"> <span style="box-sizing:inherit;font-weight:600;">Dr. Frank LoVecchio</span> is a professor of Emergency Medicine at the University of Arizona in Phoenix, and he joins The Takeaway to discuss what he is seeing, and how health care workers are reacting to the crisis.</p> <p style="box-sizing:inherit;line-height:1.5;">Check out our ongoing coverage of the COVID-19 pandemic <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" href="https://www.wnycstudios.org/podcasts/takeaway/projects/covid-19-ongoing-coverage-coronavirus-outbreak" target="_blank"><em style="box-sizing:inherit;">here</em></a>. </p> <p style="box-sizing:inherit;line-height:1.5;">Click on the 'Listen' button above to hear this segment. Don't have time to listen right now? Subscribe for free to our podcast <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" href="https://itunes.apple.com/us/podcast/the-takeaway/id363143310?mt=2" target="_blank">via iTunes</a>, <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" target="_blank" href="https://tunein.com/radio/The-Takeaway-p150731/">TuneIn</a>, <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" target="_blank" href="https://www.stitcher.com/podcast/the-takeaway">Stitcher</a>, or wherever you get your podcasts to take this segment with you on the go.</p> <p style="box-sizing:inherit;line-height:1.5;"> <em style="box-sizing:inherit;">Want to comment on this story? Share your thoughts on our <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" target="_blank" href="https://www.facebook.com/thetakeaway">Facebook page</a>, <a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" href="https://twitter.com/TheTakeaway" target="_blank">Twitter</a>, or<span style="box-sizing:inherit;"> </span><a style="box-sizing:inherit;background-color:transparent;color:rgb(4, 141, 153);font-weight:600;" href="http://instagram.com/thetakeaway" target="_blank">Instagram</a>.</em> </p> <div> <em style="box-sizing:inherit;"> <br> </em> </div> </div> </div> </div> </div> </div> </div> <div style="box-sizing:inherit;font-family:"open sans", "segoe ui", tahoma, sans-serif;max-width:850px;padding:0px;margin:0px auto;font-size:18px;line-height:1.5;" class="story-credits ember-view"> <div style="box-sizing:inherit;" class="story-credits__appearance-credits"></div> <div style="box-sizing:inherit;margin-top:30px;" class="story-credits__producing-org-credits producing-org-credits">​<br></div> </div> <span id="ms-rterangepaste-end"></span> <p style="text-align:left;"> <br> </p> <p> <br> </p> </html></div>2020-06-30T07:00:00ZUA
The Classic ‘Chicken-or-Egg’ Question Comes to CancerThe Classic ‘Chicken-or-Egg’ Question Comes to Cancer<div class="ExternalClassF962247EB86845EB90EF51B399640A55"><html> <p style="text-align:center;">​<span style="font-family:miloweb, -apple-system, blinkmacsystemfont, "segoe ui", roboto, "helvetica neue", arial, "noto sans", sans-serif, "apple color emoji", "segoe ui emoji", "segoe ui symbol", "noto color emoji";font-size:12px;">Melissa Herbst-Kralovetz, PhD</span><br></p> <p style="text-align:left;"></p> <span id="ms-rterangepaste-start"></span>Can Bacteria be Harnessed to Defend Against Disease?<br>Unanswered questions swirl around the microbiome — habitats in our bodies that diverse species of bacteria call home. Scientists are only just starting to scratch the surface of how these bacteria interact with our unique body chemistries to influence our health. One of those scientists is Melissa Herbst-Kralovetz, PhD, associate professor of Basic Medical Sciences and Obstetrics/Gynecology at the University of Arizona College of Medicine – Phoenix, director of the Women’s Health Microbiome Initiative, and member of the UArizona Cancer Center, who says the riddles posed by the vaginal microbiome captivated her early in her career.<br>Paweł Łaniewski, PhD, and Melissa Herbst-Kralovetz, PhD, Dip into Their Cell Supply, Which is Stored at −80° Celsius<br>“At first, I wanted nothing to do with it, because it was too difficult to model,” she recalled. “Then you get hooked on it and you’re like, ‘I need to learn more!’ It’s really complex, but really fun, too.”<br>Today, from her lab on the Phoenix Biomedical Campus in downtown Phoenix, Dr. Herbst-Kralovetz leads a team of researchers who are working to better understand how to predict, prevent and treat gynecologic cancers.<br>Bad Bugs and Gynecologic Cancer<br>One of the microbiome’s many mysteries involves the single-celled version of the eternal question: What came first, the chicken or the egg? In the Herbst-Kralovetz Lab, that question is more like: What came first, the cancer or the bugs? It’s a deceptively complex question, and the answer can tell us if we can prevent certain types of cancer or simply predict them — and gets to the heart of one of the most important concepts in science: causation.<br>Research coming out of the Herbst-Kralovetz Lab and across the world is pointing to similar conclusions: that there are “good” vaginal bacteria that are associated with health, and “bad” bacteria that are associated with diseases like cancer. But are these “bad” bacteria causing cancer, or are they simply bystanders?<br>“Association versus causation is a major issue in the field,” Dr. Herbst-Kralovetz said. “These bacteria are in the specimens we collect, but the big question is, are they influencing carcinogenesis? Were they there the whole time or do they favor this new environment?”<br>Dr. Herbst-Kralovetz has conducted studies examining the vaginal microbiomes of women with and without cervical cancer — which is caused by a virus that is usually cleared by the immune system but can sometimes persist, leading to cancer. It turns out that “good” bacteria called lactobacilli are associated with cervical health, while “bad” bugs like Sneathia and other anaerobic bacteria are associated with the persistence of the viral infection and possibly the development of cervical cancer. Her lab has begun uncovering interesting associations between the vaginal microbiome and endometrial cancer related to pH. More optimal microbiomes are dominated by lactobacilli, which lower the vaginal pH by releasing lactic acid.<br>“Our studies are really preliminary right now, but we’ve seen a significant difference in the vaginal pH between women with and without endometrial cancer, which is a really low-tech way to look at the vaginal community,” Dr. Herbst-Kralovetz said. “When you have a depletion of lactobacilli, you have an overgrowth of these bad bacteria. Then you increase your pH.”<br>“Good” Vaginal Bacteria, Shown Here in Green Inhabiting the Vaginal Tissue, Appear to Support Women’s Health, while “Bad” Bacteria, Shown Here in Red, are Associated with Disease<br>Her lab is conducting the largest study in history to investigate the connection between the vaginal microbiome and endometrial cancer. When the results are in, she hopes to shed light on whether any particular species of bacteria might be associated with the development of endometrial cancer.<br>“We’ve really tried to make our studies stand apart from others. Right now, we have 200 specimens. Other studies have collected 30 or 40 samples,” Dr. Herbst-Kralovetz said. “It’s taking time because I wanted to be thorough.”<br>Drivers and Passengers<br>Dr. Herbst-Kralovetz talks of cancer progression as a journey with a beginning and an end. We don’t know if the “bad” cancer-associated bacteria are along for the ride — or if they’re in the driver’s seat on the road to cancer. If Sneathia or another bug is shown to be behind the wheel, potential therapeutic interventions could be developed to target the cancer early — and force a U-turn. Scientists also would be able to devise powerful new strategies for cancer prevention by figuring out how to kill the bad bugs and replace them with beneficial bugs.<br>Bustling with Activity, the Herbst-Kralovetz Lab is Focused on Solving Complex Problems in Women’s Health<br>“If these bacteria are drivers of carcinogenesis, blocking them would make sense,” Dr. Herbst-Kralovetz said. “Figuring out how to reinstate beneficial bacteria also would be really important.”<br>But if the so-called bad bugs are in the passenger’s seat, they might just be sitting there quietly, hoping to get to their destination: a cancerous environment where they can thrive. Once they get there, they might proliferate wildly, obscuring the actual drivers from view. If a bug is a passenger rather than a driver, targeting it for destruction wouldn’t help — but its presence could be a sign that the body is on the road to cancer.<br>“Using them as a potential biomarker could give us an early prediction of cancer,” Dr. Herbst-Kralovetz said. “We could intervene before cancer occurs.”<br>Improving Cancer Survivorship<br>Once someone has cancer, however, it’s too late to prevent or predict it. But even at this point, solving the mysteries of the microbiome can still help improve survival and quality of life.<br>To prevent Contamination with Other Bacteria, Dr. Herbst-Kralovetz Sterilizes Her Tools with an Open Gas Flame<br>Immunotherapy, a cancer treatment that trains the immune system to attack cancer cells, might be affected by the composition of the vaginal microbiome. Studies of the gut microbiome show that patients who respond to immunotherapy have different populations of bacteria, which might be boosting the treatment’s effectiveness — and experiments in mice show that a fecal transplant from a responder to a non-responder can enhance the transplant recipient’s response to immunotherapy. But those studies are in the gut, not the vagina, and in mice, not humans. Scientists are a long way from figuring out if altering the vaginal microbiome might work hand in hand with immunotherapy to defeat cancer.<br>There also is compelling evidence that radiation and chemotherapy can throw the microbiome out of balance — and that an off-kilter microbiome somehow interferes with these treatments, making them less effective and more toxic.<br>“We think these therapies probably alter the vaginal microenvironment, especially if you’re getting pelvic radiation for gynecologic cancer,” Dr. Herbst-Kralovetz said. “But we don’t have any data yet.”<br>That lack of data means that, so far, there isn’t a recipe to create synthetic microbial cocktails of “good” bacteria that might boost cancer treatments’ effectiveness and blunt their negative side effects.<br>It can take a lifetime to untangle even one of the connections between myriad species of vaginal bacteria, several types of gynecologic cancer and countless other variables. Dr. Herbst-Kralovetz says she is up to the task, because for her, this riddle isn’t just a mesmerizing brainteaser — the answers she finds will benefit anyone at risk for gynecologic cancer.<br>The story originally appeared on University of Arizona Health Sciences' website and was written by Anna Christensen, MPH.​<span id="ms-rterangepaste-end"></span><p style="text-align:left;"><br></p></html></div>https://biomedicalphoenix.com/Lists/News/Attachments/63/herbst-kralovetz-uahs-header.jpg2020-06-17T07:00:00ZUA
Reinventing Medical Residencies During COVID-19Reinventing Medical Residencies During COVID-19<div class="ExternalClassA5CE3AC77C75409E85F211BA9FC54CEC"><html> <p style="text-align:center;"><span style="font-size:14.6667px;"></span><span style="font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:14.6667px;">By </span><a style="color:rgb(26, 133, 181);font-weight:bold;font-family:"helvetica neue", helvetica, arial, sans-serif;" href="https://kjzz.org/staff/400" target="_blank"><span style="font-size:14.6667px;">Nicholas Gerbis</span></a><span style="font-size:14.6667px;">​</span><span style="font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;background-color:window;color:windowtext;display:inline-block;text-align:justify;vertical-align:bottom;width:83px;height:20px;"></span><span style="text-align:left;font-family:"helvetica neue", helvetica, arial, sans-serif;color:rgb(102, 102, 102);font-size:2em;background-color:window;">​​</span><img style="font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;color:windowtext;border-width:0px;border-style:initial;text-align:right;background-color:window;max-width:100%;margin:5px;width:0px;" class="file-icon" alt="Audio icon" title="audio/mpeg" src="https://kjzz.org/modules/file/icons/audio-x-generic.png" /><span style="font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;color:windowtext;text-align:right;background-color:window;"> </span><span style="font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;text-align:right;background-color:window;cursor:pointer;font-weight:bold;color:rgb(54, 184, 243);">Download mp3</span><span style="font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;color:windowtext;text-align:right;background-color:window;"> </span><span style="font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;color:windowtext;text-align:right;background-color:window;" class="file-size">(1.04 MB)</span></p><div><div class="panel-separator" style="margin:0px 0px 0em;font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;"></div><div class="panel-pane pane-custom pane-4 node-body no-title block" style="margin-bottom:0px;border-top:none;clear:both;padding-top:20px;font-family:"helvetica neue", helvetica, arial, sans-serif;font-size:16px;"><div class="block-inner clearfix" style="zoom:1;margin-left:10px;margin-right:10px;"><div class="block-content"><p style="margin:0px 0px 1.5em;">Coronavirus has profoundly changed how we educate and employ a whole cohort of students — including the next generation of doctors seeking residencies.</p><p style="margin:0px 0px 1.5em;">Medical residencies train students in prospective specialties. Applying for them involves a stressful and pricey process.</p><p style="margin:0px 0px 1.5em;">Students know distinguishing themselves on board exams or during rotations can help them stand out and acquire letters of recommendation. By curtailing such activities, COVID-19 injects even more uncertainty into an often perplexing process.</p><p style="margin:0px 0px 1.5em;">To cope, medical schools are considering deferring certain requirements and shifting key deadlines.</p><p style="margin:0px 0px 1.5em;">Dr. Cheryl O'Malley, associate dean of graduate medical education at the University of Arizona College of Medicine – Phoenix, says the Coalition on Physician Accountability has recommended against traveling for rotations and in-person visits.</p><p style="margin:0px 0px 1.5em;">"That's really creating a significant change in the usual processes for consideration of programs on the medical student's side and also consideration of applicants on the program side," she said.</p><p style="margin:0px 0px 1.5em;">In-person visits and interviews provide an essential chance for students and programs to find out if they're a good match. But they also represent a sizable share of applicants' considerable travel expenses — costs some can better afford than others.</p><p style="margin:0px 0px 1.5em;">"By having the interviews and visits be virtual, it does level the playing field," said O'Malley.</p><p style="margin:0px 0px 1.5em;">Virtual interviews and visits also make more efficient use of another resource doctors and med students have in short supply: time.</p><p style="margin:0px 0px 1.5em;">But some experts worry students, now more uncertain than ever about how programs will evaluate them, might apply for even more residencies. That could worsen an already troubling trend of application inflation.</p><p style="margin:0px 0px 1.5em;">"There's been a lot of creative discussion about how to approach that in a way that doesn't limit choice, but that really eliminates some of the waste," said O'Malley.</p><p style="margin:0px 0px 1.5em;">Some solutions inspired by current conditions might prove effective enough to keep.</p><p style="margin:0px 0px 1.5em;">For example, if programs evaluated students more holistically and were less bound to formulas, applicants might obsess less about hitting every requirement or deferring exams.</p><p style="margin:0px 0px 1.5em;">O'Malley said the medical school has been moving towards more a holistic approach, but it presents substantial challenges.</p><p style="margin:0px 0px 1.5em;">"We can look at their academic performance; you can look at activities and research that they've participated in. And some of those are really hard to put numbers behind," she said.</p><p style="margin:0px 0px 1.5em;">O'Malley also emphasized the importance of interpersonal skills and finding the right fit. Remote interviews could support those types of evaluations.​<br></p></div></div></div></div><span id="ms-rterangepaste-end"></span><p style="text-align:left;"><span style="font-size:14.6667px;"><br></span></p> </html></div>2020-06-15T07:00:00ZUA
3 Arizona startups compete in international bioscience competition3 Arizona startups compete in international bioscience competition<div class="ExternalClassDE7643A1236E4FB483C2BE385E6995EF"><html> <p>​​</p> <span id="ms-rterangepaste-start"></span> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Pamela Turbeville only has six minutes to pitch a product she spent six years working on. </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">If her pitch is successful, she could land meetings with big-name investors at one of the largest bioscience conferences globally.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;text-align:center;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <em style="box-sizing:border-box;">By Amanda Morris for The Arizona Republic</em> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">She is one of 30 finalists competing at this year's Bio International Startup Stadium contest, which helps to launch early-stage bioscience companies.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">In this year's virtual competition, judges will review six-minute pitch videos submitted by each finalist and select several winners.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Each competitor must be a small bioscience startup that has less than 20 employees. The idea, said Nareg Sagherian, a Bio International managing director, is to spotlight promising young companies that might otherwise be overlooked at a large international conference.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Read the full story at <a href="https://www.azcentral.com/story/news/local/arizona-science/2020/06/11/three-arizona-startups-compete-international-bioscience-competition-covid/5324319002/" target="_blank" style="color:rgb(32, 173, 149);background:transparent;font-family:hind, sans-serif;transition:all 0.2s ease-in-out 0s;box-sizing:border-box;">AZCentral​</a>​</span> </div> <span id="ms-rterangepaste-end"></span> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/54/NEWSROOM_CED_0075.jpg2020-06-11T07:00:00ZPhoenix Bio News
Listen to Phoenix Leaders Share Insights about the Rising Bioindustry in the Nation’s 5th Largest City Listen to Phoenix Leaders Share Insights about the Rising Bioindustry in the Nation’s 5th Largest City <div class="ExternalClass85477EA12D3E483194E93A2800419195"><html> Listen to conversations with Phoenix Mayor Kate Gallego and other leaders as they share their insights with Tom Osha, Senior Vice President of Innovation and Economic Development at Wexford Science+Technology, about Phoenix’s growing and thriving bioindustry ecosystem.<br><br>Listen to these conversations beginning June 8, 2020 <a target="_blank" href="https://wexfordscitech.com/thecommons/"><strong><em>here</em></strong></a>:<br><ul><li><strong>Episode 1 –</strong> <em>The Role of Innovation Districts in Restarting the Economy</em><br></li><li><strong>Episode 2 </strong>– <em>Arizona’s Life Sciences Roadmap</em><br></li><li><strong>Episode 3 </strong>– <em>Phoenix is HOT! And so is the Phoenix Biomedical Campus</em></li><li><strong>Episode 4 </strong>– <em>ASU #1 for Innovation</em></li><li><strong>Episode </strong><strong>5 </strong>– <em>A Fertile Environment for Start-Ups: The OncoMyx Story</em></li><li><strong>Episode </strong><strong>6 </strong>– <em>Building the Life Sciences Workforce</em></li><li><strong>Episode </strong><strong>7 </strong>– <em>The Wexford Knowledge Community</em></li></ul>Sparking collaboration is the purpose of the Phoenix bioindustry ecosystem. Phoenix, Arizona, where each day is a relentless pursuit of cures. From discovery to delivery, join Phoenix companies and the leading edge of personalized medicine. Come to a young, vibrant community in an environment where ideas thrive. With a lack of barriers to enter the market, America’s fastest-growing population, and an entrepreneurial pioneer spirit, this is the place for rising to success. Join Translational Genomics Research Institute, three research universities, and world class bioscientists on the Phoenix Biomedical Campus. Located in dynamic Downtown Phoenix, home to Wexford Science and Technology’s collaboration-designed bioscience research building, the Center for Entrepreneurial Innovation, and unlimited opportunities. Learn more at <a target="_blank" href="/"><strong>www.biomedicalphoenix.com</strong></a> and <a target="_blank" href="https://www.phoenix.gov/econdev/bio"><strong>www.phoenix.gov/econdev/bio</strong> </a> <p> <br> </p> </html></div>2020-06-05T07:00:00ZWexford
Three Phoenix Startups to Compete on BIO International World StageThree Phoenix Startups to Compete on BIO International World Stage<div class="ExternalClass545019A208DD486DB24BA73FA8872060"><html> <p>​​<span style="font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;background-color:window;color:windowtext;">“Think about the thousands and thousands of bioscience startups around the world. Then out of all those companies located in hundreds of different global cities, only 30 have been selected as the best to compete in the Startup Stadium,” said Christine Mackay, director, Phoenix Community and Economic Development. “Of those 30 companies, three are from the city of Phoenix. That is an incredible accomplishment for the three companies and the Phoenix bioscience ecosystem.”</span></p> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;text-align:center;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;text-align:center;"> <em style="box-sizing:border-box;">By Eric Jay Toll for PHXNewsroom. Athena Sanchez contributed to this story</em> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;"></span> <span style="box-sizing:border-box;font-size:13.3333px;">BioMedical Sustainable Elastic Electronic Devices</span>​​<span style="box-sizing:border-box;"></span>, Equus Innovations and i-calQ will face off in front of an international panel of judges in a “Shark Tank” competition of bioscience startups in competition for venture capital, strategic partnerships and collaborative opportunities at the BIO International 2020 Startup Stadium, June 8-12, 2020.  This year’s event will be virtual. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Phoenix-based Humabiologics, a Phoenix Startup Stadium finalist from last year’s competition, closed a $1 million seed money investment deal in May.<br style="box-sizing:border-box;"><br style="box-sizing:border-box;"></div> <span style="font-weight:700;box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:17.3333px;">BMSEED to Provide Traumatic Brain Injury Repair Technology to U.S. Army</span> <span style="font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"></span> <br style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">​With an estimated 2.5 million Americans suffering a Traumatic Brain Injury each year, Oliver Graudejus turned a research project that he worked on at Princeton University into a groundbreaking biotechnology achievement today.<br style="box-sizing:border-box;"></div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <img src="https://www.phoenix.gov/econdevsite/MediaAssets/Other/NEWSROOM_CED_0067.jpg" style="border-width:0px;border-style:initial;width:495px;max-width:100%;box-sizing:border-box;margin:5px;" class="" />Graudejus, founder and CEO of BioMedical Sustainable Elastic Electronic Devices, headquartered in Phoenix, Arizona, said that the company’s long-term goal is go to market with a “neuromodulation” brain implant that a patient’s body will not recognize as a foreign object, and therefore won’t reject it. The innovation landed BMSEED its first customer, the U.S. Army.<br style="box-sizing:border-box;"></div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">BMSEED’s technological advance is a more effective manner of sending electrical impulses to the brain to treat the symptoms of TBI. “Neuromodulation” is the name for the electronic impulse technique that helps repair and reverse TBI and other brain diseases.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“BMSEED’s quest to help treat traumatic brain injuries brings both a solution and hope for affected individuals and their loved ones,” said Phoenix Mayor Kate Gallego. “They are a great example of the many vibrant startups that have made Phoenix home.“</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">BMSEED’s first product is a research tool that helps researchers develop treatments to mitigate the damage after a traumatic brain injury. This product, called the MicroElectrode Array Stretching Stimulating and Recording Equipment, or “MEASSuRE,” is urgently needed because all of the 30 clinical trials to develop treatments for traumatic brain injury over the past 25 years have failed, according to professor Barclay Morrison III, director of the Neurotrauma and Repair Laboratory at the Biomedical Engineering Department at Columbia University, New York City. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“The product reproduces the biomechanical environment of cells during the injury, and our stretchable electrodes allow the assessment of cell health and function,” Graudejus said. “That’s where BMSEED technology comes in, making soft, flexible and stretchable electrodes. The next step is to use these electrodes inside the body, with the goal that the body doesn’t see the device as a foreign object and try to reject it.” </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Mackay says that the discoveries by Phoenix bioscience companies seem like medical practices from a futuristic science fiction movie.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“Phoenix and our partners have invested hundreds of millions of dollars into building a bioscience ecosystem,” she said. “It took patience, strong partnerships like GateWay Community College, and today we see the results of relentless pursuits of cures.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">BMSEED is headquarters in the Center for Entrepreneurial Innovation at GateWay Community College on East Washington Street.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="font-weight:700;box-sizing:border-box;font-size:17.3333px;">Turning Smartphones into Diagnostic Labs; i-calQ has an App for that</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">For mom and dad, an early-morning “I don’t feel good” from one of the kids while scrambling to get ready for work often means a calendar-clogging wait with other sick patients at the doctor’s office. While major medical incidents still need the office call, the Covid-19 pandemic has increased the use of telemedicine.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Telemedicine provides opportunities for patients and medical providers to converse face-to-face. One of the challenges facing telemedicine is the inability to conduct remote lab tests.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">A biotechnology discovery by Phoenix-based i-calQ could change that. Though home testing is not yet approved, someday mom or dad may be able to perfume basic tests at home and send the test results from their mobile phone right to the pharmacy, where a prescription can be processed and perhaps delivered home by drone.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“That’s just where my brain went when I started thinking about all the ways we could help people with this type of technology,” said Pamela J. Turbeville, CEO and founder of the Phoenix, Arizona, U.S.-based startup. “Long-term, you remove the need to go to urgent care and getting exposed to other sick people who are carrying a variety of different things. This will also protect your family with whom you live.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">The immediate use is bringing remote areas of the world direct access to high technology laboratories. Routine tests can save children’s lives with expedited results. The i-calQ device works in any setting where there is internet access without the need for costly local laboratory and testing infrastructure.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“The importance of high-quality telemedicine has perhaps never been greater than it is now during Covid-19,” said Mayor Kate Gallego. “This technology can truly help revolutionize how we interact with healthcare providers. I-calQ is a true testament to the diverse innovation ecosystem housed in our city.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">i-calQ, headquartered at Grand Canyon University’s Canyon Ventures incubator, is another example of the innovation and creativity coming from Phoenix startups, says Mackay. She points out that GCU’s rent-free program for startups helps spread bioscience collaboration across the city.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“Watching how the i-calQ device went from a concept to a marketable product with life-saving possibilities is typical of the kinds of innovation Phoenix and our partners are supporting,” Mackay said. “Seeing the bioscience work from our desert recognized by the international scientific community is something special.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="font-weight:700;box-sizing:border-box;">Horses Need Advanced Healthcare Too</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Find a problem and solve it. That’s what drives bioscience entrepreneurs. And Grant Senner MD, DABRM, CEO of Equus Innovations in Phoenix, believes that it’s time to move solutions for equine health and performance into the marketplace.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“We’re taking century-old human medical science, applying current bioscience techniques, and using it as a next-generation clinical option for use in horses,” said Grant Senner MD, DABRM and CEO of Equus Innovations. “We saw a critical need (in equine health care) for a highly (effective), cost-effective, off-the-shelf product to bring truly regenerative medicine to this field.”<br style="box-sizing:border-box;"></div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Equus Innovations, a Phoenix, Arizona, U.S. startup, has the first product of its kind on the market.  RenoV¬¬ō is an acellular, liquid allograft comprised of amnion and amniotic fluid intended to cover and protect tissues. An allograft is a tissue transplant from one, in this case, horse to another horse.  </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“Ranching and agriculture are engrained in Arizona’s economic and cultural traditions. Horses have played a key role in that history,” said Mayor Kate Gallego. “Equus Innovations shows just how much can come from looking at existing technology with fresh eyes to create new solutions.” </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">RenoVō, used in treatments for more than 2,000 horses, is enjoying rapid adoption among owners and veterinarians as the preferred alternative to other clinical options. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Senner said that with the support from the city of Phoenix and GateWay Community College’s Center for Entrepreneurial Innovation, Equus Innovations is “an entrepreneurial success story.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“Equus is an example of the companies the Phoenix innovation ecosystem is generating, and not just in human health solutions,” said Mackay. “We are recognized as a city where it doesn’t matter how long your roots have been in the Valley. Phoenix is the place where discoveries are welcome, and collaboration is a routine way of life.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="font-weight:700;box-sizing:border-box;">Innovation and Collaboration Build Phoenix’s Global Reputation in Bioscience Discovery</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <img src="https://www.phoenix.gov/econdevsite/MediaAssets/Other/NEWSROOM_CED_0071.jpg" style="border-width:0px;border-style:initial;width:495px;max-width:100%;box-sizing:border-box;margin:5px;" class="" />The Center for Entrepreneurial Innovation at GateWay Community College is expanding from its East Washington Street origin into the new 850 North Fifth Street building under development by Wexford Science + Technology. CEI attracts the emerging bioscience companies for incubation and acceleration.  The collaboration between tenant companies propels each forward from discovery to delivery. CEI is a major player in the Phoenix innovation ecosystem.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">The city of Phoenix has America’s fastest population growth for the fourth year in a row. Phoenix is the anchor of the Phoenix-Mesa-Chandler, metropolitan area, which in 2019 passed Boston-Cambridge Newton Massachusetts and New Hampshire, to become the 10th most populous U.S. metropolitan area. The city and its partners have invested more than $500 million into development of the Downtown Phoenix Biomedical Campus. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">The doubling in size of the Mayo Clinic campus with the Arizona State University Health Solutions Campus in northeast Phoenix is nearly a $1 billion investment. Bioscience and healthcare organizations in the city of Phoenix are in the process of investing more than $3 billion into 4.6 million square feet of new primary research and treatment facilities. Including Mayo Clinic and ASU, there are more than $1.3 billion in facilities under construction today.<br style="box-sizing:border-box;"></div> <div> <br>​<br></div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/52/NEWSROOM_CED_0070.jpg2020-06-01T07:00:00ZCity of Phoenix
Repair for Traumatic Brain Injury Coming Now from Phoenix-Based Startup BMSEEDRepair for Traumatic Brain Injury Coming Now from Phoenix-Based Startup BMSEED<div class="ExternalClassEBF69601CE5B4284864CA4344A3B80D6"><html> <p>​<span style="font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;background-color:window;color:windowtext;">“</span><span style="font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;background-color:window;color:windowtext;">It was the pivotal moment,” said Oliver Graudejus. It was 2007, and he was sitting in a workshop at the University of Michigan. In what seems a lifetime ago, Graudejus watched a demonstration of neuromodulation change a Parkinson’s Disease patient’s life from unlivable to near-normal.</span></p> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;text-align:center;"> <em style="box-sizing:border-box;">By Eric Jay Toll and Athena Sanchez for PhxNewsroom</em> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <img class="" style="border-width:0px;border-style:initial;width:150px;max-width:100%;box-sizing:border-box;margin:5px;vertical-align:baseline;float:right;height:210px;" alt="Photo, Oliver Graudejus, Founder and CEO, BMSEED" src="https://www.phoenix.gov/econdevsite/MediaAssets/Other/NEWSROOM_CED_0066.jpg" />It wasn’t that devices at that time were technological “iron lungs,” but some were inconvenient for daily patient life. It’s the belief there was a better way. That was the eureka moment for Graudejus, founder and CEO of BioMedical Sustainable Elastic Electronic Devices, headquartered in Phoenix, Arizona, U.S. He was determined to invent a more effective manner of pushing electrical pulses to a patient’s brain-implanted stimulator. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Neuromodulation is a technique that addresses one of the most profound challenges in the medical profession, how to repair and reverse the consequences of traumatic brain injuries and other brain diseases. TBI is one of the leading causes of death and disability among children and young adults in the United States, according to the Centers for Disease Control. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">BMSEED is one of three Phoenix companies to be selected to compete globally in the Bio International organization’s 2020 Startup Stadium. The Stadium selects 30 startups from hundreds of applicants around the world to compete for venture capital, strategic partnerships and customers in early June. This is the second year in the row three startups from Phoenix made it to the final round. Last year, more than 16,000 people attended the Bio International conference, where the Phoenix companies competed. This year the conference is virtual.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“BMSEED’s quest to help treat traumatic brain injuries brings both a solution and hope for affected individuals and their loved ones,” said Phoenix Mayor Kate Gallego. “They are a great example of the many vibrant startups that have made Phoenix home.“</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">An estimated 2.5 million Americans each year suffer a TBI.  Over a quarter million are hospitalized and survive, but often with overwhelming physical and mental impairment. This is all about biomimetic technology, fooling the body’s immune system not to recognize the device as a foreign object, which makes it far more effective and sustainable for human use.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“BMSEED’s first product is a research tool that helps researchers develop treatments to mitigate the damage after a traumatic brain injury. This product, called the MicroElectrode Array Stretching Stimulating und Recording Equipment, called “MEASSuRE”, is urgently needed because all of the 30 clinical trials to develop treatments for traumatic brain injury over the past 25 years have failed. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">The product reproduces the biomechanical environment of cells during the injury, and our stretchable electrodes allow the assessment of cell health and function,” Graudejus said. “That’s where BMSEED technology comes in, making soft, flexible and stretchable electrodes. The next step is to use these electrodes inside the body, with the goal that the body doesn’t see the device as a foreign object and try to reject it.” Neural interface technology faces the fundamental challenge of the body’s reaction to expel foreign objects. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Previous generations of biotech interfaces between the devices and the human body have resulted in cumbersome hard-material electrodes and uncomfortably large external devices that the body tries to reject. This is the problem that our electrodes could help solve.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> “It’s important working and collaborating with people who aren’t like-minded,” he said. “Failing to do so may result in something you think is good, but it may not be relevant for anybody.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <img class="" style="border-width:0px;border-style:initial;width:125px;max-width:100%;box-sizing:border-box;margin:5px;vertical-align:baseline;float:right;height:175px;" alt="Barclay Morrison III, PhD" src="https://www.phoenix.gov/econdevsite/MediaAssets/Other/NEWSROOM_CED_0068.jpg" />BMSEED collaborates with professor Barclay Morrison III’s Neurotrauma and Repair Laboratory at the Biomedical Engineering Department at Columbia University, New York City. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> “This profound need for improvements in the prevention and treatment of TBI is the driving force behind our research,” said Barclay Morrison III, PhD, professor of biomedical engineering, Columbia University, New York. Dr. Morrison leads the Neurotrauma and Repair Laboratory at the university. “Our long-term goal is to understand the consequences of mechanical forces on the most complex system of the human body, the brain.” </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> BMSEED’s development of smaller, softer and thinner electrodes is a new generation of technology creating flexible implants. Made from a proprietary micro-cracked gold film embedded between two layers of silicone, Graudejus developed the core principle from 2006 to 2009 while working at Princeton University, Princeton, New Jersey.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“The MEASSure system will provide researchers with a valuable new tool for mechanically stimulating cells while recording electrophysiological activity,” said Dr. Morrison. “Those capabilities open up a world of novel studies that weren't possible before.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> “I wanted to do something with the rest of my life that was going to have an impact,” said Graudejus. “The very different challenge from the technical issues that we have to overcome is there's always more you can do to a product to improve. I would say that's our biggest challenge.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Getting the company name out there is another challenge BMSEED is facing. Already its product is at a stage adequate to sell to the prototype to its first commercial customer, the United States Army. Being on the virtual Startup Stadium stage will help overcome this challenge, with thousands of bioscience professionals being exposed to the company.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Sales, marketing and growing to scale are the biggest funding needs BMSEED faces, according to the CEO. Non-dilutive funding from foundations and the National Institute of Health paid for development costs. The company has raised nearly $3 million from the two sources. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“Some improvements on intellectual property, a proper manufacturing facility along with the sales and marketing, this is what we need to fund now,” he said. “With development costs covered by others, we believe this is an attractive opportunity for investors.”</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Graudejus said that they’d had excellent success with his team working in the laboratory at the Gateway College Center for Entrepreneurial Innovation. The pandemic has created some challenges with the CEO working at home and other team members dividing time between the CEI lab and home-based work environments.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">“I’m grateful to my team for keeping the work going,” he said.</div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">CEI, which is developing its second location in Downtown Phoenix, is part of the Phoenix Bioscience Ecosystem and is another milestone on the Flinn Foundation Arizona Bioscience Roadmap. </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <br style="box-sizing:border-box;"> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;">Phoenix is America’s fifth-largest with the most population growth of any U.S. city for the last four years. The city has invested over $500 million with its partners into the downtown Phoenix Biomedical Campus. The city has also invested millions into the Arizona Health Solutions campus of Mayo Clinic and Arizona State University. Public and private bioscience and healthcare organizations are committing more than $3 billion to develop 4.6 million square feet of new facilities in the city of Phoenix. The Phoenix-Mesa-Chandler metro area is the tenth most populous in the U.S., having passed the Boston-Cambridge-Newton Massachusetts-New Hampshire metro area in 2019.<br style="box-sizing:border-box;"></div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <img class="" style="border-width:0px;border-style:initial;width:495px;max-width:100%;box-sizing:border-box;margin:5px;" src="https://www.phoenix.gov/econdevsite/MediaAssets/Other/NEWSROOM_CED_0069.jpg" /> <br> <br> </div> <p> <br> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/49/BMSEED.jpg2020-05-28T07:00:00ZCity of Phoenix
Phoenix Startup i-calQ Turns Smartphones into Diagnostic LabsPhoenix Startup i-calQ Turns Smartphones into Diagnostic Labs<div class="ExternalClass668C3EA565FA4A5F8D03FD05F8BA1658"><html> <p><span style="color:windowtext;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;background-color:window;">K</span><span style="color:windowtext;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;background-color:window;">evin is complaining about a sore throat, and his mother is concerned it might be strep throat. It’s a moment that could mean staying home from work and hauling Kevin to urgent care or waiting to see a doctor. It used to mean that, but someday there could be a home test for that.</span><br></p> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;text-align:center;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <em style="box-sizing:border-box;">By Eric Jay Toll and Athena Sanchez for PhxNewsroom</em> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Though a home test is not approved now, someday Kevin’s mom may be able to send the test results from her smartphone and then head to the pharmacy for an antibiotic or ask for drone delivery.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“That’s just where my brain went when I started thinking about all the ways we could help people with this type of technology,” said Pamela J. Turbeville, CEO and founder of the Phoenix, Arizona, U.S.-based startup. “Long-term, you remove the need to go to urgent care and getting exposed to other sick people who are carrying a variety of different things. This will also protect your family with whom you live.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Out of hundreds of startups from around the world, i-calQ is one of three from Phoenix, Arizona, U.S., to join 27 others in the 2020 BIO International Startup Stadium. The Stadium is a “Shark Tank” competition among the startups for venture capital, strategic partnerships and collaborative opportunities. BMSEED and Equus Innovations are the other Phoenix companies entering the competition in June.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“The importance of high-quality telemedicine has perhaps never been greater than it is now during Covid-19,” said Mayor Kate Gallego. “This technology can truly help revolutionize how we interact with healthcare providers. I-calQ is a true testament to the diverse innovation ecosystem housed in our city.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Six years and millions of dollars later, the platform functions well with both iOS and Android mobile operating systems. </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“Even when issues were needing to be corrected, we never doubted that we would get the test platform to where it needed to be,” said Turbeville. “The combination of people we could help and the impact we could have on the community was the focus.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">The CEO calls herself a “Phoenix kid just trying to make the world a better place.” She’s a fourth-generation Arizona native and is a part of a family of cowboys. Turbeville has worked all over the United States and Canada but returned to her Arizona roots to find the ecosystem to make her idea a reality.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">i-calQ technology opens the world to rapid medical testing. In developed nations, the application means time- and money-saving convenience. In the developing world, it means access to testing and diagnostics in places where the infrastructure of laboratories and technicians are not readily available. Test results return in about ten minutes, and treatments can start immediately.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“i-calQ’s Covid-19 test is awaiting approval and then can be used on the spot to test students to get back to class, employees to go back to work, safely,” Turbeville said. “Similarly, the thyroid-stimulating hormone test will allow testing babies in remote areas where there aren’t facilities.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">She says that this technology is among the first steps for bringing down the overall cost of medicine in the U.S. and opening access across the world.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Like many startups, Turbeville is ready to launch the product to market. The company is seeking working capital to scale up.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Seven patents are already in the house, “a lot for a startup,” according to Turbeville. Once launched, i-calQ could be reducing test-result delays and getting patients to treatment more quickly.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">The CEO calls it a “platform for change.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“We can test for COVID-19 now and, if we know what the next global pandemic will be, we can plan for it,” she said. “This wasn’t our original charter, but the company has developed this capability.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“The net result is that i-calQ will make a difference in the lives of many people by saving lives and improving the quality of individual life,” Turbeville said. </span> </div> <p> <br> </p> </html></div>2020-05-28T07:00:00ZPhoenix Bio News
Bio and life science discoveries are helping more than just peopleBio and life science discoveries are helping more than just people<div class="ExternalClassFC5F973143A6470CA3E5C1C4EA2B7C59"><html> <p>​<span style="font-size:13.3333px;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;background-color:window;color:windowtext;">“We’re taking century-old human medical science, applying current bioscience techniques, and using it as a next-generation clinical option for use in horses,” said Grant Senner MD, DABRM and CEO of Equus Innovations. “We saw a critical need (in equine health care) for a highly efficacious, cost-effective, off-the-shelf product to bring truly regenerative medicine to this field.”</span></p> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;text-align:center;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;text-align:center;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <em style="box-sizing:border-box;">By Eric Jay Toll and Athena Sanchez for PHXNewsroom</em> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Senner and his co-founder, COO and Chief Scientific Officer, Christian Beaudry, saw a need to bring regenerative medicine to the equine world. They found the opportunity to take existing technologies and successfully apply them to the emerging branch of veterinary science.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Equus is one of three Phoenix companies selected to join 27 others selected from among hundreds of startups around the world to compete in the Biotechnology Innovation Organization’s 2020 International Startup Stadium. The BIO International Startup Stadium is a “Shark Tank” of bioscience startups presenting to a global panel of judges in hopes of winning venture capital, strategic partnerships and product collaborations.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Equus Innovations, a Phoenix, Arizona, U.S. startup, has the first product of its kind on the market.  RenoVō is an acellular, liquid allograft comprised of amnion and amniotic fluid intended to cover and protect tissues. An allograft is a tissue transplant from one, in this case, horse to another horse.  </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Donor tissues harmlessly collected with owner consent during live birth do not harm the mare or foal. Amniotic birth tissues are rich sources of bioactive factors involved in tissue regeneration with reported anti-inflammatory, anti-bacterial and anti-fibrotic properties. RenoVō is cryopreserved and maintained frozen before use, to preserve beneficial proteins. </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“Our mission is to create and provide innovative products to maximize the health and performance of horses across all breeds and athletic disciplines,” said Senner. “We are the market leader in the development of novel, advanced allografts for veterinary use.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <img class="" style="border-width:0px;border-style:initial;width:495px;max-width:100%;box-sizing:border-box;margin:5px;" src="https://www.phoenix.gov/econdevsite/MediaAssets/Other/NEWSROOM_CED_0071.jpg" />RenoVō, used in treatments for more than 2,000 horses, is enjoying rapid adoption among owners and veterinarians as the preferred alternative to other clinical options. </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“Ranching and agriculture are engrained in Arizona’s economic and cultural traditions. Horses have played a key role in that history,” said Mayor Kate Gallego. “Equus Innovations shows just how much can come from looking at existing technology with fresh eyes to create new solutions.” </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">As with all good entrepreneurial ventures, the identification of the problem is step one. Equus Innovations saw that a highly effective and strong regenerative medicine component, and the solution for equine use, was glaringly absent from the market.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“That was the driver behind the creation of the company,” Senner said. “(Our) team has really dedicated itself and devoted the time, energy and financial resources into advancing the clinical data. We have a first-of-its-kind field study in over 200 horses, evaluating the product in soft tissue and orthopedic injuries in equine subjects.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Senner sees the results of the clinical research, and getting that information into the marketplace, as the key for even greater adoption of RenoVō. Equus works closely with its sister company and national distributor, Equine Amnio Solutions, located in Argyle, Texas. The company’s near-term focus includes leveraging ongoing studies with the research and development program, and to continue the dialogue for a strategic partnership with larger operators seeking innovative products for veterinary use.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Senner is a multiple-startup entrepreneur of companies in the biotechnology sector. Equus Innovations is his first foray into veterinary sciences.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">“Veterinarians in this sector are just a delight to work with. They’re a different group of clinicians than my MD counterparts on the human health side,” Senner said. “I find them very scientifically driven. They have a very healthy and balanced skepticism. They’re to be admired for their dedication to the animals and putting the patient health above all else.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Senner said that with the support from the city of Phoenix and GateWay Community College’s Center for Entrepreneurial Innovation, Equus Innovations is “an entrepreneurial success story.”</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <br style="box-sizing:border-box;"> </span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;">Phoenix is America’s fifth-largest city with the most population growth of any U.S. city for the last four years. The city has invested over $500 million with its partners into the downtown Phoenix Biomedical Campus. The city has also invested millions into the Arizona Health Solutions campus of Mayo Clinic and Arizona State University. Public and private bioscience and healthcare organizations are committing more than $3 billion to develop 4.6 million square feet of new facilities in the city of Phoenix. The Phoenix-Mesa-Chandler metro area is the tenth most populous in the U.S., having passed the Boston-Cambridge-Newton Massachusetts-New Hampshire metro area in 2019.</span> </div> <div style="box-sizing:border-box;font-family:"segoe ui", segoe, tahoma, helvetica, arial, sans-serif;font-size:16px;"> <span style="box-sizing:border-box;font-size:13.3333px;"> <img class="" style="border-width:0px;border-style:initial;width:495px;max-width:100%;box-sizing:border-box;margin:5px;" src="https://www.phoenix.gov/econdevsite/MediaAssets/Other/NEWSROOM_CED_0073.jpg" />​</span> </div> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/51/NEWSROOM_CED_0072.jpg2020-05-28T07:00:00ZCity of Phoenix
Biotech - Finding the DNA for Success Biotech - Finding the DNA for Success <div class="ExternalClass801A4CC2F58B4E2BA6BD6C27B8746B10"><html> <p>​</p>According to Deloitte's 2020 Global Life Sciences Outlook, the biotech sector<br>is at an inflection point. To prepare for the future and remain relevant in<br>the ever- evolving business landscape, biopharma and medtech organizations<br>will be looking for new ways to create value and new metrics to make sense of<br>today's wealth of data, the report overview says.<br><br>As data- driven technologies provide biopharma and medtech organizations<br>with treasure troves of information, and automation takes over some mundane<br>tasks, new talent models are emerging based on purpose and meaning. The integration<br>of artificial intelligence (Al) and machine learning approaches within life sciences<br>is making drug discovery and development more innovative, time-effective<br>and cost- effective, the Deloitte report states.<br><br>Click <a target="_blank" href="/Documents/PHX%20BIO%20news%20in%20Business%20Facilities%20March_April%202020.pdf"><span style="color:rgb(0, 0, 139);"><strong>Here </strong></span></a>​To Read More.<br><p><br></p></html></div>2020-05-13T07:00:00ZPhoenix Bio News
An ASU researcher is working on a virus that's harmless to humans, but kills cancer cellsAn ASU researcher is working on a virus that's harmless to humans, but kills cancer cells<div class="ExternalClass2F5AA84CA8B245129FE95F9ED5606E45"><html> <p>​</p> <span id="ms-rterangepaste-start"></span> <a href="https://www.azcentral.com/staff/2683965001/amanda-morris" target="_blank"> <strong> <em>Amanda Morris</em> </strong> </a> <strong> <em>, Arizona Republic</em> </strong> <br> <em>Published 4:00 p.m. MT May 10, 2020 | </em> <em> <strong>Updated 4:08 p.m. MT May 11, 2020</strong> </em>​<span id="ms-rterangepaste-end"></span><p><br></p><p>Grant McFadden has spent over two decades studying the myxoma virus.</p><p>The ASU virologist grew interested in the myxoma virus because it is extremely deadly in European rabbits but virtually harmless in non-rabbit hosts — including humans. He wanted to figure out why.</p><p>So he began testing its ability to infect lab-grown cells.</p><p>Along the way, he made a startling discovery.</p><p>"We accidentally stumbled upon the fact that if we take this virus and put it onto cancer cells … the virus treated them just like rabbit cells, it infected them, killed them, in a way that was really quite dramatic," McFadden said.</p><p>With those results, the idea to use the virus as a cancer treatment was born.  </p><p>After several successful experiments in mice, McFadden co-founded a company in June 2019 to develop the virus into a type of cancer treatment known as virotherapy.</p><p>The company, called OncoMyx, has raised over $25 million to perfect the virotherapy and get the data needed to get approval for clinical trials. Though the first human trials are a long way off — about two and half years away — OncoMyx CEO and co-founder Steve Potts believes the treatment has a lot of potential.</p><p>"We'll start by targeting the most promising and effective cancer treatments," Potts said. "My hope is that we have a significant impact on one or two cancers."<br><br></p><h2 style="text-align:center;">TESTS IN MICE SHOW PROMISE</h2><p>To test the virus' ability to treat cancer, McFadden injected the virus into micethat had an aggressive form of brain cancer called glioblastoma. </p><p>Glioblastoma typically has a poor survival rate; only 5% of patients survive more than five years. It is the same type of cancer Arizona Sen. John McCain battled before succumbing to it in 2018.</p><p>McFadden conducted his first test with two groups of mice infected with glioblastoma. The control mice weren't given the virus treatment. All of them died.</p><p>But the mice treated with the virus produced a dramatically different result: All of them survived.</p><p>The mice treated with the virus also had no traces of glioblastoma left in their bodies. </p><p>In this test, McFadden also injected healthy, cancer-free mice with the myxoma virus. All the healthy mice emerged unscathed, with no side effects, and were fine.</p><p>Since that first test, McFadden has tested the virus against about a dozen different cancers in mice so far, including lung and blood cancers.<br></p><p>A common misconception is that cancer is a single disease, but it is actually an umbrella to describe hundreds of different diseases that can be quite different from each other. Because of this, some types of cancer might respond differently to the myxoma virotherapy and need to be tested separately, according to McFadden.</p><p>“It's worked exceedingly well in everything we've tested," he said. “All of them have had results that vary from good to great."</p><p>These successes don't mean that this virus could be a "holy grail" for curing cancer. Just because the virotherapy seems so promising in mice doesn't mean the results will be as effective in human trials.</p><p>In studying the myxoma virus, ASU virologist Grant McFadden is infecting cells with the virus. Cells infected with the virus are shown in green.<br><br></p><h2 style="text-align:center;">HOW VIROTHERAPY WORKS</h2><p>The treatment works like this: First, a modified version of the myxoma virus is injected into a host with cancer.</p><p>Rather than using an unaltered, natural form of the myxoma virus, researchers at OncoMyx are working to change the genetics of the virus to make it even more aggressive and lethal against different forms of cancer. This also allows them to use different formulas to target certain cancers.</p><p>“Mother Nature has given us a virus that is pretty good at growing in cancer cells and killing cancer cells, but … what everyone wants to do is improve upon what Mother Nature has done," McFadden said.</p><p>Once injected, the virus will attack cancer cells, but it also has 80 genes that stimulate the human immune system, Potts said. This triggers a strong immune system response in which the body starts destroying both the virus itself and the nearby cancer cells. By genetically altering the virus, OncoMyx hopes to further strengthen that immune system response. </p><p>“We want to make our immune system respond more to the tumor than to the virus," Potts said.<br><span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;"><br>Making the virotherapy stronger is also important because it's only a matter of time before the immune system is successful in flushing out the virus itself from the body. This means that when researchers administer the virotherapy, the virus will only stay in the body for a short time frame, and researchers want the treatment to be as effective as possible during that window.</span><br></p><p>To do this, they are adding additional genes to the virus that will further stimulate the immune system. Researchers have about 40 genes to work with.</p><p>Out of those 40 additional genes they could add to the virus, Potts said they will likely settle on adding only a few additional genes, although there are many different possible combinations. Re-engineering the virus to add or change its genetic makeup can take two or three months. For every additional genetic concoction OncoMyx makes, it takes another two to three months to test the new virotherapy. </p><p>In all, tweaking the virus to give it better ammunition against cancer and testing each new version can take up to six months.</p><p>McFadden said researchers are also investigating the best way to deliver the virus and how they can use the virotherapy to treat cancer hiding in hard-to-find places, such as when cancer has spread throughout a person's bone marrow.</p><p>Workers at Oncomyx are developing a new cancer treatment using a virus.<br><br><br></p><h2 style="text-align:center;">LONG ROAD TO HUMAN TRIALS</h2><p>Turning laboratory research into a new medicine or treatment takes a lot of time, money and effort.</p><p>That's where Skysong Innovations comes in. Skysong Innovations is a company that acts as a proxy for ASU to get funding and intellectual property rights for ASU research so that it can be marketed and applied in the real world. In McFadden's case, Skysong Innovations was instrumental in helping him get the funding needed for OncoMyx's research.</p><p>"Researchers cure cancer in mice all the time — but getting to the next step takes a lot more work," said Augustine V. Cheng, Skysong Innovations' CEO and chief legal officer.</p><p>For OncoMyx to start human trials, the company needs to submit an Initial New Drug Application to the Food and Drug Administration and get that application approved. The application needs to include a great deal of data from mice trials to prove that the product is reasonably safe for initial testing in humans.</p><p>Proving safety and effectiveness of the treatment is a high bar, meaning the company must spend the next year or two testing the virotherapy in mice and collecting data from those trials. Because each mouse trial takes at least eight weeks, each trial is also expensive.</p><p>"Yes, I would love all of this to be faster and cheaper but the truth is ultimately we have the obligation to be safe," McFadden said. “To prove safety is absolutely critical and it's not cheap, that's the bottom line."</p><p style="text-align:left;"><span style="background-color:window;color:windowtext;font-family:inherit;font-size:10pt;">In all, Potts determined that they would need at least $25 million to launch OncoMyx and complete the testing for the Initial New Drug Application.</span><br></p><p>To get the money, Potts and his fellow co-founders started raising funds in early 2018 and began pitching the treatment to investors around the world in a process that Potts called "Shark Tank for nerds," a reference to the popular television show.</p><p>In June 2019, with global investors from places like Hong Kong, OncoMyx succeeded in raising the full amount needed to start conducting mouse trials for the Initial New Drug Application.</p><p>If all goes well, Potts said the first phase of human trials would likely start in about two to three years.</p><p>This first phase would take a few months and, if it is a success, the company would start a second phase of human trials, which is a larger, longer-term study. This second phase would likely take another two to five years before the company could submit the virotherapy to the FDA for final approval as a treatment.</p><p>All together, this treatment could reach a commercial market in four to eight years. Any unsuccessful trials or other hiccups in the process could prolong the process.</p><p>Cheng believes this treatment is well worth the time and effort. </p><p>"Virotherapy is one of the hottest areas in cancer treatment right now," he said. "And nobody else is working with myxoma virus.</p><p>"This virus may end up curing many cancers." <br></p><p><br></p></html></div>2020-05-10T07:00:00ZOncoMyx Therapeutics
Phoenix’s CRE Transformation Pours $3B Into Biotech And ResearchPhoenix’s CRE Transformation Pours $3B Into Biotech And Research<div class="ExternalClassC89965F8DDC245DF99E1DA26CD6181F2"><html> <p>​The rare absence of both spring break and spring training tourists has changed Phoenix’s current focus.</p><p> Now, instead of tourism, city officials are shifting gears to the needs of the service and healthcare sectors, which have seen a boom in development and capital inflows.</p><p>“In a 24-month span, we have over $3B in current and proposed construction projects in the health services, hospital and medical research industries within the Phoenix city limits,” said Claudia Whitehead, a spokesperson for the city. </p><p>“These projects cover over 4.5M SF and will provide over 7,000 jobs. Our status as a ‘young’ big city means there are less boundaries in the medical field, and that opens the industry to collaboration and innovation," she said. "Most people do not associate Phoenix with cutting-edge medical technology, but we are hoping that changes this decade.” </p><p>In news that has not been shared with the general public, biotech company Caris Life Sciences, which has two commercial projects underdevelopment in Phoenix, will announce Tuesday a new artificial intelligence process being used to treat cancer. </p><p>Caris Life Sciences' Molecular Intelligence Folfox, which uses AI in oncology treatments, has earned breakthrough therapy designation from the Food and Drug Administration.  </p><p>Caris currently has two projects underway: a 45K SF lab addition scheduled to open in mid-April at The Cotton Center, Arizona’s largest business park; and a brand-new lab opening in late April in the First Solar building at 202 Highway and Mill Ave. </p><p>Both are prime examples of how CRE is advancing medical innovation across Phoenix.  </p><p>“Phoenix has become a hotbed for molecular diagnostics and attracting therapeutic companies,” Caris President David Spetzler said. “Since it is close to the airport, our Cotton Center location provides us perfect functionality to ship our specimens. The lack of natural disasters and lack of humidity makes Phoenix an ideal location to set up laboratories and the [commercial real estate] industry is definitely reaping the benefit.” </p><p>Central Phoenix and downtown Phoenix are both enjoying a research renaissance, as food and beverage chains give way to medical research and biotech buildings. </p><p>The Phoenix Biomedical Campus is a 30-acre site downtown that runs south to north from Van Buren Street to Garfield Street, and from east to west from Seventh Street to Fourth Street. The Translational Genomics Research Institute, a nonprofit medical research institute, was the foundation for the campus, and has been downtown for almost 15 years. Since then, 16 companies that came out of TGen have a commercial real estate presence in Phoenix.</p><p>The Phoenix Biomedical Campus is also home to the University of Arizona’s colleges of Medicine, Nursing, Pharmacy, Public Health, and Telemedicine, as well as Northern Arizona University’s College of Health and Human Services and four additional allied health programs. Arizona State University’s College of Health Solutions is also based on the campus, which has a partnership with Wexford Science & Technology. </p><p>Wexford Science & Technology's topping out ceremony to showcase Okland Construction's completion of the 226K SF Innovation Center at 850 North Fifth St., a partnership with Arizona State, was supposed to be held March 27. The coronavirus pandemic scuttled that plan, leading to a mass video distribution of the current construction site to the public. The project is now slated to be completed in late 2020.</p><p>“Finding a place in the Phoenix Biomedical Campus has been a priority for us, because of the environment for private and academic research collaboration,” Wexford Science & Technology Director of Development Kyle Jardine said. “The academic and medical communities have dropped their boundaries, so private companies feel free to join collaboration opportunities by expanding their office and laboratory presence.” </p><p>It is an expanding presence that will include Maricopa Community College as a tenant, along with over 100K SF over two floors that will be occupied by Arizona State. The fifth, sixth and seventh floors will be fully developed for private laboratories.<br></p><p>“The combination of affordable land and a ‘new’ big city open to innovation is why we see this as just the beginning phase for Phoenix as a medical research and resource destination,” Jardine said. </p><p>Traditional healthcare heavyweights, including Banner Health and the Mayo Clinic, are expanding their Phoenix-area facilities, too. Banner Health has one project in the southeast valley in Chandler and another in the northwest valley in Sun City. </p><p>Its newest hospital is planned to open in November 2020 in Chandler and is spread across 18 acres. The four-story Banner Ocotillo Medical Center will include a Level 2 emergency room as well as cardiology, gastroenterology, gynecology, labor and delivery, imaging, intensive care, orthopedic and surgical services. The building will contain 96 licensed beds and 24 observation beds with a staff of over 65 physicians and 430 full-time employees. </p><p>Exactly 50 miles away from Chandler in Sun City, Banner Health is in the middle of building a new $106M, six-story emergency room and patient tower at Banner Boswell Medical Center, scheduled to open this fall. The new emergency room increases space to 56 beds total, and increases annual patient capacity to 60,000 from 45,000. </p><p>“We are Arizona’s largest nonprofit healthcare system, so we are constantly evaluating the growing healthcare needs across the state, not just in Phoenix,” Banner Health spokesperson Nancy Neff said. “We have responded with expansions, new builds, new partnerships and mergers and acquisitions to meet those needs.” </p><p>Just within Phoenix city limits on the north side of the valley, the Mayo Clinic is undergoing perhaps the most visible project, right off the highly traveled Loop 101 freeway off the 56th Street exit. The Mayo Clinic’s expansion will add an additional 1.4M SF, almost doubling the size of the campus, in a $648M expansion project that is scheduled for completion by April 2023. </p><p>The project will include a new six-story patient tower, a new three-story building for an expanded emergency department, a three-floor addition to the current building and expanded parking. A Future Health Solutions campus, a 150K SF collaboration with Arizona State, is being created adjacent to the Mayo Clinic. </p><p>“We call the city of Phoenix the frontier of medical collaboration and innovation because both the newcomers and the longtime residents are choosing this opportunity to expand,” Whitehead said. </p><p>There are now over a dozen other healthcare or biotech projects under development in Phoenix, including Valleywise Health’s 673K SF medical center at 2601 East Roosevelt St. The 10-story medical center is located next to the current medical center and is scheduled to open in late 2023. </p><p>The new tower will increase instructional resources at the state’s only public teaching hospital, while making facility improvements to the Arizona Burn Center and the Level 1 Trauma Center. </p><p>“After the Great Recession of 2008, we decided as a city that we could not just be built on tourism and growth anymore,” City of Phoenix Community and Economic Development Manager Chris Mackay said. </p><p>“We made a conscious effort then to attract the healthcare and medical biosciences industries because they are resilient industries that thrive regardless of the state of the economy. That investment is starting to pay off during these unfortunate times, and hopefully these innovative research opportunities can be tomorrow’s solutions to today’s medical problems.”<br><br><br><br></p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/30/CRE.jpg2020-03-30T07:00:00ZPhoenix Bio News
Paradigm Diagnostics Receives Expanded Medicare Coverage for PCDx for Solid TumorsParadigm Diagnostics Receives Expanded Medicare Coverage for PCDx for Solid Tumors<div class="ExternalClassF932B21F7EB64FC1B21E8679D599EE89"><html> <p>​</p> <p> <em>Paradigm Diagnostics, Inc. announced that Palmetto GBA, the Medicare Administrative Contractor (MAC) for the Molecular Diagnostics MolDX program, has reviewed the technical dossier and broadly approved the Paradigm Cancer Diagnostic (PCDx) assay under the Local Coverage Determination for next-generation sequencing for solid tumors.</em> <br> </p> <p> <em>The PCDx test provides physicians and their patients with a blueprint of the underlying mechanisms of a patient's disease, potential treatment approaches, and inventory of relevant clinical trials. The test gets results back to physicians in three to five business days, rather than weeks.  The PCDx assay detects substitutions, insertion and deletion alterations (indels), and copy number alterations in 234 genes and select gene rearrangements. PCDx also detects genomic signatures, including micro satellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens in addition to select immunohistochemistry tests.</em> </p> <p> <em>"After an extensive technical review, the expanded Medicare coverage significantly enhances Paradigm's ability to enable broader and earlier access to biomarker-driven treatments that may improve survival for cancer patients," said David Mallery, CEO.</em> <br> </p> <p> <strong>Source: </strong> <a href="https://www.paradigmdx.com/" target="_blank"> <strong>https://www.paradigmdx.com</strong> </a> <br> </p> <p> <br> </p> </html></div>https://biomedicalphoenix.com/Lists/News/Attachments/32/NEWSROOM-20200110-Paradigm-Diagnostics.jpg2020-01-10T07:00:00ZExact Sciences

© City of Phoenix Community and Economic Development